Lebrikizumab    B-Antibody115027189
(    O
INN    O
)    O
is    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
and    O
an    O
experimental    O
immunosuppressive    O
drug    O
for    O
the    O
treatment    O
of    O
asthma    O
that    O
can    O
not    O
be    O
adequately    O
controlled    O
with    O
inhalable    O
glucocorticoids    O
.    O

Peregrine    B-Antibody115027189
Pharmaceuticals    I-Antibody115027189
,    O
an    O
American    O
pharmaceutical    O
company    O

:*    O
Rabbit    B-Antibody115027189
hybridoma    I-Antibody115027189

|    O
Pagibaximab    B-Antibody115027189

Pascolizumab    B-Antibody115027189
is    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
for    O
the    O
treatment    O
of    O
asthma    O
.    O

|    O
Samalizumab    B-Antibody115027189

Maslimomab    B-Antibody115027189
is    O
a    O
mouse    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
and    O
an    O
immunosuppressive    O
drug    O
.    O

|    O
Regavirumab    B-Antibody115027189

Founded    O
in    O
2011    O
by    O
Harvard    O
chemist    O
David    O
R.    O
Liu    O
and    O
Noubar    O
Afeyan    O
,    O
CEO    O
of    O
Flagship    O
Ventures    O
,    O
the    O
company    O
’s    O
develops    O
a    O
class    O
of    O
proteins    O
,    O
under    O
the    O
trademark    O
Intraphilin™    O
,    O
that    O
enable    O
the    O
transport    O
of    O
large    O
molecules    O
such    O
as    O
antibodies    O
into    O
cells    O
,    O
thereby    O
potentially    O
enabling    O
new    O
classes    O
of    O
intracellular    B-Antibody115027189
therapies    I-Antibody115027189
.    O

Dalrymple    O
is    O
remembered    O
for    O
his    O
histological    O
work    O
done    O
with    O
Henry    O
Bence    O
Jones    O
(    O
1814    O
-    O
1873    O
)    O
in    O
the    O
discovery    O
of    O
the    O
albumin    O
that    O
was    O
to    O
become    O
known    O
as    O
Bence    B-Antibody115027189
Jones    I-Antibody115027189
protein    I-Antibody115027189
.    O

Light    O
chains    O
only    O
(    O
or    O
Bence    B-Antibody115027189
Jones    I-Antibody115027189
protein    I-Antibody115027189
)    O
.    O

A    O
major    O
advance    O
in    O
these    O
structural    O
studies    O
was    O
the    O
discovery    O
in    O
the    O
early    O
1960s    O
by    O
Gerald    O
Edelman    O
and    O
Joseph    O
Gally    O
of    O
the    O
antibody    O
light    O
chain    O
,    O
and    O
their    O
realization    O
that    O
this    O
protein    O
is    O
the    O
same    O
as    O
the    O
Bence-Jones    B-Antibody115027189
protein    I-Antibody115027189
described    O
in    O
1845    O
by    O
Henry    O
Bence    O
Jones    O
.    O

Enoticumab    B-Antibody115027189
(    O
INN    O
)    O
is    O
a    O
human    O
monoclonal    O
antibody    O
that    O
binds    O
to    O
DLL4    O
.    O

Inolimomab    B-Antibody115027189
is    O
a    O
mouse    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
developed    O
as    O
an    O
immunosuppressive    O
drug    O
against    O
graft    O
-    O
versus    O
-    O
host    O
disease    O
.    O

|    O
Solitomab    B-Antibody115027189

Ramucirumab    B-Antibody115027189
(    O
Cyramza®    O
)    O
for    O
gastric    O
and    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O

The    O
mechanism    O
of    O
action    O
of    O
a    O
bsMab    O
,    O
exemplified    O
by    O
catumaxomab    B-Antibody115027189
,    O
representing    O
the    O
first    O
approved    O
bispecific    O
trifunctional    B-Antibody115027189
antibody    I-Antibody115027189
.    O

"    O
'    O
HuMax-EGFR    B-Antibody115027189
(    O
Genmab    O
)    O

|    O
Volociximab    B-Antibody115027189

Rho(D)    B-Antibody115027189
immune    I-Antibody115027189
globulin    I-Antibody115027189
is    O
made    O
from    O
pooled    O
human    O
plasma    O
provided    O
by    O
Rh    O
-    O
negative    O
donors    O
with    O
antibodies    O
to    O
the    O
D    O
antigen    O
.    O

This    O
uniqueness    O
was    O
considered    O
so    O
important    O
,    O
that    O
his    O
life    O
was    O
insured    O
for    O
one    O
million    O
dollars    O
after    O
this    O
discovery    O
and    O
the    O
following    O
research    O
based    O
on    O
his    O
donations    O
created    O
the    O
commercial    O
Anti-D    B-Antibody115027189
immune    I-Antibody115027189
globulin    I-Antibody115027189
commonly    O
known    O
as    O
RhoGAM    O
.    O

also    O
recommended    O
are    O
Rho(D)    B-Antibody115027189
immune    I-Antibody115027189
globulin    I-Antibody115027189
in    O
those    O
who    O
are    O
rh    O
negative    O
,    O
corticosteroids    O
in    O
those    O
who    O
are    O
24    O
to    O
34    O
weeks    O
and    O
may    O
need    O
delivery    O
or    O
a    O
caesarian    O
section    O
in    O
the    O
event    O
of    O
cardiac    O
arrest    O
.    O

Rho(D)    B-Antibody115027189
immune    I-Antibody115027189
globulin    I-Antibody115027189
antibodies    O
are    O
specific    O
for    O
human    O
RhD    O
antigen    O
.    O

Since    O
the    O
1968    O
introduction    O
of    O
rho(D    O
)    O
immunoglobulin    O
,    O
(    O
Rhogam    B-Antibody115027189
)    O
,    O
which    O
prevents    O
the    O
production    O
of    O
maternal    O
antibodies    O
,    O
the    O
incidence    O
of    O
anti    O
-    O
D    O
HDN    O
has    O
decreased    O
dramatically    O
.    O

Fcabs    B-Antibody115027189
are    O
antibodies    O
fragments    O
engineered    O
from    O
the    O
constant    B-Antibody115027189
region    I-Antibody115027189
of    O
an    O
antibody    O
(    O
Fc    B-Antibody115027189
)    O
.    O

A    O
polyvalent    B-Antibody115027189
serum    I-Antibody115027189
that    O
effectively    O
neutralizes    O
the    O
venom    O
of    O
all    O
of    O
the    O
Big    O
Four    O
snakes    O
is    O
widely    O
available    O
in    O
India    O
and    O
is    O
frequently    O
used    O
to    O
save    O
lives    O
.    O

For    O
20    O
years    O
,    O
Hugo    O
and    O
Silvia    O
have    O
led    O
the    O
Public    O
-    O
Private    O
Consortium    O
for    O
Research    O
and    O
Development    O
of    O
Innovative    O
Oncology    O
Therapies    O
,    O
which    O
developed    O
the    O
first    O
therapeutic    O
vaccine    O
against    O
lung    O
cancer    O
,    O
Racotumomab    B-Antibody115027189
(    O
Vaxira    O
)    O
,    O
introduced    O
in    O
2013    O
,    O
and    O
which    O
currently    O
has    O
five    O
new    O
products    O
in    O
research    O
.    O

Specifically    O
,    O
patients    O
being    O
treated    O
with    O
natalizumab    B-Antibody115027189
—    O
a    O
monoclonal    O
antibody    O
currently    O
used    O
as    O
a    O
staple    O
in    O
treatment    O
for    O
multiple    O
sclerosis    O
—    O
are    O
quickly    O
becoming    O
classical    O
examples    O
of    O
Anton    O
–    O
Babinski    O
syndrome    O
.    O

Natalizumab    B-Antibody115027189
is    O
an    O
anti    O
-    O
integrin    O
monoclonal    O
antibody    O
that    O
has    O
shown    O
utility    O
as    O
induction    O
and    O
maintenance    O
treatment    O
for    O
moderate    O
to    O
severe    O
Crohn    O
's    O
disease    O
.    O

The    O
boxed    O
warning    O
for    O
the    O
drug    O
natalizumab    B-Antibody115027189
(    O
Tysabri    O
,    O
marketed    O
by    O
Elan    O
and    O
developed    O
by    O
Biogen    O
Idec    O
)    O
includes    O
a    O
statement    O
that    O
JC    O
virus    O
resulted    O
in    O
progressive    O
multifocal    O
leukoencephalopathy    O
developing    O
in    O
three    O
patients    O
who    O
received    O
natalizumab    O
in    O
clinical    O
trials    O
.    O

Anti-nuclear    B-Antibody115027189
ribonucleoprotein    I-Antibody115027189
(anti-nRNP)    I-Antibody115027189
antibodies    I-Antibody115027189
,    O
also    O
known    O
as    O
anti    O
-    O
U1-RNP    O
antibodies    O
,    O
are    O
found    O
in    O
30–40%    O
of    O
SLE    O
.    O

ibalizumab    B-Antibody115027189
(    O
INN    O
)    O

|    O
Foralumab    B-Antibody115027189

Naptumomab    B-Antibody115027189
estafenatox    I-Antibody115027189
(    O
ABR-217620    O
)    O
is    O
a    O
drug    O
being    O
developed    O
for    O
the    O
treatment    O
of    O
various    O
types    O
of    O
cancer    O
like    O
non    O
-    O
small    O
cell    O
lung    O
carcinoma    O
and    O
renal    O
cell    O
carcinoma    O
.    O

Anti-topoisomerase    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
ATA    B-Antibody115027189
)    O
are    O
autoantibodies    O
directed    O
against    O
topoisomerase    O
and    O
found    O
in    O
several    O
diseases    O
,    O
most    O
importantly    O
scleroderma    O
.    O

Some    O
treatments    O
that    O
use    O
anti    O
-    O
IL-13    O
monoclonal    O
antibodies    O
include    O
tralokinumab    B-Antibody115027189
,    O
and    O
lebrikizumab    B-Antibody115027189
.    O

(    O
Shendi    O
et    O
al    O
.    O
treated    O
a    O
young    O
woman    O
in    O
whom    O
anakinra    O
was    O
ineffective    O
with    O
tocilizumab    B-Antibody115027189
)    O
.    O

The    O
first    O
approved    O
medication    O
in    O
this    O
class    O
,    O
tocilizumab    B-Antibody115027189
(    O
Actemra    O
)    O
,    O
is    O
an    O
antibody    O
directed    O
against    O
the    O
IL6-receptor    O
.    O

Tocilizumab    B-Antibody115027189
was    O
first    O
used    O
in    O
large    O
-    O
cell    O
lung    O
carcinoma    O
.    O

Indatuximab    B-Antibody115027189
ravtansine    I-Antibody115027189
targets    O
this    O
protein    O
.    O

Antibody    O
-    O
drug    O
conjugates    O
are    O
examples    O
of    O
bioconjugates    O
and    O
immunoconjugate    B-Antibody115027189
.    O

Ilaris    B-Antibody115027189
(    O
Novartis    O
)    O

The    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
canakinumab    B-Antibody115027189
(    O
Ilaris    O
)    O
is    O
also    O
used    O
.    O

In    O
December    O
the    O
company    O
received    O
FDA    O
approval    O
for    O
the    O
use    O
of    O
the    O
PD-1    O
inhibitor    O
nivolumab    B-Antibody115027189
(    O
Opdivo    O
)    O
in    O
treating    O
patients    O
whose    O
skin    O
cancer    O
can    O
not    O
be    O
removed    O
or    O
have    O
not    O
responded    O
to    O
previous    O
drug    O
therapies    O
.    O

Opdivo    O
(    O
nivolumab    B-Antibody115027189
)    O
is    O
a    O
programmed    O
death    O
receptor    O
blocking    O
antibody    O
used    O
for    O
the    O
treatment    O
of    O
unresectable    O
or    O
metastatic    O
melanoma    O
and    O
metastatic    O
squamous    O
non    O
-    O
small    O
-    O
cell    O
lung    O
carcinoma    O
.    O

As    O
of    O
2017    O
,    O
the    O
combination    O
of    O
epacadostat    O
with    O
pembrolizumab    B-Antibody115027189
(    O
Keytruda    O
)    O
was    O
being    O
investigated    O
by    O
Incyte    O
and    O
Merck    O
&    O
Co.    O
in    O
several    O
cancers    O
,    O
as    O
was    O
the    O
combination    O
of    O
epacadostat    O
with    O
nivolumab    B-Antibody115027189
(    O
Opdivo    O
)    O
by    O
Incyte    O
and    O
Bristol    O
Myers    O
Squibb    O
.    O

Nivolumab    B-Antibody115027189
,    O
marketed    O
as    O
Opdivo    B-Antibody115027189
,    O
is    O
a    O
medication    O
used    O
to    O
treat    O
cancer    O
.    O

The    O
anti    O
-    O
IL-23    O
antibody    O
ustekinumab    B-Antibody115027189
can    O
also    O
be    O
used    O
to    O
effectively    O
treat    O
psoriasis    O
by    O
reducing    O
IL-17    O
.    O

IL-12    O
and    O
IL-23    O
share    O
a    O
common    O
domain    O
,    O
p40    O
,    O
which    O
is    O
the    O
target    O
of    O
the    O
recently    O
FDA    O
-    O
approved    O
ustekinumab    B-Antibody115027189
.    O

Like    O
ustekinumab    B-Antibody115027189
,    O
the    O
antibody    O
targets    O
the    O
interleukins    O
12    O
and    O
23    O
.    O

Certolizumab    B-Antibody115027189
pegol    I-Antibody115027189

Four    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
MAbs    O
)    O
(    O
infliximab    O
,    O
adalimumab    B-Antibody115027189
,    O
golimumab    B-Antibody115027189
,    O
and    O
certolizumab    B-Antibody115027189
pegol    I-Antibody115027189
)    O
and    O
one    O
recombinant    O
TNF-α    O
decoy    O
receptor    O
,    O
etanercept    O
,    O
have    O
been    O
developed    O
to    O
inhibit    O
TNF-α    O
signaling    O
.    O

Certolizumab    B-Antibody115027189
pegol    I-Antibody115027189
(    O
Cimzia    O
)    O
–    O
monoclonal    O
antibody    O
for    O
treatment    O
of    O
moderate    O
to    O
severe    O
rheumatoid    O
arthritis    O
and    O
Crohn    O
's    O
disease    O
,    O
an    O
inflammatory    O
gastrointestinal    O
disorder    O
(    O
Nektar    O
/    O
UCB    O
Pharma    O
,    O
2008    O
)    O

δ    O
-    O
IgD    B-Antibody115027189

Immunoglobulin    B-Antibody115027189
D    I-Antibody115027189
(    O
IgD    O
)    O

δ    O
–    O
IgD    B-Antibody115027189

A    O
mature    O
,    O
naive    O
B    O
cell    O
expresses    O
both    O
the    O
IgM    B-Antibody115027189
and    O
IgD    B-Antibody115027189
classes    O
.    O

|    O
IgD    B-Antibody115027189

edrecolomab    B-Antibody115027189
(    O
INN    O
)    O

TRAIL    O
and    O
its    O
receptors    O
have    O
been    O
used    O
as    O
the    O
targets    O
of    O
several    O
anti    O
-    O
cancer    O
therapeutics    O
since    O
the    O
mid-1990s    O
,    O
such    O
as    O
Mapatumumab    B-Antibody115027189
.    O

|    O
Abagovomab    B-Antibody115027189

The    O
boxed    O
warning    O
was    O
added    O
on    O
Feb.    O
19    O
,    O
2009    O
,    O
for    O
the    O
drug    O
efalizumab    B-Antibody115027189
(    O
Raptiva    O
,    O
marketed    O
in    O
the    O
U.S.    O
by    O
Genentech    O
,    O
and    O
marketed    O
in    O
Europe    O
by    O
Swiss    O
drugmaker    O
Merck    O
Serono    O
)    O
includes    O
a    O
statement    O
that    O
JC    O
virus    O
,    O
resulting    O
in    O
progressive    O
multifocal    O
leukoencephalopathy    O
,    O
developed    O
in    O
three    O
patients    O
who    O
received    O
efalizumab    O
in    O
clinical    O
trials    O
.    O

Two    O
drugs    O
that    O
target    O
T    O
cells    O
are    O
efalizumab    B-Antibody115027189
and    O
alefacept    O
.    O

Touted    O
as    O
a    O
drug    O
of    O
the    O
future    O
,    O
metelimumab    O
was    O
dropped    O
from    O
further    O
development    O
in    O
favour    O
of    O
fresolimumab    B-Antibody115027189
,    O
which    O
is    O
currently    O
being    O
developed    O
by    O
Genzyme    O
.    O

|    O
Tregalizumab    B-Antibody115027189

Zanolimumab    B-Antibody115027189
(    O
expected    O
trade    O
name    O
HuMax-CD4    B-Antibody115027189
)    O
is    O
a    O
human    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
and    O
an    O
immunosuppressive    O
drug    O
.    O

#    O
positive    O
LKM-1    B-Antibody115027189
(    O
typically    O
female    O
children    O
and    O
teenagers    O
;    O
disease    O
can    O
be    O
severe    O
)    O
,    O
LKM-2    B-Antibody115027189
or    O
LKM-3    B-Antibody115027189
;    O

|    O
Drozitumab    B-Antibody115027189

|    O
Tucotuzumab    B-Antibody115027189
celmoleukin    I-Antibody115027189

Telimomab    B-Antibody115027189
aritox    I-Antibody115027189

|    O
Rafivirumab    B-Antibody115027189

Siltuximab    B-Antibody115027189
is    O
approved    O
for    O
treatment    O
of    O
human    O
immunodeficiency    O
virus    O
-    O
negative    O
and    O
HHV-8-negative    O
patients    O
with    O
multicentric    O
Castleman    O
's    O
disease    O
.    O

|    O
Sevirumab    B-Antibody115027189

|    O
Bimagrumab    B-Antibody115027189

|    O
Placulumab    B-Antibody115027189

Smaller    O
doses    O
may    O
be    O
used    O
to    O
induce    O
salivation    O
in    O
order    O
to    O
collect    O
samples    O
of    O
saliva    O
,    O
for    O
instance    O
,    O
to    O
obtain    O
information    O
about    O
IgA    B-Antibody115027189
antibodies    O
.    O

Selective    O
deficiency    O
of    O
immunoglobulin    O
A    O
(    O
IgA    B-Antibody115027189
)    O

Systemic    O
vasculitis    O
due    O
to    O
tissue    O
deposition    O
of    O
IgA    B-Antibody115027189
-    O
containing    O
immune    O
complexes    O
.    O

Those    O
who    O
produced    O
envelope    O
specific    O
IgA    B-Antibody115027189
were    O
54%    O
more    O
likely    O
to    O
become    O
infected    O
,    O
but    O
no    O
more    O
susceptible    O
than    O
trial    O
subjects    O
receiving    O
the    O
placebo    O
.    O

For    O
example    O
,    O
those    O
that    O
bind    O
the    O
most    O
common    O
class    O
of    O
antibody    O
,    O
IgG    B-Antibody115027189
,    O
are    O
called    O
"    O
Fc    O
-    O
gamma    O
receptors    O
"    O
(    O
FcγR    O
)    O
,    O
those    O
that    O
bind    O
IgA    B-Antibody115027189
are    O
called    O
"    O
Fc    O
-    O
alpha    O
receptors    O
"    O
(    O
FcαR    O
)    O
and    O
those    O
that    O
bind    O
IgE    B-Antibody115027189
are    O
called    O
"    O
Fc    O
-    O
epsilon    O
receptors    O
"    O
(    O
FcεR    O
)    O
.    O

Most    O
Immunoglobulin    B-Antibody115027189
A    I-Antibody115027189
produced    O
by    O
tonsillar    O
B    O
cells    O
in    O
vitro    O
appears    O
to    O
be    O
7S    O
monomers    O
,    O
although    O
a    O
significant    O
proportion    O
may    O
be    O
l0S    O
dimeric    O
IgA.    O

Diets    O
lacking    O
sufficient    O
protein    O
are    O
associated    O
with    O
impaired    O
cell    O
-    O
mediated    O
immunity    O
,    O
complement    O
activity    O
,    O
phagocyte    O
function    O
,    O
IgA    B-Antibody115027189
antibody    O
concentrations    O
,    O
and    O
cytokine    O
production    O
.    O

It    O
has    O
been    O
studied    O
for    O
capturing    O
O    O
-    O
glycoproteins    O
such    O
as    O
mucins    O
and    O
IgA    B-Antibody115027189
,    O
for    O
potential    O
applications    O
in    O
human    O
immunology    O
.    O

|    O
IgA    B-Antibody115027189

Passive    O
immunity    O
is    O
also    O
provided    O
through    O
colostrum    O
and    O
breast    O
milk    O
,    O
which    O
contain    O
IgA    B-Antibody115027189
antibodies    O
that    O
are    O
transferred    O
to    O
the    O
gut    O
of    O
the    O
infant    O
,    O
providing    O
local    O
protection    O
against    O
disease    O
causing    O
bacteria    O
and    O
viruses    O
until    O
the    O
newborn    O
can    O
synthesize    O
its    O
own    O
antibodies    O
.    O

Ovine    O
uterine    O
serpin    O
also    O
binds    O
to    O
activin    O
,    O
IgM    B-Antibody115027189
and    O
IgA    B-Antibody115027189

Immunoglobulin    B-Antibody115027189
A    I-Antibody115027189
:    O
0.24(0.061    O
)    O

It    O
is    O
characterised    O
by    O
deposits    O
of    O
IgA    B-Antibody115027189
in    O
the    O
space    O
between    O
glomerular    O
capillaries    O
.    O

These    O
include    O
deficiency    O
in    O
CD27    O
+    O
B    O
memory    O
cells    O
,    O
overrepresentation    O
of    O
CD10    O
+    O
transitional    O
B    O
cells    O
,    O
expanded    O
effector    O
(    O
CCR7-    O
)    O
T    O
cells    O
,    O
expanded    O
CD57    O
+    O
senescent    O
CD8    O
+    O
T    O
cells    O
,    O
and    O
alterations    O
in    O
serum    O
immunoglobulin    O
concentrations    O
,    O
most    O
with    O
normal    O
to    O
elevated    O
concentrations    O
of    O
IgM    B-Antibody115027189
and    O
reduced    O
concentrations    O
of    O
IgA    B-Antibody115027189

CCL28    O
has    O
also    O
been    O
implicated    O
in    O
the    O
migration    O
of    O
IgA    B-Antibody115027189
-    O
expressing    O
cells    O
to    O
the    O
mammary    O
gland    O
,    O
salivary    O
gland    O
,    O
intestine    O
and    O
other    O
mucosal    O
tissues    O
.    O

While    O
most    O
of    O
these    O
early    O
studies    O
focused    O
on    O
IgM    O
and    O
IgG    O
,    O
other    O
immunoglobulin    O
isotypes    O
were    O
identified    O
in    O
the    O
1960s    O
:    O
Thomas    O
Tomasi    O
discovered    O
secretory    O
antibody    O
(    O
IgA    B-Antibody115027189
)    O
;    O
David    O
S.    O
Rowe    O
and    O
John    O
L.    O
Fahey    O
discovered    O
IgD    O
;    O
and    O
Kimishige    O
Ishizaka    O
and    O
Teruko    O
Ishizaka    O
discovered    O
IgE    B-Antibody115027189
and    O
showed    O
it    O
was    O
a    O
class    O
of    O
antibodies    O
involved    O
in    O
allergic    O
reactions    O
.    O

Finally    O
,    O
increased    O
biliary    O
pressure    O
decreases    O
production    O
of    O
IgA    B-Antibody115027189
immunoglobulins    O
in    O
the    O
bile    O
.    O

For    O
example    O
the    O
total    O
levels    O
of    O
antibodies    O
isotypes    O
or    O
classes    O
:    O
Immunoglobulin    B-Antibody115027189
M    I-Antibody115027189
,    O
Immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
,    O
and    O
Immunoglobulin    B-Antibody115027189
A    I-Antibody115027189
It    O
is    O
important    O
in    O
quantification    O
of    O
free    O
light    O
chains    O
in    O
diseases    O
such    O
as    O
multiple    O
myeloma    O
.    O

The    O
IgG    B-Antibody115027189
antibody    O
is    O
similar    O
to    O
AGA    O
IgA    B-Antibody115027189
,    O
but    O
is    O
found    O
at    O
higher    O
levels    O
in    O
patients    O
with    O
the    O
IgA    O
-    O
less    O
phenotype    O
.    O

SMIP    O
,    O
or    O
small    B-Antibody115027189
modular    I-Antibody115027189
immunopharmaceutical    I-Antibody115027189
,    O
therapeutics    O
are    O
single    O
chain    O
polypeptides    O
comprising    O
one    O
binding    O
domain    O
,    O
one    O
hinge    O
domain    O
and    O
one    O
effector    O
domain    O
designed    O
in    O
an    O
effort    O
to    O
meet    O
predetermined    O
therapeutic    O
specifications    O
for    O
specific    O
diseases    O
.    O

|    O
Imgatuzumab    B-Antibody115027189

Several    O
agents    O
are    O
in    O
clinical    O
trials    O
:    O
olokizumab    B-Antibody115027189
(    O
CDP6038    O
)    O
elsilimomab    B-Antibody115027189
,    O
BMS-945429    B-Antibody115027189
)    O
,    O
sirukumab    O
(    O
CNTO    O
136    O
)    O
,    O
and    O
CPSI-2364    O
an    O
apparent    O
macrophage    O
-    O
specific    O
inhibitor    O
of    O
the    O
p38    O
mitogen    O
-    O
activated    O
protein    O
kinase    O
pathway    O
.    O
ALX-0061    O
.    O

Reslizumab    B-Antibody115027189
is    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
against    O
human    O
interleukin-5(IL    O
5    O
)    O
.    O

Vorsetuzumab    B-Antibody115027189
mafodotin    I-Antibody115027189
(    O
antibody    O
conjugated    O
to    O
monomethyl    O
auristatin    O
F    O
)    O
.    O

The    O
Edmonton    O
protocol    O
uses    O
a    O
combination    O
of    O
immunosuppressive    O
drugs    O
,    O
including    O
daclizumab    B-Antibody115027189
(    O
Zenapax    O
)    O
,    O
sirolimus    O
(    O
Rapamune    O
)    O
and    O
tacrolimus    O
(    O
Prograf    O
)    O
.    O

Daclizumab    B-Antibody115027189

Daclizumab    B-Antibody115027189
(    O
trade    O
name    O
Zinbryta    B-Antibody115027189
,    O
by    O
Biogen    O
)    O
is    O
a    O
therapeutic    O
humanized    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
used    O
for    O
the    O
treatment    O
of    O
adults    O
with    O
relapsing    O
forms    O
of    O
multiple    O
sclerosis    O
(    O
MS    O
)    O
.    O

Anti    O
-    O
IL-2Rα    O
receptor    O
antibodies    O
such    O
as    O
basiliximab    B-Antibody115027189
and    O
daclizumab    B-Antibody115027189
are    O
increasingly    O
being    O
used    O
in    O
place    O
of    O
ATG    O
as    O
an    O
induction    O
therapy    O
,    O
as    O
they    O
do    O
not    O
cause    O
cytokine    O
release    O
syndrome    O
and    O
(    O
theoretically    O
)    O
improve    O
the    O
development    O
of    O
tolerance    O
.    O

Parsatuzumab    B-Antibody115027189
(    O
INN    O
)    O
is    O
a    O
humanized    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
cancer    O
.    O

Downregulation    O
of    O
DCX    O
begins    O
after    O
2    O
weeks    O
,    O
and    O
occurs    O
at    O
the    O
same    O
time    O
that    O
these    O
cells    O
begin    O
to    O
express    O
NeuN    B-Antibody115027189
,    O
a    O
marker    O
for    O
mature    O
neurons    O
.    O

mavrilimumab    B-Antibody115027189
(    O
INN    O
)    O

Toralizumab    B-Antibody115027189
(    O
IDEC    B-Antibody115027189
131    I-Antibody115027189
)    O
was    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
and    O
an    O
immunosuppressive    O
drug    O
.    O

|    O
Conatumumab    B-Antibody115027189

The    O
radioactive    O
isotope    O
yttrium-90    O
is    O
used    O
in    O
drugs    O
such    O
as    O
Yttrium    O
Y    O
90-DOTA    O
-    O
tyr3-octreotide    O
and    O
Yttrium    B-Antibody115027189
Y    I-Antibody115027189
90    I-Antibody115027189
ibritumomab    I-Antibody115027189
tiuxetan    I-Antibody115027189
for    O
the    O
treatment    O
of    O
various    O
cancers    O
,    O
including    O
lymphoma    O
,    O
leukemia    O
,    O
liver    O
,    O
ovarian    O
,    O
colorectal    O
,    O
pancreatic    O
and    O
bone    O
cancers    O
.    O

These    O
include    O
Zevalin    B-Antibody115027189
and    O
Bexxar    B-Antibody115027189
.    O

It    O
is    O
associated    O
with    O
mothers    O
who    O
carry    O
the    O
Ro/SSA    B-Antibody115027189
antibodies    O
.    O

|    O
anti-SS-A    B-Antibody115027189
(    O
Ro    O
)    O

|    O
Crenezumab    B-Antibody115027189

igovomab    B-Antibody115027189
(    O
INN    O
)    O

The    O
humanized    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
"    O
cantuzumab    O
"    O
(    O
huC242    O
)    O
is    O
linked    O
to    O
a    O
cytotoxic    O
agent    O
,    O
ravtansine    O
(    O
DM4    O
)    O
.    O

Usually    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
used    O
for    O
the    O
targeted    O
blockade    O
of    O
RTK    O
,    O
which    O
block    O
the    O
extracellular    O
domain    O
of    O
the    O
receptor    O
and    O
prevent    O
the    O
binding    O
of    O
a    O
ligand    O
.    O

Because    O
CD3    O
is    O
required    O
for    O
T    O
-    O
cell    O
activation    O
,    O
drugs    O
(    O
often    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
)    O
that    O
target    O
it    O
are    O
being    O
investigated    O
as    O
immunosuppressant    O
therapies    O
(    O
e.g.    O
,    O
otelixizumab    B-Antibody115027189
)    O
for    O
type    O
1    O
diabetes    O
and    O
other    O
autoimmune    O
diseases    O
.    O

2004    O
–    O
Avastin    B-Antibody115027189
(    O
bevacizumab    O
)    O
:    O
Anti    O
-    O
VEGF    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
for    O
the    O
treatment    O
of    O
metastatic    O
cancer    O
of    O
the    O
colon    O
or    O
rectum    O
.    O

Epitope    O
mapping    O
is    O
an    O
important    O
component    O
in    O
the    O
development    O
of    O
therapeutic    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
mAbs    O
)    O
and    O
vaccines    O
.    O

Monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
have    O
also    O
been    O
used    O
against    O
inhibitory    O
factors    O
such    O
as    O
NI-35    O
and    O
NOGO    O
.    O

recombinant    O
protein    O
,    O
or    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
)    O
.    O

Research    O
conducted    O
at    O
the    O
institute    O
has    O
contributed    O
to    O
discoveries    O
in    O
the    O
areas    O
of    O
recombinant    O
DNA    O
technology    O
,    O
gene    O
therapy    O
and    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

This    O
translation    O
of    O
basic    O
research    O
discoveries    O
into    O
clinical    O
applications    O
led    O
to    O
the    O
development    O
with    O
Innate    O
Pharma    O
of    O
a    O
first    O
-    O
in    O
-    O
class    O
therapeutic    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
to    O
KIR    O
(    O
lirilumab    B-Antibody115027189
)    O
,    O
the    O
efficacy    O
of    O
which    O
against    O
various    O
cancers    O
is    O
currently    O
being    O
assessed    O
.    O

Most    O
rheumatic    O
diseases    O
are    O
treated    O
with    O
analgesics    O
,    O
NSAIDs    O
(    O
Non    O
-    O
Steroid    O
Anti    O
-    O
Inflammatory    O
Drugs    O
)    O
,    O
steroids    O
(    O
in    O
serious    O
cases    O
)    O
,    O
DMARDs    O
(    O
Disease    O
-    O
Modifying    O
Anti    O
-    O
Rheumatic    O
Drugs    O
)    O
,    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
such    O
as    O
infliximab    O
and    O
adalimumab    B-Antibody115027189
,    O
and    O
the    O
soluble    O
TNF    O
receptor    O
etanercept    O
and    O
Methotrexate    O
for    O
moderate    O
to    O
severe    O
Rheumatoid    O
arthritis    O
.    O

Typically    O
,    O
these    O
receptors    O
are    O
used    O
to    O
graft    O
the    O
specificity    O
of    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
onto    O
a    O
T    O
cell    O
,    O
with    O
transfer    O
of    O
their    O
coding    O
sequence    O
facilitated    O
by    O
retroviral    O
vectors    O
.    O

Unlike    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
which    O
are    O
often    O
produced    O
in    O
mammalian    O
cell    O
cultures    O
,    O
scFvs    O
are    O
more    O
often    O
produced    O
in    O
bacteria    O
cell    O
cultures    O
such    O
as    O
"    O
E.    O
coli    O
"    O
.    O

Etanercept    O
was    O
developed    O
by    O
researchers    O
at    O
Immunex    O
,    O
and    O
was    O
released    O
for    O
commercial    O
use    O
in    O
late    O
1998    O
,    O
soon    O
after    O
the    O
release    O
of    O
infliximab    O
(    O
"    O
Remicade    O
"    O
)    O
,    O
which    O
was    O
the    O
first    O
chimeric    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
against    O
TNFα    O
to    O
be    O
marketed    O
for    O
clinical    O
use    O
.    O

Anti    O
-    O
TNF    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189

Several    O
such    O
products    O
are    O
being    O
developed    O
,    O
including    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

#    O
Monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

Monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
Various    O
)    O

Mertansine    O
,    O
also    O
called    O
DM1    O
(    O
and    O
in    O
some    O
of    O
its    O
forms    O
emtansine    O
)    O
,    O
is    O
a    O
thiol    O
-    O
containing    O
maytansinoid    O
that    O
for    O
therapeutic    O
purposes    O
is    O
attached    O
to    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
through    O
reaction    O
of    O
the    O
thiol    O
group    O
with    O
a    O
linker    O
structure    O
to    O
create    O
an    O
antibody    O
-    O
drug    O
conjugate    O
(    O
ADC    O
)    O
.    O

Mertansine    O
linked    O
to    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
(    O
mab    O
)    O
.    O

The    O
term    O
pegol    O
in    O
the    O
names    O
of    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
indicates    O
pegylation    O
,    O
as    O
in    O
:    O

The    O
term    O
aritox    O
occurs    O
in    O
names    O
of    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
and    O
indicates    O
that    O
they    O
are    O
linked    O
to    O
an    O
A    O
chain    O
of    O
the    O
ricin    O
protein    O
.    O

The    O
term    O
ozogamicin    O
in    O
the    O
names    O
of    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
or    O
antibody    O
-    O
drug    O
conjugates    O
indicates    O
that    O
they    O
are    O
linked    O
to    O
a    O
cytotoxic    O
agent    O
from    O
the    O
class    O
of    O
calicheamicins    O
,    O
as    O
in    O
:    O

Omalizumab    O
is    O
a    O
recombinant    O
DNA    O
-    O
derived    O
humanized    O
IgG1k    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
that    O
specifically    O
binds    O
to    O
free    O
human    O
immunoglobulin    B-Antibody115027189
E    I-Antibody115027189
(    O
IgE    O
)    O
in    O
the    O
blood    O
and    O
interstitial    O
fluid    O
and    O
to    O
membrane    O
-    O
bound    O
form    O
of    O
IgE    O
(    O
mIgE    O
)    O
on    O
the    O
surface    O
of    O
mIgE    O
-    O
expressing    O
B    O
lymphocytes    O
.    O

Libraries    O
of    O
genes    O
and    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
maintained    O
in    O
phages    O
.    O

This    O
method    O
is    O
used    O
to    O
produce    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

Biological    O
products    O
produced    O
by    O
recombinant    O
DNA    O
(    O
rDNA    O
)    O
technology    O
in    O
animal    O
cell    O
cultures    O
include    O
enzymes    O
,    O
synthetic    O
hormones    O
,    O
immunobiologicals    O
(    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
interleukins    O
,    O
lymphokines    O
)    O
,    O
and    O
anticancer    O
agents    O
.    O

Polyclonal    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
pAbs    O
)    O
are    O
antibodies    O
that    O
are    O
secreted    O
by    O
different    O
B    O
cell    O
lineages    O
within    O
the    O
body    O
(    O
whereas    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
come    O
from    O
a    O
single    O
cell    O
lineage    O
)    O
.    O

By    O
contrast    O
,    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
derived    O
from    O
a    O
single    O
cell    O
line    O

Today    O
CIM    O
produces    O
biopharmaceutical    O
products    O
,    O
such    O
as    O
anti    O
-    O
CD3    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
for    O
the    O
treatment    O
of    O
patients    O
with    O
organ    O
transplant    O
rejection    O
,    O
human    O
recombinant    O
erythropoietin    O
for    O
the    O
treatment    O
of    O
anemia    O
,    O
granulocyte    O
colony    O
-    O
stimulating    O
factor    O
for    O
the    O
treatment    O
of    O
neutropenia    O
,    O
and    O
a    O
humanized    O
monoclonal    O
antibody    O
that    O
recognizes    O
the    O
epidermal    O
growth    O
factor    O
receptor    O
for    O
cancer    O
treatment    O
,    O
as    O
well    O
as    O
other    O
monoclonal    O
antibodies    O
for    O
tumor    O
imaging    O
.    O

Since    O
1992    O
CIMAB    O
S.A.    O
has    O
been    O
devoted    O
to    O
the    O
commercialization    O
of    O
biopharmaceutical    O
products    O
for    O
the    O
Cuban    O
market    O
and    O
abroad    O
,    O
especially    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
and    O
other    O
recombinant    O
proteins    O
for    O
the    O
diagnosis    O
and    O
treatment    O
of    O
cancer    O
and    O
other    O
diseases    O
related    O
to    O
the    O
immune    O
system    O
.    O

Mice    O
injected    O
with    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
targeting    O
IL-17    O
blocked    O
,    O
or    O
neutralized    O
,    O
down    O
stream    O
signaling    O
of    O
this    O
cytokine    O
and    O
decreased    O
epidermal    O
hyperplasia    O
.    O

In    O
January    O
2015    O
,    O
the    O
FDA    O
approved    O
the    O
use    O
of    O
secukinumab    O
(    O
trade    O
name    O
Cosentyx    O
)    O
,    O
an    O
IL-17    O
inhibiting    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
,    O
for    O
the    O
treatment    O
of    O
moderate    O
to    O
severe    O
plaque    O
psoriasis    O
.    O

Epitomics    O
was    O
a    O
privately    O
held    O
biotech    O
company    O
in    O
San    O
Francisco    O
,    O
California    O
(    O
US    O
)    O
and    O
Hangzhou    O
(    O
China    O
)    O
that    O
focused    O
on    O
the    O
development    O
,    O
production    O
,    O
and    O
distribution    O
of    O
rabbit    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
for    O
biomedical    O
research    O
and    O
diagnostic    O
applications    O
.    O

It    O
works    O
by    O
adhering    O
to    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
which    O
in    O
turn    O
bind    O
to    O
cancer    O
cells    O
and    O
kill    O
them    O
via    O
intense    O
β-radiation    O
from    O
the    O
yttrium-90    O
(    O
see    O
Monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
therapy    I-Antibody115027189
)    O
.    O

A    O
number    O
of    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
being    O
studied    O
as    O
treatments    O
including    O
dupilumab    B-Antibody115027189
.    O

Because    O
ricin    O
is    O
a    O
protein    O
,    O
it    O
can    O
be    O
linked    O
to    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
to    O
target    O
cancerous    O
cells    O
recognized    O
by    O
the    O
antibody    O
.    O

Abituzumab    O
is    O
a    O
humanized    O
IgG2    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
(    O
mAb    O
)    O
targeted    O
at    O
CD51    O
(    O
an    O
integrin    O
)    O
currently    O
in    O
development    O
by    O
Merck    O
KGaA    O
Darmstadt    O
,    O
Germany    O
in    O
an    O
attempt    O
to    O
prevent    O
bone    O
lesion    O
metastases    O
in    O
castration    O
-    O
resistant    O
prostate    O
cancer    O
.    O

It    O
is    O
a    O
human    O
IgG4    B-Antibody115027189
anti    O
-    O
PD-1    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
.    O

He    O
is    O
best    O
known    O
for    O
the    O
motion    O
analysis    O
of    O
living    O
cells    O
,    O
the    O
discovery    O
of    O
"    O
Candida    O
albicans    O
"    O
phenotypic    O
switching    O
and    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
technology    O
.    O

It    O
is    O
targeted    O
through    O
immunotherapy    O
in    O
neuroblastoma    O
treatment    O
using    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

Atezolizumab    O
(    O
trade    O
name    O
Tecentriq    O
)    O
is    O
a    O
fully    O
humanized    O
,    O
engineered    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
of    O
IgG1    B-Antibody115027189
isotype    O
against    O
the    O
protein    O
programmed    O
cell    O
death    O
-    O
ligand    O
1    O
(    O
PD    O
-    O
L1    O
)    O
.    O

The    O
American    O
biotech    O
company    O
Celldex    O
Therapeutics    O
is    O
working    O
on    O
CDX-1127    O
,    O
an    O
agonistic    O
anti    O
-    O
CD27    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
which    O
in    O
animal    O
models    O
has    O
been    O
shown    O
to    O
be    O
effective    O
in    O
the    O
context    O
of    O
T    O
cell    O
receptor    O
stimulation    O
.    O

It    O
is    O
a    O
human    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
that    O
belongs    O
to    O
a    O
novel    O
class    O
of    O
anti    O
-    O
cholesterol    O
drugs    O
,    O
known    O
as    O
PCSK9    O
inhibitors    O
,    O
and    O
it    O
was    O
the    O
first    O
such    O
agent    O
to    O
receive    O
FDA    O
approval    O
.    O

Alirocumab    O
is    O
a    O
human    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
of    O
the    O
IgG1    O
isotype    O
.    O

:    O
Trials    O
began    O
in    O
2015    O
to    O
evaluate    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
to    O
be    O
used    O
as    O
a    O
possible    O
complementary    O
treatment    O
for    O
humans    O
exposed    O
to    O
Hendra    O
virus    O
infected    O
horses    O
.    O

Benralizumab    B-Antibody115027189
(    O
INN    O
,    O
trade    O
name    O
Fasenra    B-Antibody115027189
)    O
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
which    O
is    O
being    O
developed    O
by    O
MedImmune    O
for    O
the    O
treatment    O
of    O
asthma    O
.    O

Researchers    O
looking    O
at    O
slides    O
of    O
cultures    O
of    O
cells    O
that    O
make    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

Early    O
CLL    O
is    O
not    O
treated    O
,    O
and    O
late    O
CLL    O
is    O
treated    O
with    O
chemotherapy    O
and    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

Priliximab    O
(    O
cMT    O
412    O
)    O
is    O
a    O
human    O
-    O
mouse    O
chimeric    O
anti    O
-    O
CD4    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
.    O

Four    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
MAbs    O
)    O
(    O
infliximab    O
,    O
adalimumab    B-Antibody115027189
,    O
golimumab    B-Antibody115027189
,    O
and    O
certolizumab    B-Antibody115027189
pegol    I-Antibody115027189
)    O
and    O
one    O
recombinant    O
TNF-α    O
decoy    O
receptor    O
,    O
etanercept    O
,    O
have    O
been    O
developed    O
to    O
inhibit    O
TNF-α    O
signaling    O
.    O

This    O
method    O
uses    O
either    O
naturally    O
occurring    O
lectins    O
or    O
artificial    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
where    O
both    O
are    O
immobilized    O
on    O
a    O
certain    O
chip    O
and    O
incubated    O
with    O
a    O
fluorescent    O
glycoprotein    O
sample    O
.    O

The    O
process    O
of    O
"    O
humanization    O
"    O
is    O
usually    O
applied    O
to    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
developed    O
for    O
administration    O
to    O
humans    O
(    O
for    O
example    O
,    O
antibodies    O
developed    O
as    O
anti    O
-    O
cancer    O
drugs    O
)    O
.    O

Artificially    O
acquired    O
passive    O
immunity    O
is    O
a    O
short    O
-    O
term    O
immunization    O
achieved    O
by    O
the    O
transfer    O
of    O
antibodies    O
,    O
which    O
can    O
be    O
administered    O
in    O
several    O
forms    O
;    O
as    O
human    O
or    O
animal    O
blood    O
plasma    O
or    O
serum    O
,    O
as    O
pooled    O
human    O
immunoglobulin    O
for    O
intravenous    O
(    O
IVIG    B-Antibody115027189
)    O
or    O
intramuscular    O
(    O
IG    O
)    O
use    O
,    O
as    O
high    O
-    O
titer    O
human    O
IVIG    O
or    O
IG    O
from    O
immunized    O
donors    O
or    O
from    O
donors    O
recovering    O
from    O
the    O
disease    O
,    O
and    O
as    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
MAb    O
)    O
.    O

It    O
is    O
a    O
recombinant    O
humanized    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
that    O
was    O
discovered    O
and    O
developed    O
by    O
Napoleone    O
Ferrara    O
.    O
a    O
scientist    O
at    O
Genentech    O
.    O

Rontalizumab    B-Antibody115027189
is    O
a    O
humanized    B-Antibody115027189
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
being    O
developed    O
by    O
Genentech    O
.    O

For    O
instance    O
,    O
emerging    O
promising    O
targeted    O
drug    O
therapies    O
,    O
antibody    O
-    O
drug    O
conjugates    O
,    O
are    O
constituted    O
of    O
three    O
main    O
components    O
:    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
,    O
a    O
cytotoxic    O
drug    O
,    O
and    O
a    O
linker    O
molecule    O
often    O
containing    O
a    O
maleimide    O
group    O
,    O
which    O
binds    O
the    O
drug    O
and    O
the    O
antibody    O
.    O

Recombinant    O
antibodies    O
are    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
generated    O
in    O
vitro    O
using    O
synthetic    O
genes    O
.    O

The    O
monoclonal    B-Antibody115027189
anti    O
-    O
T    O
cell    O
antibody    O
OKT3    B-Antibody115027189
,    O
once    O
used    O
to    O
prevent    O
rejection    O
,    O
and    O
still    O
occasionally    O
used    O
to    O
treat    O
severe    O
acute    O
rejection    O
,    O
has    O
fallen    O
into    O
disfavor    O
,    O
as    O
it    O
commonly    O
brings    O
severe    O
cytokine    O
release    O
syndrome    O
and    O
late    O
post    O
-    O
transplant    O
lymphoproliferative    O
disorder    O
.    O

Daclizumab    B-Antibody115027189
(    O
trade    O
name    O
Zinbryta    B-Antibody115027189
,    O
by    O
Biogen    O
)    O
is    O
a    O
therapeutic    O
humanized    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
used    O
for    O
the    O
treatment    O
of    O
adults    O
with    O
relapsing    O
forms    O
of    O
multiple    O
sclerosis    O
(    O
MS    O
)    O
.    O

Cytokine    O
release    O
syndrome    O
is    O
an    O
adverse    O
effect    O
of    O
some    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
drugs    O
,    O
as    O
well    O
as    O
adoptive    O
T    O
-    O
cell    O
therapies    O
.    O

The    O
CD33    O
antibody    O
is    O
attached    O
to    O
a    O
potent    O
DNA    O
binding    O
agent    O
,    O
a    O
pyrrolobenzodiazepine    O
(    O
PBD    O
)    O
dimer    O
(    O
SGD-1882    O
)    O
,    O
via    O
a    O
cleavable    O
(    O
valine    O
-    O
alanine    O
dipeptide    O
as    O
cathepsin    O
B    O
cleavage    O
site    O
)    O
maleimidocaproyl    O
type    O
linker    O
,    O
to    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
with    O
engineered    O
cysteines    O
(    O
EC    O
-    O
mAb    O
)    O
.    O

It    O
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
that    O
binds    O
to    O
CD52    O
,    O
a    O
protein    O
present    O
on    O
the    O
surface    O
of    O
mature    O
lymphocytes    O
,    O
but    O
not    O
on    O
the    O
stem    O
cells    O
from    O
which    O
these    O
lymphocytes    O
are    O
derived    O
.    O

Like    O
the    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
belimumab    B-Antibody115027189
,    O
atacicept    O
blocks    O
the    O
binding    O
of    O
BLyS    O
,    O
but    O
it    O
also    O
blocks    O
APRIL    O
.    O

Few    O
PD    O
-    O
L1    O
inhibitors    O
have    O
been    O
approved    O
for    O
use    O
to    O
date    O
,    O
though    O
extensive    O
target    O
validation    O
has    O
been    O
shown    O
through    O
phase    O
II    O
and    O
III    O
clinical    O
trials    O
using    O
different    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
therapies    O
.    O

Immunoscintigraphy    O
incorporates    O
99mTc    O
into    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
,    O
an    O
immune    O
system    O
protein    O
,    O
capable    O
of    O
binding    O
to    O
cancer    O
cells    O
.    O

The    O
drugs    O
to    O
treat    O
RA    O
range    O
from    O
corticosteroids    O
to    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
given    O
intravenously    O
.    O

An    O
abzyme    B-Antibody115027189
(    O
from    O
antibody    O
and    O
enzyme    O
)    O
,    O
also    O
called    O
"    O
catmab    O
"    O
(    O
from    O
"    O
catalytic    O
monoclonal    O
antibody    O
"    O
)    O
,    O
and    O
most    O
often    O
called    O
"    O
catalytic    O
antibody    O
"    O
,    O
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
with    O
catalytic    O
activity    O
.    O

The    O
activation    O
of    O
natural    O
killer    O
cells    O
by    O
antibodies    O
initiates    O
a    O
cytotoxic    O
mechanism    O
known    O
as    O
antibody    O
-    O
dependent    O
cell    O
-    O
mediated    O
cytotoxicity    O
(    O
ADCC    O
)    O
–    O
this    O
process    O
may    O
explain    O
the    O
efficacy    O
of    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
used    O
in    O
biological    O
therapies    O
against    O
cancer    O
.    O

In    O
contrast    O
,    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
monovalent    O
for    O
the    O
same    O
epitope    O
.    O

Single    O
hybridoma    O
cells    O
are    O
isolated    O
by    O
dilution    O
cloning    O
to    O
generate    O
cell    O
clones    O
that    O
all    O
produce    O
the    O
same    O
antibody    O
;    O
these    O
antibodies    O
are    O
called    O
"    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
"    O
.    O

Monoclonal    B-Antibody115027189
antibody    I-Antibody115027189

Monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
:    O
Anti    O
-    O
CD3    O

M13    O
phage    O
-    O
malformation    O
-    O
mapping    O
-    O
marker    O
-    O
melanoma    O
-    O
melting    O
-    O
Johann    O
Mendel    O
-    O
Mendelian    O
inheritance    O
-    O
message    O
-    O
messenger    O
RNA    O
-    O
metaphase    O
-    O
microarray    O
technology    O
-    O
microsatellite    O
-    O
missense    O
mutation    O
-    O
mitochondrial    O
DNA    O
-    O
mobility    O
shift    O
-    O
molecular    O
weight    O
size    O
marker    O
-    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
-    O
monosomy    O
-    O
mouse    O
model    O
-    O
mRNA    O
-    O
multicistronic    O
message    O
-    O
multicopy    O
plasmid    O
-    O
multiple    O
cloning    O
site    O
-    O
multiple    O
endocrine    O
neoplasia    O
,    O
type    O
1    O
-    O
mutation    O
-    O

Briakinumab    B-Antibody115027189
(    O
ABT-874    B-Antibody115027189
)    O
is    O
a    O
human    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
being    O
developed    O
by    O
Abbott    O
Laboratories    O
for    O
the    O
treatment    O
of    O
rheumatoid    O
arthritis    O
,    O
inflammatory    O
bowel    O
disease    O
,    O
and    O
multiple    O
sclerosis    O
.    O

Only    O
in    O
the    O
last    O
10    O
years    O
of    O
it    O
existence    O
were    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
and    O
molecular    O
approaches    O
adopted    O
.    O

1975    O
–    O
Method    O
for    O
producing    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
developed    O
by    O
Köhler    O
and    O
César    O
Milstein    O
.    O

After    O
developing    O
an    O
immune    O
response    O
,    O
B    O
-    O
cells    O
from    O
mice    O
can    O
be    O
fused    O
with    O
immortalizing    O
cells    O
to    O
form    O
a    O
hybridoma    O
that    O
produces    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
Mab    O
or    O
MoAb    O
)    O
.    O

Vapaliximab    B-Antibody115027189
is    O
a    O
chimeric    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
and    O
an    O
immunosuppressive    O
drug    O
.    O

The    O
protein    O
sequences    O
of    O
antibodies    O
produced    O
in    O
this    O
way    O
are    O
partially    O
distinct    O
from    O
homologous    O
antibodies    O
occurring    O
naturally    O
in    O
humans    O
,    O
and    O
are    O
therefore    O
potentially    O
immunogenic    O
when    O
administered    O
to    O
human    O
patients    O
(    O
see    O
also    O
Human    B-Antibody115027189
anti-mouse    I-Antibody115027189
antibody    I-Antibody115027189
)    O
.    O

Different    O
antibody    O
idiotypes    B-Antibody115027189
,    O
each    O
have    O
distinctly    O
formed    O
complementarity    O
determining    O
regions    O
.    O

Blincyto    B-Antibody115027189
(Blinatumomab)    I-Antibody115027189
(    O
for    O
the    O
treatment    O
of    O
acute    O
lymphoblastic    O
leukemia    O
)    O
.    O

First    O
line    O
treatment    O
for    O
aplastic    O
anemia    O
consists    O
of    O
immunosuppressive    O
drugs    O
,    O
typically    O
either    O
anti-lymphocyte    B-Antibody115027189
globulin    I-Antibody115027189
or    O
anti-thymocyte    B-Antibody115027189
globulin    I-Antibody115027189
,    O
combined    O
with    O
corticosteroids    O
and    O
ciclosporin    O
.    O

Medical    O
therapy    O
of    O
aplastic    O
anemia    O
often    O
includes    O
a    O
course    O
of    O
antithymocyte    B-Antibody115027189
globulin    I-Antibody115027189
(    O
ATG    O
)    O
and    O
several    O
months    O
of    O
treatment    O
with    O
ciclosporin    O
to    O
modulate    O
the    O
immune    O
system    O
.    O

First    O
line    O
treatment    O
for    O
aplastic    O
anemia    O
consists    O
of    O
immunosuppressive    O
drugs    O
,    O
typically    O
either    O
anti-lymphocyte    B-Antibody115027189
globulin    I-Antibody115027189
or    O
anti-thymocyte    B-Antibody115027189
globulin    I-Antibody115027189
,    O
combined    O
with    O
corticosteroids    O
and    O
ciclosporin    O
.    O

gavilimomab    B-Antibody115027189
(    O
INN    O
)    O

Ocaratuzumab    B-Antibody115027189
(    O
AME-133v    O
,    O
LY2469298    O
)    O
is    O
a    O
humanized    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
cancer    O
and    O
autoimmune    O
disorders    O
.    O

This    O
follows    O
in    O
the    O
wake    O
of    O
Crucell    O
's    O
discovery    O
of    O
CR6261    B-Antibody115027189
,    O
a    O
potent    O
human    O
antibody    O
that    O
neutralizes    O
a    O
broad    O
range    O
of    O
influenza    O
A    O
viruses    O
.    O

detumomab    B-Antibody115027189
(    O
INN    O
)    O

#    O
positive    O
LKM-1    B-Antibody115027189
(    O
typically    O
female    O
children    O
and    O
teenagers    O
;    O
disease    O
can    O
be    O
severe    O
)    O
,    O
LKM-2    B-Antibody115027189
or    O
LKM-3    B-Antibody115027189
;    O

Anti-cholesterol    B-Antibody115027189
is    O
a    O
naturally    O
occurring    O
antibody    O
to    O
cholesterol    O
produced    O
by    O
mammals    O
.    O

The    O
immediate    O
products    O
of    O
these    O
systems    O
are    O
antibody    O
fragments    O
,    O
normally    O
Fab    B-Antibody115027189
or    O
scFv    B-Antibody115027189
)    O
.    O

The    O
ability    O
to    O
manipulate    O
the    O
antibody    O
genes    O
makes    O
it    O
possible    O
to    O
generate    O
new    O
antibodies    O
and    O
antibody    O
fragments    O
,    O
such    O
as    O
Fab    B-Antibody115027189
fragments    I-Antibody115027189
and    O
scFv    B-Antibody115027189
in    O
vitro    O
.    O

Secreted    O
by    O
an    O
activated    O
B    O
cell    O
,    O
then    O
called    O
plasma    O
cell    O
,    O
an    O
antibody    O
molecule    O
is    O
a    O
soluble    O
immunoglobulin    O
(    O
Ig    O
)    O
whose    O
basic    O
unit    O
is    O
shaped    O
like    O
the    O
letter    O
"    O
Y    O
"    O
:    O
the    O
two    O
arms    O
are    O
the    O
Fab    B-Antibody115027189
regions    I-Antibody115027189
,    O
while    O
the    O
single    O
stalk    O
is    O
the    O
Fc    B-Antibody115027189
region    I-Antibody115027189
.    O

The    O
targeting    O
portion    O
is    O
composed    O
of    O
the    O
Fab    B-Antibody115027189
portion    I-Antibody115027189
of    I-Antibody115027189
an    I-Antibody115027189
antibody    I-Antibody115027189
that    O
targets    O
a    O
specific    O
cell    O
type    O
.    O

At    O
the    O
molecular    O
level    O
,    O
an    O
antigen    O
can    O
be    O
characterized    O
by    O
its    O
ability    O
to    O
bind    O
to    O
an    O
antibody    O
's    O
variable    B-Antibody115027189
Fab    I-Antibody115027189
region    I-Antibody115027189
.    O

The    O
antibody    O
recognizes    O
a    O
unique    O
molecule    O
of    O
the    O
pathogen    O
,    O
called    O
an    O
antigen    O
,    O
via    O
the    O
Fab's    B-Antibody115027189
variable    I-Antibody115027189
region    I-Antibody115027189
.    O

IgE    O
's    O
Fab    B-Antibody115027189
paratope    O
binds    O
to    O
allergic    O
antigen    O
,    O
for    O
example    O
house    O
dust    O
mite    O
particles    O
,    O
while    O
its    O
Fc    O
region    O
binds    O
to    O
Fc    O
receptor    O
ε.    O
The    O
allergen    O
-    O
IgE    O
-    O
FcRε    O
interaction    O
mediates    O
allergic    O
signal    O
transduction    O
to    O
induce    O
conditions    O
such    O
as    O
asthma    O
.    O

This    O
region    O
of    O
the    O
antibody    O
is    O
called    O
the    O
"    O
Fab    B-Antibody115027189
(fragment,    I-Antibody115027189
antigen-binding)    I-Antibody115027189
region    I-Antibody115027189
"    O
.    O

Each    O
Ig    O
unit    O
(    O
labeled    O
1    O
)    O
has    O
two    O
epitope    O
binding    O
Fab    B-Antibody115027189
region    I-Antibody115027189
,    O
so    O
IgM    O
is    O
capable    O
of    O
binding    O
up    O
to    O
10    O
epitopes    O
.    O

|    O
Robatumumab    B-Antibody115027189

FI6    B-Antibody115027189
is    O
an    O
antibody    O
that    O
targets    O
a    O
protein    O
found    O
on    O
the    O
surface    O
of    O
all    O
influenza    O
A    O
viruses    O
called    O
hemagglutinin    O
.    O

|    O
Anti-sp100    B-Antibody115027189
antibodies    I-Antibody115027189

Anti    B-Antibody115027189
Scl-70    I-Antibody115027189
antibodies    I-Antibody115027189
(    O
also    O
called    O
"    O
anti-topoisomerase    B-Antibody115027189
I    I-Antibody115027189
"    O
after    O
the    O
type    O
I    O
topoisomerase    O
target    O
)    O
is    O
a    O
type    O
of    O
anti-nuclear    B-Antibody115027189
autoantibody    I-Antibody115027189
seen    O
mainly    O
in    O
diffuse    O
systemic    O
scleroderma    O
,    O
but    O
is    O
also    O
seen    O
the    O
more    O
limited    O
form    O
of    O
systemic    O
scleroderma    O
called    O
CREST    O
syndrome    O
.    O

A    O
boxed    O
warning    O
for    O
brentuximab    B-Antibody115027189
vedotin    I-Antibody115027189
(    O
Adcetris    O
)    O
was    O
issued    O
by    O
the    O
FDA    O
on    O
January    O
13    O
,    O
2011    O
after    O
two    O
cases    O
of    O
PML    O
were    O
reported    O
,    O
bringing    O
the    O
total    O
number    O
of    O
associated    O
cases    O
to    O
three    O
.    O

The    O
second    O
and    O
third    O
marketed    O
ADCs    O
are    O
Brentuximab    B-Antibody115027189
vedotin    I-Antibody115027189
(    O
trade    O
name    O
:    O
Adcetris®    O
,    O
marketed    O
by    O
Seattle    O
Genetics    O
and    O
Millennium    O
/    O
Takeda    O
)    O
and    O
Trastuzumab    B-Antibody115027189
emtansine    I-Antibody115027189
(    O
trade    O
name    O
:    O
Kadcyla    O
,    O
marketed    O
by    O
Genentech    O
and    O
Roche    O
)    O
.    O

Brentuximab    B-Antibody115027189
vedotin    I-Antibody115027189
was    O
granted    O
accelerated    O
approval    O
by    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
on    O
August    O
19    O
,    O
2011    O
for    O
relapsed    O
HL    O
and    O
relapsed    O
sALCL    O
and    O
conditional    O
Marketing    O
authorization    O
from    O
the    O
European    O
Medicines    O
Agency    O
in    O
October    O
2012    O
for    O
relapsed    O
or    O
refractory    O
HL    O
and    O
relapsed    O
or    O
refractory    O
sALCL    O
.    O

Brentuximab    B-Antibody115027189
vedotin    I-Antibody115027189
includes    O
an    O
enzyme    O
-    O
sensitive    O
"    O
cleavable    O
linker    O
"    O
that    O
delivers    O
the    O
potent    O
and    O
highly    O
toxic    O
antimicrotubule    O
agent    O
monomethyl    O
auristatin    O
E    O
or    O
MMAE    O
,    O
a    O
synthetic    O
antineoplastic    O
agent    O
,    O
to    O
human    O
specific    O
CD30-positive    O
malignant    O
cells    O
.    O

|    O
Namilumab    B-Antibody115027189

faralimomab    B-Antibody115027189
(    O
INN    O
)    O

:    O
:    O
:    O
:    O
Framework    B-Antibody115027189
region    I-Antibody115027189

Lumiliximab    B-Antibody115027189
is    O
an    O
IgG1k    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
that    O
targets    O
CD23    O
.    O

morolimumab    B-Antibody115027189
(    O
INN    O
)    O

Zolimomab    B-Antibody115027189
aritox    I-Antibody115027189

Synthetic    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
affinity    O
reagents    O
generated    O
entirely    O
in    O
vitro    O
,    O
thus    O
completely    O
eliminating    O
animals    O
from    O
the    O
production    O
process    O
.    O

|    O
Eldelumab    B-Antibody115027189

In    O
the    O
next    O
year    O
,    O
the    O
company    O
converted    O
one    O
candidate    O
antibody    O
to    O
a    O
chimeric    O
antibody    O
(    O
which    O
was    O
later    O
named    O
CGP51901    O
and    O
further    O
developed    O
into    O
a    O
humanized    O
antibody    O
,    O
TNX-901    B-Antibody115027189
or    O
talizumab    B-Antibody115027189
)    O
.    O

Ocrelizumab    B-Antibody115027189
,    O
ofatumumab    B-Antibody115027189
and    O
"    O
third    O
generation    O
"    O
anti    O
-    O
CD20    O
monoclonals    O
are    O
in    O
development    O
.    O

Ofatumumab    B-Antibody115027189
(    O
HuMax    O
-    O
CD20    O
)    O
a    O
fully    O
human    O
antibody    O
that    O
is    O
directed    O
against    O
CD20    O

Rituximab    B-Antibody115027189
,    O
ofatumumab    B-Antibody115027189
,    O
and    O
obinutuzumab    B-Antibody115027189
are    O
antibodies    O
against    O
CD20    O
used    O
to    O
treat    O
CLL    O
.    O

|    O
Radretumab    B-Antibody115027189

|    O
Felvizumab    B-Antibody115027189

Three    O
types    O
of    O
bispecific    O
antibodies    O
:    O
trifunctional    B-Antibody115027189
antibody    I-Antibody115027189
,    O
chemically    B-Antibody115027189
linked    I-Antibody115027189
Fab    I-Antibody115027189
and    O
bi-specific    B-Antibody115027189
T-cell    I-Antibody115027189
engager    I-Antibody115027189
(    O
bottom    O
row    O
)    O
.    O

|    O
Icrucumab    B-Antibody115027189

When    O
adopting    O
a    O
gluten    O
-    O
free    O
diet    O
,    O
disease    O
severity    O
generally    O
decreases    O
in    O
people    O
with    O
celiac    O
disease    O
and    O
those    O
with    O
anti-gliadin    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

Anti-gliadin    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
produced    O
in    O
response    O
to    O
gliadin    O
,    O
a    O
prolamin    O
found    O
in    O
wheat    O
.    O

eculizumab    B-Antibody115027189
(    O
USAN    O
)    O

David    O
L.    O
Hallal    O
,    O
B.A.    O
in    O
psychology    O
,    O
President    O
and    O
CEO    O
Alexion    O
Pharmaceuticals    O
,    O
best    O
known    O
for    O
its    O
development    O
of    O
Soliris    B-Antibody115027189

In    O
such    O
cases    O
treatment    O
with    O
the    O
complement    O
-    O
inhibitory    O
anti    O
-    O
C5    O
monoclonal    O
antibody    O
,    O
eculizumab    B-Antibody115027189
,    O
is    O
found    O
to    O
be    O
highly    O
effective    O
.    O

An    O
abzyme    B-Antibody115027189
(    O
from    O
antibody    O
and    O
enzyme    O
)    O
,    O
also    O
called    O
"    O
catmab    O
"    O
(    O
from    O
"    O
catalytic    O
monoclonal    O
antibody    O
"    O
)    O
,    O
and    O
most    O
often    O
called    O
"    O
catalytic    O
antibody    O
"    O
,    O
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
with    O
catalytic    O
activity    O
.    O

|    O
Cixutumumab    B-Antibody115027189

Neutralisation    B-Antibody115027189
,    O
in    O
which    O
neutralizing    B-Antibody115027189
antibodies    I-Antibody115027189
block    O
parts    O
of    O
the    O
surface    O
of    O
a    O
bacterial    O
cell    O
or    O
virion    O
to    O
render    O
its    O
attack    O
ineffective    O

Blood    O
samples    O
,    O
nasal    O
swabs    O
and    O
semen    O
can    O
be    O
used    O
for    O
isolation    O
of    O
the    O
virus    O
,    O
detection    O
of    O
the    O
viral    O
RNA    O
by    O
polymerase    O
chain    O
reaction    O
(    O
PCR    O
)    O
,    O
and    O
detection    O
of    O
antibodies    O
by    O
ELISA    O
and    O
virus    O
neutralisation    B-Antibody115027189
tests    O
.    O

Diagnosis    O
is    O
usually    O
made    O
by    O
detecting    O
elevated    O
levels    O
of    O
anti-thyroid    B-Antibody115027189
peroxidase    I-Antibody115027189
antibodies    I-Antibody115027189
(    O
TPOAb    O
)    O
in    O
the    O
serum    O
,    O
but    O
seronegative    O
(    O
without    O
circulating    O
autoantibodies    O
)    O
thyroiditis    O
is    O
also    O
possible    O
.    O

It    O
can    O
also    O
be    O
caused    O
by    O
an    O
infection    O
,    O
like    O
a    O
virus    O
or    O
bacteria    O
,    O
which    O
works    O
in    O
the    O
same    O
way    O
as    O
antibodies    O
to    O
cause    O
inflammation    O
in    O
the    O
glands    O
..    O
Certain    O
people    O
make    O
thyroid    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
and    O
thyroiditis    O
can    O
be    O
considered    O
an    O
autoimmune    O
disease    O
,    O
because    O
the    O
body    O
acts    O
as    O
if    O
the    O
thyroid    O
gland    O
is    O
foreign    O
tissue    O
.    O

Yttrium    B-Antibody115027189
(90Y)    I-Antibody115027189
clivatuzumab    I-Antibody115027189
tetraxetan    I-Antibody115027189

|    O
Pritumumab    B-Antibody115027189

|    O
Inclacumab    B-Antibody115027189

File    O
:    O
Y-90    O
tacatuzumab    O
tetraxetan    O
structure.svg|DOTA    O
linked    O
to    O
the    O
monoclonal    O
antibody    O
tacatuzumab    B-Antibody115027189
and    O
chelating    O
yttrium-90    O

Fontolizumab    B-Antibody115027189
(    O
planned    O
trade    O
name    O
HuZAF    B-Antibody115027189
)    O
is    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
and    O
an    O
immunosuppressive    O
drug    O
for    O
the    O
treatment    O
of    O
auto    O
-    O
immune    O
diseases    O
like    O
Crohn    O
's    O
disease    O
.    O

Atorolimumab    B-Antibody115027189
is    O
an    O
immunosuppressive    O
drug    O
directed    O
against    O
the    O
Rhesus    O
factor    O
.    O

Indium    B-Antibody115027189
(111In)    I-Antibody115027189
capromab    I-Antibody115027189
pendetide    I-Antibody115027189
(    O
prostate    O
cancer    O
)    O

Several    O
agents    O
are    O
in    O
clinical    O
trials    O
:    O
olokizumab    B-Antibody115027189
(    O
CDP6038    O
)    O
elsilimomab    B-Antibody115027189
,    O
BMS-945429    B-Antibody115027189
)    O
,    O
sirukumab    O
(    O
CNTO    O
136    O
)    O
,    O
and    O
CPSI-2364    O
an    O
apparent    O
macrophage    O
-    O
specific    O
inhibitor    O
of    O
the    O
p38    O
mitogen    O
-    O
activated    O
protein    O
kinase    O
pathway    O
.    O
ALX-0061    O
.    O

|    O
Nimotuzumab    B-Antibody115027189

The    O
Center    O
of    O
molecular    O
immunology    O
(    O
CIM    O
)    O
developed    O
nimotuzumab    B-Antibody115027189
,    O
a    O
monoclonal    O
antibody    O
used    O
to    O
treat    O
cancer    O
.    O

Anti-glutamate    B-Antibody115027189
receptor    I-Antibody115027189
antibodies    I-Antibody115027189

Anrukinzumab    B-Antibody115027189
(    O
IMA-638    O
)    O
is    O
a    O
humanized    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
asthma    O
.    O

Epratuzumab    B-Antibody115027189
(    O
Lymphocide    O
)    O
.    O

|    O
Tildrakizumab    B-Antibody115027189

|    O
Enavatuzumab    B-Antibody115027189

|    O
Vesencumab    B-Antibody115027189

|    O
Anti-citrullinated    B-Antibody115027189
protein    I-Antibody115027189
antibodies    I-Antibody115027189

It    O
has    O
been    O
suggested    O
that    O
it    O
is    O
an    O
abortive    O
form    O
of    O
rheumatoid    O
arthritis    O
(    O
RA    O
)    O
,    O
since    O
anti    O
-    O
cyclic    B-Antibody115027189
citrullinated    I-Antibody115027189
peptide    I-Antibody115027189
antibodies    O
(    O
anti    O
-    O
CCP    O
)    O
and    O
antikeratin    O
antibodies    O
(    O
AKA    O
)    O
are    O
present    O
in    O
a    O
high    O
proportion    O
of    O
patients    O
,    O
as    O
is    O
the    O
case    O
in    O
rheumatoid    O
arthritis    O
.    O

Anti-citrullinated    B-Antibody115027189
protein    I-Antibody115027189
antibody    I-Antibody115027189
is    O
frequently    O
associated    O
.    O

Adalimumab    B-Antibody115027189

Some    O
investors    O
were    O
concerned    O
that    O
the    O
split    O
was    O
done    O
to    O
protect    O
the    O
value    O
of    O
the    O
device    O
business    O
from    O
the    O
loss    O
of    O
value    O
facing    O
the    O
drug    O
division    O
due    O
to    O
the    O
imminent    O
expiration    O
of    O
patents    O
on    O
Humira    B-Antibody115027189
,    O
which    O
accounted    O
for    O
about    O
half    O
of    O
the    O
drug    O
division    O
's    O
revenue    O
.    O

Drug    O
-    O
induced    O
psoriasis    O
may    O
occur    O
with    O
beta    O
blockers    O
,    O
lithium    O
,    O
antimalarial    O
medications    O
,    O
non    O
-    O
steroidal    O
anti    O
-    O
inflammatory    O
drugs    O
,    O
terbinafine    O
,    O
calcium    O
channel    O
blockers    O
,    O
captopril    O
,    O
glyburide    O
,    O
granulocyte    O
colony    O
-    O
stimulating    O
factor    O
,    O
interleukins    O
,    O
interferons    O
,    O
lipid    O
-    O
lowering    O
drugs    O
,    O
and    O
paradoxically    O
TNF    B-Antibody115027189
inhibitor    I-Antibody115027189
such    O
as    O
infliximab    O
or    O
adalimumab    B-Antibody115027189
.    O

Four    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
MAbs    O
)    O
(    O
infliximab    O
,    O
adalimumab    B-Antibody115027189
,    O
golimumab    B-Antibody115027189
,    O
and    O
certolizumab    B-Antibody115027189
pegol    I-Antibody115027189
)    O
and    O
one    O
recombinant    O
TNF-α    O
decoy    O
receptor    O
,    O
etanercept    O
,    O
have    O
been    O
developed    O
to    O
inhibit    O
TNF-α    O
signaling    O
.    O

Adalimumab    B-Antibody115027189
(    O
Humira    O
)    O
is    O
an    O
example    O
of    O
an    O
antibody    O
approved    O
for    O
human    O
therapy    O
that    O
was    O
created    O
through    O
phage    O
display    O
.    O

The    O
PsAQoL    O
has    O
been    O
used    O
to    O
evaluate    O
infliximab    O
and    O
adalimumab    B-Antibody115027189
.    O

As    O
a    O
result    O
of    O
the    O
protracted    O
royalty    O
dispute    O
over    O
Humira    B-Antibody115027189
Abbott    O
agreed    O
to    O
pay    O
CAT    O
a    O
reduced    O
royalty    O
of    O
4.75%    O
on    O
any    O
future    O
sales    O
of    O
ABT-874    O
,    O
from    O
which    O
CAT    O
will    O
pay    O
a    O
portion    O
to    O
the    O
MRC    O
and    O
other    O
licensors    O
(    O
according    O
to    O
CAT    O
's    O
1997    O
agreement    O
with    O
the    O
MRC    O
)    O
.    O

daratumumab    B-Antibody115027189
(    O
INN    O
)    O

|    O
Nebacumab    B-Antibody115027189

Idiotopes    O
contrast    O
with    O
allotope    B-Antibody115027189
,    O
which    O
are    O
non    O
-    O
varying    O
structures    O
on    O
the    O
Fc    O
receptor    O
.    O

Lerdelimumab    B-Antibody115027189
(    O
CAT-152    B-Antibody115027189
,    O
intended    O
trade    O
name    O
Trabio    B-Antibody115027189
)    O
is    O
a    O
human    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
and    O
an    O
immunosuppressive    O
drug    O
developed    O
to    O
reduce    O
scarring    O
after    O
glaucoma    O
drainage    O
surgery    O
.    O

2013    O
–    O
Gazyva    B-Antibody115027189
(    O
obinutuzumab    O
)    O
:    O
For    O
use    O
in    O
combination    O
with    O
chlorambucil    O
to    O
treat    O
patients    O
with    O
previously    O
untreated    O
chronic    O
lymphocytic    O
leukemia    O
(    O
CLL    O
)    O
.    O

Rituximab    B-Antibody115027189
,    O
ofatumumab    B-Antibody115027189
,    O
and    O
obinutuzumab    B-Antibody115027189
are    O
antibodies    O
against    O
CD20    O
used    O
to    O
treat    O
CLL    O
.    O

|    O
Citatuzumab    B-Antibody115027189
bogatox    I-Antibody115027189

Also    O
known    O
as    O
huC242    B-Antibody115027189
it    O
binds    O
the    O
CanAg    B-Antibody115027189
antigen    O
.    O

|    O
Veltuzumab    B-Antibody115027189

|    O
Adecatumumab    B-Antibody115027189

Futuximab    B-Antibody115027189
(    O
INN    O
)    O
is    O
a    O
chimeric    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
cancer    O
.    O

Alacizumab    B-Antibody115027189
pegol    I-Antibody115027189

In    O
2017    O
the    O
US    O
FDA    O
approved    O
guselkumab    B-Antibody115027189
for    O
plaque    O
psoriasis    O
.    O

Among    O
them    O
are    O
Genentech    O
's    O
erlizumab    B-Antibody115027189
,    O
and    O
two    O
drugs    O
developed    O
by    O
Protein    O
Design    O
Labs    O
and    O
Centocor    O
.    O

farletuzumab    B-Antibody115027189
(    O
USAN    O
,    O
INN    O
)    O

Ligelizumab    B-Antibody115027189
(    O
INN    O
)    O
is    O
a    O
humanized    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
severe    O
asthma    O
and    O
chronic    O
spontaneous    O
urticaria    O
.    O

|    O
Amatuximab    B-Antibody115027189

Polyclonal    B-Antibody115027189
hypergammaglobulinaemia    O

The    O
nontoxic    O
recombinant    O
protein    O
can    O
induce    O
a    O
level    O
of    O
circulating    O
antibodies    O
sufficient    O
to    O
neutralize    O
the    O
toxic    O
effects    O
of    O
Tityus    O
toxins    O
and    O
is    O
a    O
good    O
candidate    O
for    O
use    O
in    O
the    O
production    O
of    O
a    O
new    O
generation    O
of    O
neutralizing    O
polyclonal    B-Antibody115027189
antibodies    I-Antibody115027189
for    O
clinical    B-Antibody115027189
use    I-Antibody115027189
.    O

Synthetic    O
antibodies    O
can    O
be    O
used    O
in    O
all    O
applications    O
where    O
traditional    O
monoclonal    O
or    O
polyclonal    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
used    O
and    O
offer    O
many    O
inherent    O
advantages    O
over    O
animal    O
-    O
derived    O
antibodies    O
,    O
including    O
comparatively    O
low    O
production    O
costs    O
,    O
reagent    O
reproducibility    O
and    O
increased    O
affinity    O
,    O
specificity    O
and    O
stability    O
across    O
a    O
range    O
of    O
experimental    O
conditions    O
.    O

Blood    O
isolated    O
from    O
these    O
animals    O
contains    O
"    O
polyclonal    B-Antibody115027189
antibodies    I-Antibody115027189
"—    O
multiple    O
antibodies    O
that    O
bind    O
to    O
the    O
same    O
antigen    O
—    O
in    O
the    O
serum    O
,    O
which    O
can    O
now    O
be    O
called    O
antiserum    O
.    O

p53    O
-    O
package    O
-    O
palindromic    O
sequence    O
-    O
Parkinson    O
's    O
disease    O
-    O
pBR322    O
-    O
PCR    O
-    O
pedigree    O
-    O
peptide    O
-    O
peptide    O
bond    O
-    O
phage    O
-    O
phagemid    O
-    O
phenotype    O
-    O
phosphatase    O
,    O
alkaline    O
-    O
phosphodiester    O
bond    O
-    O
phosphorylation    O
-    O
physical    O
map    O
-    O
plasmid    O
-    O
point    O
mutation    O
-    O
poly    O
-    O
A    O
track    O
-    O
polyA    O
tail    O
-    O
polyacrylamide    O
gel    O
-    O
polyclonal    B-Antibody115027189
antibodies    I-Antibody115027189
-    O
polydactyly    O
-    O
polymerase    O
-    O
polymerase    O
chain    O
reaction    O
-    O
polymorphism    O
-    O
polynucleotide    O
kinase    O
-    O
polypeptide    O
-    O
positional    O
cloning    O
-    O
post    O
-    O
transcriptional    O
regulation    O
-    O
post    O
-    O
translational    O
modification    O
-    O
post    O
-    O
translational    O
processing    O
-    O
post    O
-    O
translational    O
regulation    O
-    O
PRE    O
-    O
Precursor    O
mRNA    O
-    O
primary    O
immunodeficiency    O
-    O
primary    O
transcript    O
-    O
primer    O
-    O
primer    O
extension    O
-    O
probe    O
-    O
processivity    O
-    O
promoter    O
-    O
pronucleus    O
-    O
prostate    O
cancer    O
-    O
protease    O
-    O
protein    O
-    O
Protein    O
translocation    O
-    O
proto    O
-    O
oncogene    O
-    O
pseudogene    O
-    O
pseudoknot    O
-    O
pseudorevertant    O
-    O
pulse    O
sequence    O
database    O
-    O
pulsed    O
field    O
gel    O
electrophoresis    O
-    O
purine    O
-    O
pyrimidine    O

Polyclonal    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
esp    O
.    O
section    O
on    O
Titermax    O

The    O
newest    O
ADC    O
,    O
Inotuzumab    B-Antibody115027189
ozogamicin    I-Antibody115027189
,    O
was    O
approved    O
by    O
the    O
European    O
Commission    O
as    O
monotherapy    O
for    O
the    O
treatment    O
of    O
adults    O
with    O
relapsed    O
or    O
refractory    O
CD22-positive    O
B    O
-    O
cell    O
precursor    O
acute    O
lymphoblastic    O
leukemia    O
(    O
ALL    O
)    O
on    O
June    O
30    O
,    O
2017    O
under    O
the    O
trade    O
name    O
Besponsa®    O
(    O
Pfizer    O
/    O
Wyeth    O
)    O
.    O

On    O
August    O
17    O
,    O
2017    O
Inotuzumab    B-Antibody115027189
ozogamicin    I-Antibody115027189
was    O
also    O
approved    O
by    O
the    O
US    O
FDA    O
for    O
the    O
treatment    O
of    O
adults    O
with    O
relapsed    O
or    O
refractory    O
B    O
-    O
cell    O
precursor    O
acute    O
lymphoblastic    O
leukemia    O
(    O
ALL    O
)    O

mitumomab    B-Antibody115027189
(    O
INN    O
)    O

|    O
Nerelimomab    B-Antibody115027189

|    O
Urtoxazumab    B-Antibody115027189

CD33    O
is    O
the    O
target    O
of    O
gemtuzumab    B-Antibody115027189
ozogamicin    I-Antibody115027189
(    O
trade    O
name    O
:    O
Mylotarg®    O
;    O
Pfizer    O
/    O
Wyeth    O
-    O
Ayerst    O
Laboratories    O
)    O
,    O
an    O
Antibody    O
-    O
drug    O
conjugate    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
acute    O
myeloid    O
leukemia    O
.    O

Gemtuzumab    B-Antibody115027189
ozogamicin    I-Antibody115027189

However    O
,    O
after    O
a    O
request    O
from    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
,    O
Pfizer    O
/    O
Wyeth    O
,    O
the    O
developer    O
and    O
marketer    O
of    O
the    O
first    O
ADC    O
to    O
receive    O
marketing    O
approval    O
in    O
2001    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
acute    O
myelogenous    O
leukemia    O
(    O
Gemtuzumab    B-Antibody115027189
ozogamicin    I-Antibody115027189
,    O
trade    O
name    O
:    O
Mylotarg®    O
)    O
,    O
withdrew    O
the    O
drug    O
from    O
the    O
market    O
in    O
June    O
2010    O
(    O
although    O
still    O
marketed    O
in    O
Japan    O
)    O
.    O

The    O
most    O
promising    O
of    O
these    O
other    O
drugs    O
is    O
Merck    O
's    O
Zinplava    O
(    O
bezlotoxumab    B-Antibody115027189
)    O
which    O
was    O
recently    O
approved    O
.    O

Ontuxizumab    B-Antibody115027189
is    O
a    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
cancer    O
.    O

Such    O
antibodies    O
include    O
ATG    B-Antibody115027189
,    O
ALG    B-Antibody115027189
and    O
OKT3    B-Antibody115027189
.    O

CRS    O
has    O
been    O
known    O
since    O
the    O
approval    O
of    O
the    O
first    O
monoclonal    O
antibody    O
drug    O
,    O
Muromonab-CD3    B-Antibody115027189
,    O
which    O
causes    O
CRS    O
,    O
but    O
people    O
working    O
in    O
the    O
field    O
of    O
drug    O
development    O
at    O
biotech    O
and    O
pharmaceutical    O
companies    O
,    O
regulatory    O
agencies    O
,    O
and    O
academia    O
began    O
to    O
more    O
intensely    O
discuss    O
methods    O
to    O
classify    O
it    O
and    O
how    O
to    O
mitigate    O
its    O
risk    O
following    O
the    O
disastrous    O
2006    O
Phase    O
I    O
clinical    O
trial    O
of    O
TGN    O
1412    O
,    O
in    O
which    O
the    O
six    O
subjects    O
experienced    O
severe    O
CRS    O
.    O

ALG    O
is    O
more    O
likely    O
to    O
cause    O
side    O
effects    O
than    O
ATG    O
,    O
but    O
is    O
safer    O
than    O
OKT3    B-Antibody115027189
.    O

mepolizumab    B-Antibody115027189
(    O
INN    O
)    O

Mepolizumab    B-Antibody115027189
is    O
a    O
monoclonal    O
antibody    O
against    O
IL-5    O
which    O
can    O
reduce    O
excessive    O
eosinophilia    O
.    O

Ruplizumab    B-Antibody115027189
(    O
trade    O
name    O
Antova    B-Antibody115027189
)    O
is    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
intended    O
for    O
the    O
treatment    O
of    O
rheumatic    O
diseases    O
like    O
systemic    O
lupus    O
erythematosus    O
and    O
lupus    O
nephritis    O
.    O

Zatuximab    B-Antibody115027189
(    O
INN    O
)    O
is    O
a    O
chimeric    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
cancer    O
.    O

|    O
Oregovomab    B-Antibody115027189

Examples    O
of    O
chimeric    O
antibodies    O
approved    O
for    O
human    O
therapy    O
include    O
abciximab    B-Antibody115027189
(    O
ReoPro    O
)    O
,    O
basiliximab    B-Antibody115027189
(    O
Simulect    O
)    O
,    O
cetuximab    B-Antibody115027189
(    O
Erbitux    O
)    O
,    O
infliximab    O
(    O
Remicade    O
)    O
and    O
rituximab    B-Antibody115027189
(    O
MabThera    O
)    O
.    O

abciximab    B-Antibody115027189
,    O

COX    O
inhibitors    O
(    O
namely    O
aspirin    O
)    O
,    O
warfarin    O
,    O
direct    O
Xa    O
inhibitors    O
,    O
direct    O
thrombin    O
inhibitors    O
,    O
heparin    O
,    O
low    O
-    O
molecular    O
weight    O
heparins    O
,    O
antibodies    O
(    O
e.g.    O
,    O
abciximab    B-Antibody115027189
)    O
,    O
and    O
a    O
few    O
others    O
are    O
used    O
for    O
anticoagulation    O
therapy    O
.    O

The    O
mechanism    O
of    O
action    O
of    O
a    O
bsMab    O
,    O
exemplified    O
by    O
catumaxomab    B-Antibody115027189
,    O
representing    O
the    O
first    O
approved    O
bispecific    O
trifunctional    B-Antibody115027189
antibody    I-Antibody115027189
.    O

Edrecolomab    B-Antibody115027189
,    O
catumaxomab    B-Antibody115027189
and    O
other    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
designed    O
to    O
bind    O
to    O
it    O
.    O
also    O
nofetumomab    O
.    O

Bectumomab    B-Antibody115027189
(    O
marketed    O
under    O
the    O
trade    O
name    O
LymphoScan    B-Antibody115027189
)    O
is    O
a    O
mouse    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
labelled    O
with    O
the    O
radioactive    O
isotope    O
technetium-99    O
m    O
.    O

Campath    B-Antibody115027189

Alemtuzumab    B-Antibody115027189
is    O
an    O
early    O
example    O
of    O
an    O
antibody    O
whose    O
humanization    O
did    O
not    O
include    O
a    O
chimeric    O
intermediate    O
.    O

Medications    O
-    O
chemotherapy    O
(    O
antilymphocyte    O
globulin    O
therapy    O
,    O
alemtuzumab    B-Antibody115027189
,    O
glucocorticoids    O
)    O

Compston    O
's    O
research    O
focuses    O
on    O
the    O
clinical    O
science    O
of    O
human    O
demyelinating    O
disease    O
including    O
the    O
discovery    O
of    O
genetic    O
risk    O
factors    O
for    O
multiple    O
sclerosis    O
and    O
the    O
introduction    O
of    O
alemtuzumab    B-Antibody115027189
.    O

Alemtuzumab    B-Antibody115027189
is    O
a    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
chronic    O
lymphocytic    O
leukemia    O
(    O
CLL    O
)    O
,    O
cutaneous    O
T    O
-    O
cell    O
lymphoma    O
(    O
CTCL    O
)    O
and    O
T    O
-    O
cell    O
lymphoma    O
under    O
the    O
trade    O
names    O
Campath    B-Antibody115027189
,    O
MabCampath    B-Antibody115027189
and    O
Campath-1H    B-Antibody115027189
,    O
and    O
in    O
the    O
treatment    O
of    O
multiple    O
sclerosis    O
as    O
Lemtrada    B-Antibody115027189
.    O

It    O
is    O
usually    O
lethal    O
,    O
but    O
it    O
has    O
been    O
found    O
to    O
be    O
responsive    O
to    O
Mitoxantrone    O
and    O
Alemtuzumab    B-Antibody115027189
,    O
and    O
it    O
has    O
also    O
been    O
responsive    O
to    O
autologous    O
stem    O
cell    O
transplantation    O
.    O

|    O
Anti-histone    B-Antibody115027189
antibodies    I-Antibody115027189

|    O
Lampalizumab    B-Antibody115027189

Teneliximab    B-Antibody115027189
is    O
a    O
chimeric    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
binding    O
to    O
the    O
immune    O
stimulatory    O
protein    O
CD40    O
.    O

Aselizumab    B-Antibody115027189
is    O
an    O
immunosuppressive    O
drug    O
which    O
has    O
been    O
investigated    O
for    O
the    O
use    O
in    O
severely    O
injured    O
patients    O
.    O

Digoxin    B-Antibody115027189
immune    I-Antibody115027189
fab    I-Antibody115027189
is    O
the    O
best    O
way    O
to    O
cure    O
an    O
oleander    O
poisoning    O
if    O
inducing    O
vomiting    O
has    O
no    O
or    O
minimal    O
success    O
,    O
although    O
it    O
is    O
usually    O
used    O
only    O
for    O
life    O
-    O
threatening    O
conditions    O
due    O
to    O
side    O
effects    O
.    O

Digoxin    B-Antibody115027189
Immune    I-Antibody115027189
Fab    I-Antibody115027189
is    O
the    O
antigen    O
binding    O
fragment    O
of    O
polyclonal    O
antibodies    O
raised    O
to    O
digitalis    O
derivative    O
as    O
a    O
hapten    O
bound    O
to    O
a    O
protein    O
and    O
is    O
used    O
for    O
the    O
reversal    O
of    O
life    O
-    O
threatening    O
digoxin    O
or    O
digitoxin    O
toxicity    O
.    O

ertumaxomab    B-Antibody115027189
(    O
INN    O
)    O

gantenerumab    B-Antibody115027189
(    O
USAN    O
,    O
INN    O
)    O

While    O
at    O
Bristol    O
,    O
Dolan    O
was    O
involved    O
in    O
developing    O
the    O
cancer    O
-    O
treating    O
medication    O
Erbitux    B-Antibody115027189
,    O
as    O
well    O
as    O
,    O
before    O
becoming    O
chief    O
executive    O
officer    O
,    O
making    O
the    O
consumer    O
products    O
and    O
medical    O
device    O
divisions    O
of    O
Bristol    O
successful    O
.    O

The    O
list    O
of    O
offending    O
interventions    O
that    O
are    O
paid    O
for    O
and    O
widely    O
used    O
but    O
either    O
unproven    O
or    O
of    O
marginal    O
benefit    O
to    O
patients    O
is    O
vast    O
–    O
IMRT    O
and    O
proton    O
beam    O
for    O
early    O
prostate    O
cancer    O
,    O
CT    O
and    O
MRI    O
angiograms    O
,    O
Epogen    O
for    O
chemotherapy    O
induced    O
anemia    O
,    O
Erbitux    B-Antibody115027189
and    O
Avastin    B-Antibody115027189
for    O
colorectal    O
cancer    O
,    O
and    O
drug    O
eluting    O
stents    O
for    O
coronary    O
artery    O
disease    O
.    O

ImClone    O
's    O
stock    O
price    O
dropped    O
sharply    O
at    O
the    O
end    O
of    O
2001    O
when    O
its    O
drug    O
Erbitux    B-Antibody115027189
,    O
an    O
experimental    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
,    O
failed    O
to    O
get    O
the    O
expected    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
approval    O
.    O

Erbitux    O
(    O
cetuximab    B-Antibody115027189
)    O

Cetuximab    B-Antibody115027189
target    O
the    O
epidermal    O
growth    O
factor    O
receptor    O
(    O
EGFR    O
)    O
.    O

Drugs    O
such    O
as    O
panitumumab    B-Antibody115027189
,    O
cetuximab    B-Antibody115027189
,    O
gefitinib    O
,    O
erlotinib    O
,    O
afatinib    O
,    O
and    O
lapatinib    O
are    O
used    O
to    O
inhibit    O
it    O
.    O

While    O
α-galactose    O
as    O
a    O
part    O
of    O
glycoprotein    O
glycans    O
from    O
vertebrates    O
other    O
than    O
higher    O
apes    O
was    O
known    O
for    O
a    O
long    O
time    O
as    O
being    O
a    O
prominent    O
xeno    O
-    O
antigen    O
,    O
its    O
implication    O
in    O
allergy    O
only    O
began    O
to    O
materialize    O
when    O
complications    O
during    O
treatment    O
with    O
a    O
recombinant    O
monoclonal    O
antibody    O
(    O
Erbitux    B-Antibody115027189
)    O
were    O
attributed    O
to    O
IgE    O
directed    O
against    O
α-Gal    O
containing    O
N    O
-    O
glycans    O
on    O
this    O
antibody    O
.    O

Examples    O
of    O
chimeric    O
antibodies    O
approved    O
for    O
human    O
therapy    O
include    O
abciximab    B-Antibody115027189
(    O
ReoPro    O
)    O
,    O
basiliximab    B-Antibody115027189
(    O
Simulect    O
)    O
,    O
cetuximab    B-Antibody115027189
(    O
Erbitux    O
)    O
,    O
infliximab    O
(    O
Remicade    O
)    O
and    O
rituximab    B-Antibody115027189
(    O
MabThera    O
)    O
.    O

Inhibition    O
of    O
TNF    O
effects    O
can    O
be    O
achieved    O
with    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
such    O
as    O
infliximab    O
(    O
Remicade    O
)    O
,    O
adalimumab    B-Antibody115027189
(    O
Humira    O
)    O
,    O
certolizumab    B-Antibody115027189
pegol    I-Antibody115027189
(    O
Cimzia    O
)    O
,    O
and    O
golimumab    B-Antibody115027189
(    O
Simponi    O
)    O
,    O
or    O
with    O
a    O
circulating    O
receptor    O
fusion    O
protein    O
such    O
as    O
etanercept    O
(    O
Enbrel    O
)    O
.    O

Golimumab    B-Antibody115027189

Four    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
MAbs    O
)    O
(    O
infliximab    O
,    O
adalimumab    B-Antibody115027189
,    O
golimumab    B-Antibody115027189
,    O
and    O
certolizumab    B-Antibody115027189
pegol    I-Antibody115027189
)    O
and    O
one    O
recombinant    O
TNF-α    O
decoy    O
receptor    O
,    O
etanercept    O
,    O
have    O
been    O
developed    O
to    O
inhibit    O
TNF-α    O
signaling    O
.    O

As    O
of    O
November    O
2015    O
,    O
there    O
are    O
a    O
number    O
of    O
ongoing    O
and    O
recently    O
completed    O
clinical    O
trials    O
of    O
novel    O
targeted    O
agents    O
for    O
HER2    O
+    O
metastatic    O
breast    O
cancer    O
,    O
e.g.    O
margetuximab    B-Antibody115027189
.    O

|    O
Taplitumomab    B-Antibody115027189
paptox    I-Antibody115027189

|    O
Ficlatuzumab    B-Antibody115027189

TGM5    O
is    O
a    O
transglutaminase    B-Antibody115027189
enzyme    O
.    O

Transglutaminase    B-Antibody115027189
:    O
an    O
enzyme    O
that    O
helps    O
the    O
forming    O
of    O
cross    O
-    O
binding    O
proteins    O
.    O

Streptomyces    O
mobaraensis    O
"    O
produces    O
bleomycin    O
,    O
detoxin    O
,    O
piericidin    O
A    O
,    O
piericidin    O
B    O
,    O
reticulol    O
and    O
transglutaminase    B-Antibody115027189
.    O

CE    O
precursor    O
proteins    O
are    O
cross    O
-    O
linked    O
by    O
transglutaminase    B-Antibody115027189
.    O

Recently    O
it    O
was    O
introduced    O
the    O
production    O
of    O
allergoids    O
by    O
polimerization    O
through    O
the    O
microbial    O
transglutaminases    B-Antibody115027189
.    O

At    O
each    O
stage    O
of    O
differentiation    O
,    O
keratinocytes    O
express    O
specific    O
keratins    O
,    O
such    O
as    O
keratin    O
1    O
,    O
keratin    O
5    O
,    O
keratin    O
10    O
,    O
and    O
keratin    O
14    O
,    O
but    O
also    O
other    O
markers    O
such    O
as    O
involucrin    O
,    O
loricrin    O
,    O
transglutaminase    B-Antibody115027189
,    O
filaggrin    O
,    O
and    O
caspase    O
14    O
.    O

A    O
transglutaminase    B-Antibody115027189
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
formation    O
of    O
an    O
isopeptide    O
bond    O
between    O
a    O
free    O
amine    O
group    O
(    O
e.g.    O
,    O
protein-    O
or    O
peptide    O
-    O
bound    O
lysine    O
)    O
and    O
the    O
acyl    O
group    O
at    O
the    O
end    O
of    O
the    O
side    O
chain    O
of    O
protein-    O
or    O
peptide    O
-    O
bound    O
glutamine    O
.    O

It    O
reduces    O
the    O
effect    O
of    O
naturally    O
present    O
TNF    O
,    O
and    O
hence    O
is    O
a    O
TNF    B-Antibody115027189
inhibitor    I-Antibody115027189
,    O
functioning    O
as    O
a    O
decoy    O
receptor    O
that    O
binds    O
to    O
TNF    O
.    O

Newer    O
drugs    O
have    O
been    O
developed    O
recently    O
,    O
such    O
as    O
TNF    B-Antibody115027189
alpha    I-Antibody115027189
blocker    I-Antibody115027189
,    O
such    O
as    O
etanercept    O
.    O

Drug    O
-    O
induced    O
psoriasis    O
may    O
occur    O
with    O
beta    O
blockers    O
,    O
lithium    O
,    O
antimalarial    O
medications    O
,    O
non    O
-    O
steroidal    O
anti    O
-    O
inflammatory    O
drugs    O
,    O
terbinafine    O
,    O
calcium    O
channel    O
blockers    O
,    O
captopril    O
,    O
glyburide    O
,    O
granulocyte    O
colony    O
-    O
stimulating    O
factor    O
,    O
interleukins    O
,    O
interferons    O
,    O
lipid    O
-    O
lowering    O
drugs    O
,    O
and    O
paradoxically    O
TNF    B-Antibody115027189
inhibitor    I-Antibody115027189
such    O
as    O
infliximab    O
or    O
adalimumab    B-Antibody115027189
.    O

In    O
rheumatoid    O
arthritis    O
they    O
can    O
help    O
patients    O
unresponsive    O
to    O
TNF    B-Antibody115027189
inhibitor    I-Antibody115027189
.    O

Coupons    O
(    O
usually    O
in    O
the    O
form    O
of    O
co    O
-    O
pay    O
assistance    O
programs    O
)    O
for    O
specialty    O
pharmaceutical    O
products    O
,    O
particularly    O
injectable    O
drugs    O
such    O
as    O
TNF    B-Antibody115027189
inhibitor    I-Antibody115027189
can    O
be    O
worth    O
several    O
thousand    O
dollars    O
per    O
year    O
.    O

DOI    O
has    O
been    O
shown    O
to    O
be    O
an    O
extremely    O
potent    O
inhibitor    B-Antibody115027189
of    O
tumour    O
necrosis    O
factor    O
-    O
alpha    O
inflammation    O
at    O
picomolar    O
concentrations    O
in    O
cell    O
studies    O
.    O

FibriScint    B-Antibody115027189
(    O
Janssen    O
Biotech    O
)    O

The    O
immediate    O
products    O
of    O
these    O
systems    O
are    O
antibody    O
fragments    O
,    O
normally    O
Fab    B-Antibody115027189
or    O
scFv    B-Antibody115027189
)    O
.    O

The    O
ability    O
to    O
manipulate    O
the    O
antibody    O
genes    O
makes    O
it    O
possible    O
to    O
generate    O
new    O
antibodies    O
and    O
antibody    O
fragments    O
,    O
such    O
as    O
Fab    B-Antibody115027189
fragments    I-Antibody115027189
and    O
scFv    B-Antibody115027189
in    O
vitro    O
.    O

.    O
Single    B-Antibody115027189
chain    I-Antibody115027189
variable    I-Antibody115027189
fragments    I-Antibody115027189
(    O
scFv    B-Antibody115027189
)    O
are    O
connected    O
to    O
the    O
variable    O
domain    O
of    O
the    O
heavy    O
and    O
light    O
chain    O
via    O
a    O
short    O
linker    O
peptide    O
.    O

|    O
Itolizumab    B-Antibody115027189

–    O
secretory    B-Antibody115027189
component    I-Antibody115027189

Upon    O
histologic    O
examination    O
,    O
triple    O
-    O
negative    O
breast    O
tumors    O
mostly    O
fall    O
into    O
the    O
categories    O
of    O
"    O
secretory    B-Antibody115027189
cell    O
carcinoma    O
"    O
or    O
"    O
adenoid    O
cystic    O
types    O
"    O
(    O
both    O
considered    O
less    O
aggressive    O
)    O
;    O
"    O
medullary    O
cancers    O
"    O
and    O
grade    O
3    O
invasive    O
"    O
ductal    O
carcinomas    O
"    O
with    O
no    O
specific    O
subtype    O
;    O
and    O
highly    O
aggressive    O
"    O
metastatic    O
cancers    O
"    O
.    O

IGH@    B-Antibody115027189
:    O
immunoglobulin    O
heavy    B-Antibody115027189
chain    I-Antibody115027189
locus    O

The    O
chromosomal    O
region    O
that    O
encodes    O
an    O
antibody    O
is    O
large    O
and    O
contains    O
several    O
distinct    O
gene    O
loci    O
for    O
each    O
domain    O
of    O
the    O
antibody    O
—    O
the    O
chromosome    O
region    O
containing    O
heavy    O
chain    O
genes    O
(    O
IGH@    B-Antibody115027189
)    O
is    O
found    O
on    O
chromosome    O
14    O
,    O
and    O
the    O
loci    O
containing    O
lambda    O
and    O
kappa    O
light    O
chain    O
genes    O
(    O
IGL@    O
and    O
IGK@    O
)    O
are    O
found    O
on    O
chromosomes    O
22    O
and    O
2    O
in    O
humans    O
.    O

Bivatuzumab    B-Antibody115027189
mertansine    I-Antibody115027189

A    O
viral    O
load    O
greater    O
than    O
100,000    O
copies    O
/    O
mL    O
of    O
blood    O
within    O
six    O
months    O
of    O
seroconversion    B-Antibody115027189
indicates    O
a    O
greater    O
likelihood    O
of    O
developing    O
AIDS    O
within    O
five    O
years    O
.    O

It    O
improves    O
the    O
seroconversion    B-Antibody115027189
of    O
e    O
-    O
antigen    O
positive    O
hepatitis    O
B    O
and    O
also    O
improves    O
histology    O
staging    O
of    O
the    O
liver    O
.    O

Spontaneous    O
seroreversion    B-Antibody115027189
(    O
when    O
the    O
body    O
stops    O
producing    O
antibodies    O
against    O
a    O
protein    O
)    O
despite    O
the    O
ongoing    O
presence    O
of    O
the    O
virus    O
;    O
this    O
is    O
a    O
type    O
of    O
immune    O
tolerance    O
.    O

Of    O
those    O
,    O
six    O
animal    O
handlers    O
eventually    O
seroconverted    B-Antibody115027189
,    O
including    O
one    O
who    O
had    O
cut    O
himself    O
with    O
a    O
bloody    O
scalpel    O
.    O

Seroconversion    B-Antibody115027189

RatA    B-Antibody115027189

Maternal    O
antibodies    O
such    O
as    O
immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
(    O
IgG    O
)    O
,    O
which    O
are    O
readily    O
transmitted    O
to    O
the    O
young    O
across    O
the    O
placenta    O
,    O
may    O
explain    O
why    O
very    O
young    O
rabbits    O
are    O
resistant    O
to    O
RHD    O
.    O

The    O
simplest    O
form    O
is    O
the    O
hinge    O
region    O
from    O
IgG1    B-Antibody115027189
.    O

Second    O
,    O
they    O
isolated    O
the    O
DNA    O
sequence    O
that    O
codes    O
the    O
human    O
gene    O
for    O
the    O
Fc    B-Antibody115027189
end    O
of    O
immunoglobulin    B-Antibody115027189
G1    I-Antibody115027189
(    O
IgG1    O
)    O
.    O

Colostrum    O
is    O
known    O
to    O
contain    O
immune    O
cells    O
(    O
as    O
lymphocytes    O
)    O
and    O
many    O
antibodies    O
such    O
as    O
IgA    B-Antibody115027189
,    O
IgG    B-Antibody115027189
,    O
and    O
IgM    B-Antibody115027189
These    O
are    O
some    O
of    O
the    O
components    O
of    O
the    O
adaptive    O
immune    O
system    O
.    O

In    O
the    O
dairy    O
industry    O
,    O
the    O
quality    O
of    O
colostrum    O
is    O
measured    O
as    O
the    O
amount    O
of    O
IgG    O
(    O
Immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
)    O
per    O
liter    O
.    O

In    O
2012    O
,    O
OncoMed    O
sponsored    O
the    O
USAN    O
nonproprietary    O
name    O
vantictumab    B-Antibody115027189
for    O
a    O
human    O
IgG2    B-Antibody115027189
anti    O
-    O
Frizzled    O
antibody    O
,    O
an    O
anti    O
-    O
cancer    O
therapeutic    O
.    O

This    O
induces    O
the    O
B    O
-    O
lymphocytes    O
to    O
produce    O
IgG    B-Antibody115027189
immunoglobulins    O
specific    O
for    O
the    O
antigen    O
.    O

This    O
polyclonal    O
IgG    B-Antibody115027189
is    O
purified    O
from    O
the    O
mammal    O
’s    O
serum    O
.    O

Selective    O
deficiency    O
of    O
immunoglobulin    O
G    O
(    O
IgG    B-Antibody115027189
)    O
subclasses    O

Their    O
work    O
is    O
not    O
complete    O
,    O
but    O
those    O
in    O
the    O
study    O
who    O
produced    O
IgG    B-Antibody115027189
antibodies    O
that    O
recognise    O
the    O
V2    O
loop    O
in    O
the    O
HIV    O
envelope    O
protein    O
gp120    O
were    O
43%    O
less    O
likely    O
to    O
become    O
infected    O
.    O

Several    O
serological    O
tests    O
can    O
be    O
performed    O
to    O
assess    O
total    O
IgE    O
and    O
allergen    O
specific    O
IgE    B-Antibody115027189
and    O
IgG    B-Antibody115027189
:    O
ELISA    O
,    O
MAST    O
,    O
HIA    O
,    O
and    O
CAP    O
RAST    O
.    O

Thirdly    O
,    O
her    O
group    O
is    O
interested    O
in    O
micro    O
-    O
sized    O
striped    O
patterns    O
of    O
protein    O
(    O
such    O
as    O
serum    O
albumin    O
,    O
immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
,    O
laminin    O
and    O
other    O
growth    O
factors    O
)    O
on    O
biocompatible    O
polymeric    O
substrates    O
(    O
such    O
as    O
poly(methylmethacrylate    O
)    O
or    O
PMMA    O
)    O
.    O

It    O
is    O
a    O
human    O
IgG4    B-Antibody115027189
anti    O
-    O
PD-1    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
.    O

Nivolumab    O
is    O
a    O
fully    O
human    O
monoclonal    O
immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
antibody    O
to    O
PD-1    O
.    O

Defective    O
T    O
and    O
B    O
cells    O
as    O
well    O
as    O
markedly    O
decreased    O
IgG1    B-Antibody115027189
responses    O
were    O
observed    O
in    O
miR-155-deficient    O
mice    O
,    O
IgG1    O
is    O
reduced    O
whereas    O
the    O
expression    O
of    O
the    O
IgM    B-Antibody115027189
immunoglobulin    O
remains    O
normal    O
in    O
these    O
mice    O
.    O

For    O
example    O
,    O
those    O
that    O
bind    O
the    O
most    O
common    O
class    O
of    O
antibody    O
,    O
IgG    B-Antibody115027189
,    O
are    O
called    O
"    O
Fc    O
-    O
gamma    O
receptors    O
"    O
(    O
FcγR    O
)    O
,    O
those    O
that    O
bind    O
IgA    B-Antibody115027189
are    O
called    O
"    O
Fc    O
-    O
alpha    O
receptors    O
"    O
(    O
FcαR    O
)    O
and    O
those    O
that    O
bind    O
IgE    B-Antibody115027189
are    O
called    O
"    O
Fc    O
-    O
epsilon    O
receptors    O
"    O
(    O
FcεR    O
)    O
.    O

For    O
example    O
,    O
macrophages    O
begin    O
to    O
ingest    O
and    O
kill    O
an    O
IgG    B-Antibody115027189
-    O
coated    O
pathogen    O
by    O
phagocytosis    O
following    O
engagement    O
of    O
their    O
Fcγ    O
receptors    O
.    O

When    O
IgG    B-Antibody115027189
molecules    O
,    O
specific    O
for    O
a    O
certain    O
antigen    O
or    O
surface    O
component    O
,    O
bind    O
to    O
the    O
pathogen    O
with    O
their    O
Fab    B-Antibody115027189
region    I-Antibody115027189
(    O
fragment    O
antigen    O
binding    O
region    O
)    O
,    O
their    O
Fc    O
regions    O
point    O
outwards    O
,    O
in    O
direct    O
reach    O
of    O
phagocytes    O
.    O

Atezolizumab    O
(    O
trade    O
name    O
Tecentriq    O
)    O
is    O
a    O
fully    O
humanized    O
,    O
engineered    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
of    O
IgG1    B-Antibody115027189
isotype    O
against    O
the    O
protein    O
programmed    O
cell    O
death    O
-    O
ligand    O
1    O
(    O
PD    O
-    O
L1    O
)    O
.    O

a    O
decrease    O
in    O
levels    O
of    O
immunoglobulin    B-Antibody115027189
G3    I-Antibody115027189

IgM    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
detectable    O
two    O
days    O
after    O
symptom    O
onset    O
and    O
IgG    B-Antibody115027189
antibodies    I-Antibody115027189
can    O
be    O
detected    O
6    O
to    O
18    O
days    O
after    O
symptom    O
onset    O
.    O

During    O
pregnancy    O
,    O
a    O
particular    O
type    O
of    O
antibody    O
,    O
called    O
IgG    B-Antibody115027189
,    O
is    O
transported    O
from    O
mother    O
to    O
baby    O
directly    O
through    O
the    O
placenta    O
,    O
so    O
human    O
babies    O
have    O
high    O
levels    O
of    O
antibodies    O
even    O
at    O
birth    O
,    O
with    O
the    O
same    O
range    O
of    O
antigen    O
specificities    O
as    O
their    O
mother    O
.    O
Breast    O
milk    O
or    O
colostrum    O
also    O
contains    O
antibodies    O
that    O
are    O
transferred    O
to    O
the    O
gut    O
of    O
the    O
infant    O
and    O
protect    O
against    O
bacterial    O
infections    O
until    O
the    O
newborn    O
can    O
synthesize    O
its    O
own    O
antibodies    O
.    O

This    O
is    O
also    O
called    O
antibody    O
-    O
dependent    O
(    O
or    O
cytotoxic    O
)    O
hypersensitivity    O
,    O
and    O
is    O
mediated    O
by    O
IgG    B-Antibody115027189
and    O
IgM    B-Antibody115027189
antibodies    O
.    O

In    O
the    O
original    O
version    O
of    O
the    O
technique    O
,    O
the    O
protein    O
of    O
interest    O
with    O
the    O
TAP    O
tag    O
first    O
binds    O
to    O
beads    O
coated    O
with    O
IgG    B-Antibody115027189
,    O
the    O
TAP    O
tag    O
is    O
then    O
broken    O
apart    O
by    O
an    O
enzyme    O
,    O
and    O
finally    O
a    O
different    O
part    O
of    O
the    O
TAP    O
tag    O
binds    O
reversibly    O
to    O
beads    O
of    O
a    O
different    O
type    O
.    O

The    O
TAP    O
tag    O
consists    O
of    O
calmodulin    O
binding    O
peptide    O
(    O
CBP    O
)    O
from    O
the    O
N    O
-    O
terminal    O
,    O
followed    O
by    O
tobacco    O
etch    O
virus    O
protease    O
(    O
TEV    O
protease    O
)    O
cleavage    O
site    O
and    O
Protein    O
A    O
,    O
which    O
binds    O
tightly    O
to    O
IgG    B-Antibody115027189
The    O
relative    O
order    O
of    O
the    O
modules    O
of    O
the    O
tag    O
is    O
important    O
because    O
Protein    O
A    O
needs    O
to    O
be    O
at    O
the    O
extreme    O
end    O
of    O
the    O
fusion    O
protein    O
so    O
that    O
the    O
entire    O
complex    O
can    O
be    O
retrieved    O
using    O
an    O
IgG    O
matrix    O
.    O

|    O
IgG    B-Antibody115027189

The    O
combination    O
of    O
this    O
cytokine    O
and    O
IL12    O
has    O
been    O
shown    O
to    O
inhibit    O
IL-4    O
dependent    O
IgE    B-Antibody115027189
and    O
IgG1    B-Antibody115027189
production    O
,    O
and    O
enhance    O
IgG2a    O
production    O
in    O
B    O
cells    O
.    O

Immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
(    O
IgG    O
)    O
is    O
the    O
only    O
antibody    O
isotype    O
that    O
can    O
pass    O
through    O
the    O
human    O
placenta    O
,    O
and    O
is    O
the    O
most    O
common    O
antibody    O
of    O
the    O
five    O
types    O
of    O
antibodies    O
found    O
in    O
the    O
body    O
.    O

For    O
allergy    O
testing    O
,    O
Hycor    O
has    O
developed    O
specific    O
and    O
total    O
IgE    B-Antibody115027189
,    O
specific    O
IgG    B-Antibody115027189
,    O
specific    O
IgG4    B-Antibody115027189
,    O
and    O
specific    O
IgE    O
EIA    O
tests    O
.    O

This    O
is    O
an    O
IgG1    B-Antibody115027189
heterodimeric    O
antibody    O
scaffold    O
that    O
consists    O
of    O
two    O
different    O
heavy    O
chains    O
engineered    O
to    O
exclusively    O
assemble    O
into    O
a    O
single    O
molecule    O
,    O
allowing    O
bi    O
-    O
specific    O
binding    O
to    O
two    O
different    O
antigens    O
or    O
drug    O
targets    O
.    O

Immunofluorescence    O
demonstrates    O
diffuse    O
granular    O
uptake    O
of    O
IgG    B-Antibody115027189
The    O
basement    O
membrane    O
may    O
completely    O
surround    O
the    O
granular    O
deposits    O
,    O
forming    O
a    O
"    O
spike    O
and    O
dome    O
"    O
pattern    O
.    O

In    O
Goodpasture    O
syndrome    O
,    O
IgG    B-Antibody115027189
antibodies    O
directed    O
against    O
the    O
glomerular    O
basement    O
membrane    O
trigger    O
an    O
inflammatory    O
reaction    O
,    O
causing    O
a    O
nephritic    O
syndrome    O
and    O
the    O
coughing    O
up    O
of    O
blood    O
.    O

#    O
Immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
(    O
IgG    O
)    O
binds    O
specifically    O
to    O
the    O
target    O
antigen    O
presented    O
on    O
the    O
pathogen    O
extracellularly    O

Alemtuzumab    O
is    O
a    O
recombinant    O
DNA    O
-    O
derived    O
humanized    O
IgG1    B-Antibody115027189
kappa    O
monoclonal    O
antibody    O
that    O
is    O
directed    O
against    O
the    O
21–28    O
kDa    O
cell    O
surface    O
glycoprotein    O
CD52    O
.    O

Peptoids    O
have    O
been    O
developed    O
as    O
candidates    O
for    O
a    O
range    O
of    O
different    O
biomedical    O
applications    O
,    O
including    O
antimicrobial    O
agents    O
and    O
synthetic    O
lung    O
surfactants    O
,    O
as    O
well    O
as    O
ligands    O
for    O
various    O
proteins    O
including    O
Src    O
Homology    O
3    O
(    O
SH3    O
domain    O
)    O
,    O
Vascular    O
Endothelial    O
Growth    O
Factor    O
(    O
VEGF    O
)    O
receptor    O
2    O
,    O
and    O
antibody    O
Immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
biomarkers    O
for    O
the    O
identification    O
of    O
Alzheimer    O
's    O
disease    O
.    O

Hemolytic    O
disease    O
of    O
the    O
newborn    O
,    O
also    O
known    O
as    O
hemolytic    O
disease    O
of    O
the    O
fetus    O
and    O
newborn    O
,    O
HDN    O
,    O
HDFN    O
,    O
or    O
erythroblastosis    O
fetalis    O
,    O
is    O
an    O
alloimmune    O
condition    O
that    O
develops    O
in    O
a    O
fetus    O
,    O
when    O
the    O
IgG    B-Antibody115027189
molecules    O
(    O
one    O
of    O
the    O
five    O
main    O
types    O
of    O
antibodies    O
)    O
produced    O
by    O
the    O
mother    O
pass    O
through    O
the    O
placenta    O
.    O

This    O
occurs    O
due    O
to    O
the    O
decreased    O
amount    O
of    O
immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
(    O
IgG    O
)    O
levels    O
in    O
the    O
infant    O
during    O
the    O
three    O
-    O
month    O
stage    O
.    O

The    O
classical    O
complement    O
pathway    O
is    O
initiated    O
by    O
antigen    O
-    O
antibody    O
complexes    O
with    O
the    O
antibody    O
isotypes    O
IgG    B-Antibody115027189
and    O
IgM    B-Antibody115027189

The    O
IFA    O
will    O
detect    O
an    O
increase    O
in    O
IgG    B-Antibody115027189
or    O
IgM    B-Antibody115027189
antibodies    O
in    O
the    O
bloodstream    O
.    O

For    O
example    O
the    O
total    O
levels    O
of    O
antibodies    O
isotypes    O
or    O
classes    O
:    O
Immunoglobulin    B-Antibody115027189
M    I-Antibody115027189
,    O
Immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
,    O
and    O
Immunoglobulin    B-Antibody115027189
A    I-Antibody115027189
It    O
is    O
important    O
in    O
quantification    O
of    O
free    O
light    O
chains    O
in    O
diseases    O
such    O
as    O
multiple    O
myeloma    O
.    O

In    O
the    O
classical    O
pathway    O
,    O
the    O
microbial    O
pathogen    O
is    O
coated    O
in    O
antibodies    O
(    O
IgG    B-Antibody115027189
and    O
IgM    B-Antibody115027189
)    O
released    O
by    O
B    O
cells    O
.    O

The    O
IgG    B-Antibody115027189
antibody    O
is    O
similar    O
to    O
AGA    O
IgA    B-Antibody115027189
,    O
but    O
is    O
found    O
at    O
higher    O
levels    O
in    O
patients    O
with    O
the    O
IgA    O
-    O
less    O
phenotype    O
.    O

|    O
Exbivirumab    B-Antibody115027189

Microantibody    B-Antibody115027189

Cantuzumab    B-Antibody115027189
mertansine    I-Antibody115027189

Rozrolimupab    B-Antibody115027189
is    O
a    O
recombinant    O
antibody    O
mixture    O
,    O
specifically    O
containing    O
25    O
Rhesus    O
D    O
,    O
or    O
RhD    O
,    O
human    O
antibodies    O
,    O
and    O
is    O
currently    O
under    O
development    O
by    O
Symphogen    O
for    O
the    O
treatment    O
of    O
immune    O
thrombocytopenic    O
purpura    O
(    O
ITP    O
)    O
and    O
for    O
the    O
prevention    O
of    O
hemolytic    O
disease    O
of    O
the    O
newborn    O
(    O
HDN    O
)    O
.    O

Anti-saccharomyces    B-Antibody115027189
cerevisiae    I-Antibody115027189
antibody    I-Antibody115027189

IgM    B-Antibody115027189
,    O
pictured    O
,    O
is    O
an    O
example    O
of    O
a    O
macroglobulin    O
.    O

Other    O
studies    O
found    O
that    O
saliva    O
assay    O
for    O
anti    O
-    O
HAV    O
antibodies    O
(    O
IgM    B-Antibody115027189
and    O
IgG    B-Antibody115027189
)    O
was    O
an    O
effective    O
method    O
to    O
identify    O
HAV    O
-    O
infected    O
individuals    O
.    O
Hepatitis    O
C    O
has    O
also    O
been    O
identified    O
using    O
salivary    O
detection    O
methods    O
.    O

Ammann    O
,    O
Stiehm    O
and    O
James    O
D.    O
Cherry    O
identified    O
that    O
there    O
are    O
elevated    O
levels    O
of    O
Immunoglobulin    B-Antibody115027189
M    I-Antibody115027189
(    O
IgM    O
)    O
in    O
the    O
cord    O
blood    O
of    O
newborn    O
infants    O
born    O
with    O
the    O
congenital    O
rubella    O
syndrome    O
.    O

Colostrum    O
is    O
known    O
to    O
contain    O
immune    O
cells    O
(    O
as    O
lymphocytes    O
)    O
and    O
many    O
antibodies    O
such    O
as    O
IgA    B-Antibody115027189
,    O
IgG    B-Antibody115027189
,    O
and    O
IgM    B-Antibody115027189
These    O
are    O
some    O
of    O
the    O
components    O
of    O
the    O
adaptive    O
immune    O
system    O
.    O

B    O
-    O
cell    O
anergy    O
can    O
be    O
induced    O
by    O
exposure    O
to    O
soluble    O
circulating    O
antigen    O
,    O
and    O
is    O
often    O
marked    O
by    O
a    O
downregulation    O
of    O
surface    O
IgM    B-Antibody115027189
expression    O
and    O
partial    O
blockade    O
of    O
intracellular    O
signaling    O
pathways    O
.    O

Selective    O
deficiency    O
of    O
immunoglobulin    O
M    O
(    O
IgM    B-Antibody115027189
)    O

Defective    O
T    O
and    O
B    O
cells    O
as    O
well    O
as    O
markedly    O
decreased    O
IgG1    B-Antibody115027189
responses    O
were    O
observed    O
in    O
miR-155-deficient    O
mice    O
,    O
IgG1    O
is    O
reduced    O
whereas    O
the    O
expression    O
of    O
the    O
IgM    B-Antibody115027189
immunoglobulin    O
remains    O
normal    O
in    O
these    O
mice    O
.    O

Another    O
receptor    O
can    O
also    O
bind    O
IgA    O
,    O
although    O
it    O
has    O
higher    O
affinity    O
for    O
another    O
antibody    O
called    O
IgM    B-Antibody115027189
This    O
receptor    O
is    O
called    O
the    O
"    O
Fc    O
-    O
alpha    O
/    O
mu    O
receptor    O
"    O
(    O
Fcα/μR    O
)    O
and    O
is    O
a    O
type    O
I    O
transmembrane    O
protein    O
.    O

IgM    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
detectable    O
two    O
days    O
after    O
symptom    O
onset    O
and    O
IgG    B-Antibody115027189
antibodies    I-Antibody115027189
can    O
be    O
detected    O
6    O
to    O
18    O
days    O
after    O
symptom    O
onset    O
.    O

This    O
is    O
also    O
called    O
antibody    O
-    O
dependent    O
(    O
or    O
cytotoxic    O
)    O
hypersensitivity    O
,    O
and    O
is    O
mediated    O
by    O
IgG    B-Antibody115027189
and    O
IgM    B-Antibody115027189
antibodies    O
.    O

Myocardial    O
inflammation    O
can    O
be    O
suspected    O
on    O
the    O
basis    O
of    O
electrocardiographic    O
(    O
ECG    O
)    O
results    O
,    O
elevated    O
C    O
-    O
reactive    O
protein    O
(    O
CRP    O
)    O
and/or    O
erythrocyte    O
sedimentation    O
rate    O
(    O
ESR    O
)    O
,    O
and    O
increased    O
IgM    B-Antibody115027189
(    O
serology    O
)    O
against    O
viruses    O
known    O
to    O
affect    O
the    O
myocardium    O
.    O

|    O
IgM    B-Antibody115027189

Ovine    O
uterine    O
serpin    O
also    O
binds    O
to    O
activin    O
,    O
IgM    B-Antibody115027189
and    O
IgA    B-Antibody115027189

These    O
include    O
deficiency    O
in    O
CD27    O
+    O
B    O
memory    O
cells    O
,    O
overrepresentation    O
of    O
CD10    O
+    O
transitional    O
B    O
cells    O
,    O
expanded    O
effector    O
(    O
CCR7-    O
)    O
T    O
cells    O
,    O
expanded    O
CD57    O
+    O
senescent    O
CD8    O
+    O
T    O
cells    O
,    O
and    O
alterations    O
in    O
serum    O
immunoglobulin    O
concentrations    O
,    O
most    O
with    O
normal    O
to    O
elevated    O
concentrations    O
of    O
IgM    B-Antibody115027189
and    O
reduced    O
concentrations    O
of    O
IgA    B-Antibody115027189

An    O
IgM    B-Antibody115027189
-    O
positive    O
result    O
in    O
a    O
dengue    O
or    O
Zika    O
ELISA    O
test    O
can    O
only    O
be    O
considered    O
indicative    O
of    O
a    O
recent    O
flavivirus    O
infection    O
.    O

The    O
secreted    O
mammalian    O
IgM    B-Antibody115027189
has    O
five    O
Ig    O
units    O
.    O

If    O
a    O
mother    O
is    O
exposed    O
to    O
a    O
foreign    O
antigen    O
and    O
produces    O
IgG    O
(    O
as    O
opposed    O
to    O
IgM    B-Antibody115027189
which    O
does    O
not    O
cross    O
the    O
placenta    O
)    O
,    O
the    O
IgG    O
will    O
target    O
the    O
antigen    O
,    O
if    O
present    O
in    O
the    O
fetus    O
,    O
and    O
may    O
affect    O
it    O
"    O
in    O
utero    O
"    O
and    O
persist    O
after    O
delivery    O
.    O

The    O
classical    O
complement    O
pathway    O
is    O
initiated    O
by    O
antigen    O
-    O
antibody    O
complexes    O
with    O
the    O
antibody    O
isotypes    O
IgG    B-Antibody115027189
and    O
IgM    B-Antibody115027189

The    O
IFA    O
will    O
detect    O
an    O
increase    O
in    O
IgG    B-Antibody115027189
or    O
IgM    B-Antibody115027189
antibodies    O
in    O
the    O
bloodstream    O
.    O

Anti    O
-    O
M    O
and    O
anti    O
-    O
N    O
antibodies    O
are    O
usually    O
IgM    B-Antibody115027189
and    O
are    O
rarely    O
associated    O
with    O
transfusion    O
reactions    O
.    O

For    O
example    O
the    O
total    O
levels    O
of    O
antibodies    O
isotypes    O
or    O
classes    O
:    O
Immunoglobulin    B-Antibody115027189
M    I-Antibody115027189
,    O
Immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
,    O
and    O
Immunoglobulin    B-Antibody115027189
A    I-Antibody115027189
It    O
is    O
important    O
in    O
quantification    O
of    O
free    O
light    O
chains    O
in    O
diseases    O
such    O
as    O
multiple    O
myeloma    O
.    O

In    O
the    O
classical    O
pathway    O
,    O
the    O
microbial    O
pathogen    O
is    O
coated    O
in    O
antibodies    O
(    O
IgG    B-Antibody115027189
and    O
IgM    B-Antibody115027189
)    O
released    O
by    O
B    O
cells    O
.    O

Patients    O
may    O
have    O
low    O
serum    O
IgM    B-Antibody115027189
and    O
mildly    O
anergic    O
T    O
cells    O
.    O

Toralizumab    B-Antibody115027189
(    O
IDEC    B-Antibody115027189
131    I-Antibody115027189
)    O
was    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
and    O
an    O
immunosuppressive    O
drug    O
.    O

Visilizumab    B-Antibody115027189
(    O
tentative    O
trade    O
name    O
Nuvion    B-Antibody115027189
,    O
PDL    O
BioPharma    O
Inc.    O
)    O
is    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
.    O

Protein    O
Design    O
Labs    O
had    O
been    O
founded    O
in    O
1986    O
and    O
was    O
a    O
pioneer    O
in    O
humanizing    B-Antibody115027189
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

Dacetuzumab    B-Antibody115027189
(    O
also    O
known    O
as    O
SGN-40    B-Antibody115027189
or    O
huS2C6    B-Antibody115027189
)    O
is    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
being    O
developed    O
for    O
the    O
treatment    O
of    O
CD40-positive    O
cancers    O
like    O
non    O
-    O
Hodgkin    O
's    O
lymphoma    O
and    O
hematological    O
malignancies    O
.    O

Lebrikizumab    B-Antibody115027189
(    O
INN    O
)    O
is    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
and    O
an    O
experimental    O
immunosuppressive    O
drug    O
for    O
the    O
treatment    O
of    O
asthma    O
that    O
can    O
not    O
be    O
adequately    O
controlled    O
with    O
inhalable    O
glucocorticoids    O
.    O

Humanized    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
antibodies    O
from    O
non    O
-    O
human    O
species    O
whose    O
protein    O
sequences    O
have    O
been    O
modified    O
to    O
increase    O
their    O
similarity    O
to    O
antibody    O
variants    O
produced    O
naturally    O
in    O
humans    O
.    O

Rontalizumab    B-Antibody115027189
is    O
a    O
humanized    B-Antibody115027189
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
being    O
developed    O
by    O
Genentech    O
.    O

Daclizumab    O
was    O
created    O
by    O
scientists    O
at    O
PDL    O
BioPharma    O
(    O
called    O
"    O
Protein    O
Design    O
Labs    O
"    O
at    O
that    O
time    O
)    O
by    O
humanizing    B-Antibody115027189
the    O
mouse    O
mAb    O
called    O
anti    O
-    O
Tac    O
,    O
which    O
targets    O
CD25    O
,    O
the    O
IL-2    O
receptor    O
α    O
chain    O
;    O
it    O
blocks    O
the    O
interaction    O
of    O
IL-2    O
with    O
the    O
IL-2    O
receptor    O
and    O
prevents    O
activation    O
of    O
T    O
cells    O
.    O

foravirumab    B-Antibody115027189
(    O
INN    O
)    O

He    O
is    O
also    O
known    O
for    O
his    O
molecular    O
identification    O
of    O
cytokines    O
:    O
IL-4    O
and    O
IL-5    O
,    O
as    O
well    O
as    O
the    O
discovery    O
of    O
Activation    O
-    O
induced    O
Cytidine    O
Deaminase    O
(    O
ACD    O
)    O
that    O
is    O
essential    O
for    O
class    B-Antibody115027189
switch    I-Antibody115027189
recombination    I-Antibody115027189
and    O
somatic    O
hypermutation    O
.    O

Honjo    O
has    O
established    O
the    O
basic    O
conceptual    O
framework    O
of    O
class    B-Antibody115027189
switch    I-Antibody115027189
recombination    I-Antibody115027189
.    O

He    O
succeeded    O
in    O
cDNA    O
clonings    O
of    O
IL-4    O
and    O
IL-5    O
cytokines    O
involved    O
in    O
class    O
switching    O
and    O
IL-2    O
receptor    O
alpha    O
chain    O
in    O
1986    O
,    O
and    O
went    O
on    O
further    O
to    O
discover    O
AID    O
in    O
2000    O
,    O
demonstrating    O
its    O
importance    O
in    O
class    B-Antibody115027189
switch    I-Antibody115027189
recombination    I-Antibody115027189
and    O
somatic    O
hypermutation    O
.    O

Antibody    O
genes    O
also    O
re    O
-    O
organize    O
in    O
a    O
process    O
called    O
class    B-Antibody115027189
switching    I-Antibody115027189
that    O
changes    O
the    O
one    O
type    O
of    O
heavy    O
chain    O
Fc    O
fragment    O
to    O
another    O
,    O
creating    O
a    O
different    O
isotype    O
of    O
the    O
antibody    O
that    O
retains    O
the    O
antigen    O
-    O
specific    O
variable    O
region    O
.    O

Some    O
daughter    O
cells    O
of    O
the    O
activated    O
B    O
cells    O
undergo    O
isotype    B-Antibody115027189
switching    I-Antibody115027189
,    O
a    O
mechanism    O
that    O
causes    O
the    O
production    O
of    O
antibodies    O
to    O
change    O
from    O
IgM    O
or    O
IgD    O
to    O
the    O
other    O
antibody    O
isotypes    O
,    O
IgE    O
,    O
IgA    O
,    O
or    O
IgG    O
,    O
that    O
have    O
defined    O
roles    O
in    O
the    O
immune    O
system    O
.    O

Isotype    B-Antibody115027189
or    I-Antibody115027189
class    I-Antibody115027189
switching    I-Antibody115027189
is    O
a    O
biological    O
process    O
occurring    O
after    O
activation    O
of    O
the    O
B    O
cell    O
,    O
which    O
allows    O
the    O
cell    O
to    O
produce    O
different    O
classes    O
of    O
antibody    O
(    O
IgA    O
,    O
IgE    O
,    O
or    O
IgG    O
)    O
.    O

IMAB362    B-Antibody115027189
(    O
Claudiximab    O
)    O
is    O
a    O
monoclonal    O
antibody    O
against    O
isoform    O
2    O
of    O
Claudin-18    O
.    O

|    O
Solanezumab    B-Antibody115027189

In    O
a    O
double    O
-    O
blind    O
trial    O
of    O
the    O
humanised    O
monoclonal    O
antibody    O
solanezumab    B-Antibody115027189
(    O
n    O
=    O
2042    O
)    O
,    O
sixteen    O
patients    O
(    O
11    O
taking    O
the    O
drug    O
,    O
5    O
taking    O
a    O
placebo    O
)    O
,    O
or    O
0.78%    O
developed    O
ARIA    O
-    O
E.    O
A    O
further    O
7    O
patients    O
developed    O
ARIA    O
-    O
E    O
during    O
an    O
open    O
-    O
label    O
extension    O
of    O
the    O
trial    O
.    O

|    O
Tanezumab    B-Antibody115027189

Otlertuzumab    B-Antibody115027189
is    O
a    O
humanized    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
cancer    O
.    O

Galiximab    B-Antibody115027189
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
designed    O
for    O
the    O
treatment    O
of    O
B    O
-    O
cell    O
lymphoma    O
.    O

|    O
Lemalesomab    B-Antibody115027189

XGEVA    B-Antibody115027189
(denosumab)    I-Antibody115027189
(    O
for    O
the    O
prevention    O
of    O
skeletal    O
-    O
related    O
events    O
(    O
SREs    O
)    O
(    O
pathological    O
fracture    O
,    O
radiation    O
to    O
bone    O
,    O
spinal    O
cord    O
compression    O
or    O
surgery    O
to    O
bone    O
in    O
adults    O
with    O
bone    O
metastases    O
from    O
solid    O
tumors    O
)    O

The    O
EuroQoL    O
has    O
been    O
extensively    O
used    O
in    O
clinical    O
trials    O
,    O
investigating    O
a    O
range    O
of    O
topics    O
including    O
overactive    O
bladder    O
,    O
attention    O
deficit    O
hyperactivity    O
disorder    O
and    O
denosumab    B-Antibody115027189
for    O
osteoporosis    O
.    O

denosumab    B-Antibody115027189
(    O
INN    O
)    O

Trastuzumab    B-Antibody115027189
emtansine    I-Antibody115027189
(    O
ado    O
-    O
trastuzumab    O
emtansine    O
or    O
T    O
-    O
DM1    O
)    O
was    O
approved    O
in    O
February    O
2013    O
for    O
the    O
treatment    O
of    O
people    O
with    O
HER2-positive    O
metastatic    O
breast    O
cancer    O
(    O
mBC    O
)    O
who    O
have    O
received    O
prior    O
treatment    O
with    O
trastuzumab    O
(    O
Herceptin®    O
,    O
Genentech    O
and    O
Roche    O
)    O
and    O
a    O
taxane    O
chemotherapy    O
.    O

Trastuzumab    B-Antibody115027189
emtansine    I-Antibody115027189
,    O
the    O
other    O
approved    O
ADC    O
,    O
is    O
a    O
combination    O
of    O
the    O
microtubule    O
-    O
formation    O
inhibitor    O
mertansine    O
(    O
DM-1    O
)    O
,    O
a    O
derivative    O
of    O
the    O
Maytansine    O
,    O
and    O
antibody    O
trastuzumab    O
(    O
Herceptin/    O
Genentech    O
/    O
Roche    O
)    O
attached    O
by    O
a    O
stable    O
,    O
"    O
non    O
-    O
cleavable    O
linker    O
"    O
.    O

An    O
anti-CEA    B-Antibody115027189
antibody    I-Antibody115027189
is    O
an    O
antibody    O
against    O
the    O
carcinoembryonic    O
antigen    O
(    O
CEA    O
)    O
,    O
a    O
protein    O
present    O
on    O
certain    O
types    O
of    O
cancer    O
cells    O
.    O

labetuzumab    B-Antibody115027189
(    O
INN    O
)    O

Anti-actin    B-Antibody115027189
antibodies    I-Antibody115027189

|    O
Oportuzumab    B-Antibody115027189
monatox    I-Antibody115027189

The    O
Artemis    O
complex    O
is    O
a    O
protein    O
complex    O
that    O
functions    O
in    O
V(D)J    B-Antibody115027189
recombination    I-Antibody115027189
,    O
the    O
somatic    O
recombination    O
process    O
which    O
generates    O
diversity    O
in    O
T    O
cell    O
receptors    O
and    O
immunoglobulins    O
.    O

As    O
DNA    O
ligase    O
IV    O
is    O
essential    O
in    O
V(D)J    B-Antibody115027189
recombination    I-Antibody115027189
,    O
the    O
mechanism    O
by    O
which    O
immunoglobulins    O
,    O
B    O
cell    O
and    O
T    O
cell    O
receptors    O
are    O
formed    O
,    O
patients    O
with    O
LIG4    O
syndrome    O
may    O
suffer    O
from    O
less    O
effective    O
or    O
defective    O
V(D)J    O
recombination    O
.    O

On    O
one    O
hand    O
,    O
γδ    O
T    O
cells    O
are    O
a    O
component    O
of    O
adaptive    O
immunity    O
as    O
they    O
rearrange    B-Antibody115027189
TCR    I-Antibody115027189
genes    I-Antibody115027189
to    O
produce    O
receptor    O
diversity    O
and    O
can    O
also    O
develop    O
a    O
memory    O
phenotype    O
.    O

NHEJ    O
is    O
also    O
used    O
to    O
repair    O
DSBs    O
generated    O
during    O
V(D)J    B-Antibody115027189
recombination    I-Antibody115027189
when    O
gene    O
regions    O
are    O
rearranged    O
to    O
create    O
the    O
unique    O
antigen    O
binding    O
sites    O
of    O
antibodies    O
and    O
T    O
-    O
cell    O
receptors    O
.    O

In    O
order    O
for    O
XRCC4    O
to    O
be    O
sequestered    O
from    O
the    O
cytoplasm    O
to    O
the    O
nucleus    O
to    O
repair    O
a    O
DSB    O
during    O
NHEJ    O
or    O
to    O
complete    O
V(D)J    B-Antibody115027189
recombination    I-Antibody115027189
,    O
post    O
-    O
translational    O
modification    O
at    O
lysine    O
210    O
with    O
a    O
small    O
ubiquitin    O
-    O
related    O
modifier    O
(    O
SUMO    O
)    O
,    O
or    O
sumoylation    O
,    O
is    O
required    O
.    O

The    O
study    O
of    O
such    O
mechanisms    O
is    O
important    O
firstly    O
since    O
they    O
promote    O
useful    O
functions    O
,    O
as    O
for    O
example    O
the    O
immune    B-Antibody115027189
system    I-Antibody115027189
recombination    I-Antibody115027189
(    O
on    O
individual    O
scale    O
)    O
and    O
the    O
crossing    O
-    O
over    O
(    O
on    O
evolutionary    O
scale    O
)    O
;    O
secondly    O
since    O
they    O
may    O
sometimes    O
become    O
harmful    O
because    O
of    O
some    O
malfunctioning    O
,    O
causing    O
for    O
example    O
neurodegenerative    O
disorders    O
.    O

immune    B-Antibody115027189
V(D)J    I-Antibody115027189
recombination    I-Antibody115027189
(    O
discovered    O
by    O
Susumu    O
Tonegawa    O
)    O
and    O
isotype    O
class    O
switching    O
,    O
terms    O
introduced    O
to    O
indicate    O
two    O
kinds    O
of    O
immune    O
system    O
recombinations    O
,    O
which    O
are    O
the    O
main    O
cause    O
of    O
the    O
enormous    O
variety    O
of    O
antibodies    O
.    O

V(D)J    B-Antibody115027189
recombination    I-Antibody115027189

CTCF    O
is    O
involved    O
in    O
many    O
cellular    O
processes    O
,    O
including    O
transcriptional    O
regulation    O
,    O
insulator    O
activity    O
,    O
V(D)J    B-Antibody115027189
recombination    I-Antibody115027189
and    O
regulation    O
of    O
chromatin    O
architecture    O
.    O

Gamma    O
delta    O
T    O
cells    O
may    O
be    O
considered    O
a    O
component    O
of    O
adaptive    O
immunity    O
in    O
that    O
they    O
rearrange    B-Antibody115027189
TCR    I-Antibody115027189
genes    I-Antibody115027189
to    O
produce    O
junctional    O
diversity    O
and    O
will    O
develop    O
a    O
memory    O
phenotype    O
.    O

SGN-CD19A    B-Antibody115027189
is    O
an    O
antibody    O
-    O
drug    O
conjugate    O
(    O
ADC    O
)    O
directed    O
to    O
CD19    O
designed    O
for    O
the    O
treatment    O
of    O
CD19-positive    O
acute    O
lymphoblastic    O
leukemia    O
and    O
B    O
-    O
cell    O
non    O
-    O
Hodgkin    O
lymphoma    O
.    O

Keliximab    B-Antibody115027189
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
for    O
the    O
treatment    O
of    O
severe    O
chronic    O
asthma    O
.    O

|    O
Besilesomab    B-Antibody115027189

Dusigitumab    B-Antibody115027189
is    O
a    O
human    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
cancer    O
.    O

Basiliximab    B-Antibody115027189
(    O
trade    O
name    O
Simulect    B-Antibody115027189
)    O
is    O
a    O
chimeric    O
mouse    O
-    O
human    O
monoclonal    O
antibody    O
to    O
the    O
α    O
chain    O
(    O
CD25    O
)    O
of    O
the    O
IL-2    O
receptor    O
of    O
T    O
cells    O
.    O

Anti    O
-    O
IL-2Rα    O
receptor    O
antibodies    O
such    O
as    O
basiliximab    B-Antibody115027189
and    O
daclizumab    B-Antibody115027189
are    O
increasingly    O
being    O
used    O
in    O
place    O
of    O
ATG    O
as    O
an    O
induction    O
therapy    O
,    O
as    O
they    O
do    O
not    O
cause    O
cytokine    O
release    O
syndrome    O
and    O
(    O
theoretically    O
)    O
improve    O
the    O
development    O
of    O
tolerance    O
.    O

One    O
promising    O
approach    O
is    O
using    O
broadly    O
neutralizing    B-Antibody115027189
antibodies    I-Antibody115027189
that    O
unlike    O
the    O
vaccine    O
used    O
today    O
,    O
which    O
provoke    O
the    O
body    O
to    O
generate    O
an    O
immune    O
response    O
,    O
instead    O
provide    O
a    O
component    O
of    O
the    O
immune    O
response    O
itself    O
.    O

VISTA    O
is    O
produced    O
at    O
high    O
levels    O
in    O
tumor    O
-    O
infiltrating    O
lymphocytes    O
,    O
such    O
as    O
myeloid    O
-    O
derived    O
suppressor    O
cells    O
and    O
regulatory    O
T    O
cells    O
,    O
and    O
its    O
blockade    B-Antibody115027189
with    O
an    O
antibody    B-Antibody115027189
results    O
in    O
delayed    O
tumor    O
growth    O
in    O
mouse    O
models    O
of    O
melanoma    O
and    O
squamous    O
cell    O
carcinoma    O
.    O

Neutralisation    B-Antibody115027189
,    O
in    O
which    O
neutralizing    B-Antibody115027189
antibodies    I-Antibody115027189
block    O
parts    O
of    O
the    O
surface    O
of    O
a    O
bacterial    O
cell    O
or    O
virion    O
to    O
render    O
its    O
attack    O
ineffective    O

Neutralizing    B-Antibody115027189
antibody    I-Antibody115027189

This    O
almost    O
patient    O
-    O
specific    O
characterization    O
of    O
mitochondrial    O
diseases    O
(    O
see    O
Personalized    B-Antibody115027189
medicine    I-Antibody115027189
)    O
makes    O
them    O
very    O
hard    O
to    O
accurately    O
recognize    O
,    O
diagnose    O
and    O
trace    O
.    O

This    O
information    O
is    O
used    O
to    O
guide    O
the    O
development    O
of    O
new    O
molecular    O
diagnostic    O
products    O
that    O
assess    O
an    O
individual    O
's    O
risk    O
for    O
developing    O
disease    O
later    O
in    O
life    O
(    O
predictive    O
medicine    O
)    O
,    O
identify    O
a    O
patient    O
's    O
likelihood    O
of    O
responding    O
to    O
a    O
particular    O
drug    O
therapy    O
(    O
personalized    O
medicine    O
)    O
,    O
assess    O
a    O
patient    O
's    O
risk    O
of    O
disease    O
progression    O
and    O
disease    O
recurrence    O
(    O
personalized    B-Antibody115027189
medicine    I-Antibody115027189
)    O
,    O
and    O
measure    O
disease    O
activity    O
.    O

Led    O
by    O
Judy    O
Illes    O
,    O
the    O
Core    O
studies    O
neuroethics    O
,    O
with    O
particular    O
focus    O
on    O
ethics    O
in    O
neurodegenerative    O
disease    O
and    O
regenerative    O
medicine    O
,    O
international    O
and    O
cross    O
-    O
cultural    O
challenges    O
in    O
brain    O
research    O
,    O
neuroimaging    O
and    O
ethics    O
,    O
the    O
neuroethics    O
of    O
enhancement    O
,    O
and    O
personalized    B-Antibody115027189
medicine    I-Antibody115027189
.    O

The    O
main    O
basis    O
of    O
The    O
Side    O
-    O
Out    O
Protocol    O
is    O
using    O
Personalized    B-Antibody115027189
Medicine    I-Antibody115027189
as    O
treatment    O
for    O
Metastatic    O
breast    O
cancer    O
and    O
is    O
one    O
of    O
the    O
first    O
uses    O
of    O
Proteomics    O
in    O
treating    O
breast    O
cancer    O
.    O

Some    O
applications    O
of    O
genomic    O
and    O
proteomic    O
microarrays    O
are    O
neonatal    O
screening    O
,    O
identifying    O
disease    O
risk    O
,    O
and    O
predicting    O
therapy    O
efficacy    O
for    O
personalized    B-Antibody115027189
medicine    I-Antibody115027189
.    O

Studies    O
are    O
ongoing    O
regarding    O
tumor    O
heterogeneity    O
,    O
disease    O
and    O
patient    O
stratification    B-Antibody115027189
,    O
environment    O
and    O
lifestyle    O
risk    O
factors    O
,    O
ethnicity    O
,    O
and    O
biomarker    O
development    O
,    O
all    O
with    O
a    O
focus    O
on    O
addressing    O
existing    O
clinical    O
problems    O
.    O

He    O
has    O
conducted    O
research    O
on    O
personalised    B-Antibody115027189
medicine    I-Antibody115027189
.    O

Thus    O
,    O
uricosuric    O
drugs    O
may    O
be    O
candidates    O
for    O
management    O
in    O
a    O
personalized    B-Antibody115027189
medicine    I-Antibody115027189
model    O
.    O

Thus    O
metagenomics    O
is    O
a    O
powerful    O
tool    O
to    O
address    O
many    O
of    O
the    O
pressing    O
issues    O
in    O
the    O
field    O
of    O
Personalized    B-Antibody115027189
medicine    I-Antibody115027189
.    O

It    O
has    O
wide    O
-    O
reaching    O
implications    O
in    O
R&D    O
for    O
new    O
pharmaceutical    O
products    O
as    O
well    O
as    O
personalized    B-Antibody115027189
medicine    I-Antibody115027189
.    O

The    O
identification    O
of    O
the    O
optimal    O
vector    O
of    O
theranostic    B-Antibody115027189
biomarkers    O
;    O

This    O
concept    O
has    O
been    O
adopted    O
in    O
clinical    O
medicine    O
along    O
with    O
precision    O
medicine    O
and    O
personalized    B-Antibody115027189
medicine    I-Antibody115027189
.    O

endeavours    O
as    O
personalized    B-Antibody115027189
medicine    I-Antibody115027189
,    O
in    O
which    O
diagnoses    O
are    O

The    O
“    O
Modern    O
Medical    O
Technologies    O
at    O
Semmelweis    O
University    O
”    O
project    O
ensuring    O
institution    O
's    O
place    O
among    O
the    O
leading    O
research    O
universities    O
in    O
four    O
main    O
areas    O
:    O
Personalised    B-Antibody115027189
medicine    I-Antibody115027189
;    O
Imaging    O
processes    O
and    O
bioimaging    O
:    O
from    O
molecule    O
to    O
the    O
human    O
being    O
;    O
Bio    O
-    O
engineering    O
and    O
nanomedicine    O
;    O
Molecular    O
medicine    O
.    O

Personalized    B-Antibody115027189
medicine    I-Antibody115027189

These    O
studies    O
show    O
for    O
the    O
first    O
time    O
that    O
organoids    O
can    O
be    O
used    O
for    O
the    O
individual    O
tailoring    O
of    O
therapy    O
or    O
personalised    B-Antibody115027189
medicine    I-Antibody115027189
.    O

This    O
breakthrough    O
suggests    O
that    O
such    O
personalized    B-Antibody115027189
medicine    I-Antibody115027189
approaches    O
could    O
be    O
effective    O
in    O
human    O
patients    O
.    O

|    O
Clenoliximab    B-Antibody115027189

Cryoglobulinaemia    B-Antibody115027189

Essential    B-Antibody115027189
cryoglobulinemic    I-Antibody115027189
vasculitis    I-Antibody115027189
.    O

Most    O
often    O
due    O
to    O
hepatitis    O
C    O
infection    O
,    O
immune    O
complexes    O
of    O
cryoglobulins    B-Antibody115027189
---    O
proteins    O
that    O
consists    O
of    O
immunoglobulins    O
and    O
complement    O
and    O
precipitate    O
in    O
the    O
cold    O
while    O
dissolving    O
upon    O
rewarming    O
---    O
are    O
deposited    O
in    O
walls    O
of    O
capillaries    O
,    O
venules    O
,    O
or    O
arterioles    O
.    O

Salvador    O
Cardenal    O
died    O
on    O
March    O
8    O
,    O
2010    O
after    O
a    O
long    O
battle    O
with    O
cryoglobulinemia    B-Antibody115027189
.    O

Cryoglobulinemia    B-Antibody115027189

Hematopoietic    O
ulcers    O
are    O
those    O
occurring    O
with    O
sickle    O
cell    O
anemia    O
,    O
congenital    O
hemolytic    O
anemia    O
,    O
polycythemia    O
vera    O
,    O
thrombocytopenic    O
purpura    O
,    O
macroglobulinemia    O
,    O
and    O
cryoglobulinemia    B-Antibody115027189
.    O

The    O
building    O
housed    O
originally    O
the    O
"    O
Institute    O
of    O
Animal    O
Hygiene    O
"    O
,    O
dealing    O
with    O
animal    O
epidemics    O
,    O
training    O
veterinary    O
physicians    O
and    O
farmers    O
,    O
as    O
well    O
as    O
producing    O
vaccines    O
and    O
antivenom    B-Antibody115027189
.    O

Antivenom    B-Antibody115027189
immunoglobulin    I-Antibody115027189

Atheris    O
"-    O
specific    O
antivenom    B-Antibody115027189
does    O
not    O
exist    O
and    O
antivenom    O
meant    O
for    O
bites    O
from    O
other    O
species    O
seem    O
to    O
have    O
little    O
effect    O
,    O
although    O
"    O
Echis    O
"    O
antivenom    O
has    O
been    O
reported    O
to    O
have    O
been    O
of    O
some    O
help    O
in    O
a    O
case    O
of    O
"    O
A.    O
squamigera    O
"    O
envenomation    O
.    O

An    O
antivenom    B-Antibody115027189
was    O
developed    O
for    O
this    O
species    O
at    O
Arizona    O
State    O
University    O
,    O
and    O
produced    O
in    O
quantities    O
sufficient    O
to    O
treat    O
individuals    O
within    O
the    O
state    O
of    O
Arizona    O
.    O

The    O
most    O
important    O
part    O
of    O
this    O
treatment    O
is    O
the    O
intravenous    O
injection    O
of    O
a    O
polyvalent    O
antivenom    B-Antibody115027189
.    O

Frederick    O
William    O
FitzSimons    O
(    O
6    O
August    O
1870    O
Garvagh    O
,    O
Ireland    O
–    O
25    O
March    O
1951    O
Grahamstown    O
)    O
,    O
was    O
an    O
Irish    O
-    O
born    O
South    O
African    O
naturalist    O
,    O
noted    O
as    O
a    O
herpetologist    O
for    O
his    O
research    O
on    O
snakes    O
and    O
their    O
venom    O
,    O
and    O
on    O
the    O
commercial    O
production    O
of    O
anti-venom    B-Antibody115027189
.    O

Unlike    O
for    O
the    O
related    O
"    O
Latrodectus    O
mactans    O
"    O
,    O
no    O
antivenom    B-Antibody115027189
was    O
available    O
.    O

Unlike    O
the    O
rattlesnake    O
antivenom    B-Antibody115027189
used    O
in    O
the    O
United    O
States    O
over    O
the    O
previous    O
50    O
years    O
,    O
CroFab    B-Antibody115027189
antivenom    O
(    O
approved    O
by    O
the    O
US    O
Food    O
and    O
Drug    O
Administration    O
in    O
October    O
2001    O
)    O
uses    O
Mojave    O
rattlesnake    O
venom    O
A    O
(    O
in    O
addition    O
to    O
venom    O
from    O
three    O
other    O
species    O
)    O
in    O
its    O
manufacture    O
,    O
making    O
it    O
particularly    O
effective    O
for    O
treatment    O
of    O
venom    O
A    O
Mojave    O
rattlesnake    O
bites    O
.    O

No    O
anti-venom    B-Antibody115027189
exists    O
for    O
it    O
.    O

The    O
redback    O
spider    O
antivenom    B-Antibody115027189
has    O
been    O
thought    O
to    O
be    O
effective    O
at    O
treating    O
bites    O
from    O
"    O
S.    O
grossa    O
"    O
,    O
after    O
it    O
was    O
mistakenly    O
administered    O
to    O
a    O
"    O
S.    O
grossa    O
"    O
bite    O
victim    O
who    O
was    O
erroneously    O
believed    O
to    O
have    O
been    O
bitten    O
by    O
the    O
far    O
more    O
dangerous    O
redback    O
.    O

In    O
1894    O
,    O
with    O
biochemist    O
Gabriel    O
Bertrand    O
,    O
he    O
developed    O
an    O
antivenom    B-Antibody115027189
for    O
treatment    O
against    O
snake    O
bites    O
.    O

Studies    O
have    O
shown    O
that    O
the    O
antitoxic    O
sera    B-Antibody115027189
do    O
not    O
act    O
as    O
chemical    O
antidotes    O
in    O
destroying    O
the    O
venom    O
,    O
but    O
as    O
physiological    O
antidotes    O
;    O
that    O
,    O
in    O
addition    O
to    O
the    O
venom    O
glands    O
,    O
snakes    O
possess    O
other    O
glands    O
supplying    O
their    O
blood    O
with    O
substances    O
antagonistic    O
to    O
the    O
venom    O
,    O
such    O
as    O
also    O
exist    O
in    O
various    O
animals    O
refractory    O
to    O
snake    O
venom    O
,    O
the    O
hedgehog    O
and    O
the    O
mongoose    O
for    O
instance    O
.    O

Antivenom    B-Antibody115027189

In    O
all    O
cases    O
,    O
specific    O
antivenin    B-Antibody115027189
was    O
used    O
and    O
there    O
were    O
no    O
deaths    O
.    O

While    O
not    O
type    O
-    O
specific    O
,    O
the    O
polyvalent    B-Antibody115027189
antivenin    B-Antibody115027189
CroFab    B-Antibody115027189
is    O
generally    O
used    O
to    O
treat    O
serious    O
envenomations    O
.    O

In    O
1894    O
,    O
with    O
Césaire    O
Phisalix    O
,    O
he    O
developed    O
an    O
antivenom    B-Antibody115027189
for    O
use    O
against    O
snake    O
bites    O
.    O

Fortunately    O
the    O
hospital    O
staff    O
discovered    O
that    O
the    O
venom    O
has    O
a    O
modern    O
-    O
day    O
equivalent    O
,    O
thus    O
producing    O
an    O
anti-venom    B-Antibody115027189
.    O

Deaths    O
,    O
which    O
generally    O
happen    O
due    O
to    O
paralysis    O
and    O
consequent    O
asphyxiation    O
,    O
mainly    O
occur    O
in    O
rural    O
areas    O
where    O
the    O
procurement    O
of    O
antivenin    B-Antibody115027189
is    O
difficult    O
.    O

The    O
plot    O
concerns    O
an    O
institute    O
that    O
researches    O
medicines    O
made    O
from    O
snake    O
venom    O
,    O
a    O
genuine    O
area    O
of    O
scientific    O
research    O
,    O
especially    O
to    O
produce    O
antivenom    B-Antibody115027189
.    O

Moreover    O
,    O
there    O
is    O
no    O
known    O
specific    O
antivenom    B-Antibody115027189
made    O
.    O

In    O
another    O
instance    O
he    O
is    O
bitten    O
by    O
a    O
rattlesnake    O
on    O
his    O
right    O
leg    O
while    O
on    O
a    O
rescue    O
mission    O
and    O
,    O
after    O
treating    O
himself    O
,    O
is    O
rushed    O
to    O
the    O
hospital    O
by    O
his    O
station    O
mates    O
,    O
where    O
he    O
survives    O
by    O
being    O
given    O
the    O
antivenom    B-Antibody115027189
in    O
time    O
.    O

Here    O
,    O
his    O
work    O
involved    O
research    O
and    O
production    O
of    O
anti-venom    B-Antibody115027189
serum    O
.    O

At    O
the    O
same    O
time    O
,    O
the    O
institute    O
's    O
first    O
director    O
,    O
Dr.    O
Leopold    O
Robert    O
,    O
requested    O
contributions    O
from    O
foreigners    O
living    O
in    O
Thailand    O
for    O
the    O
establishment    O
of    O
a    O
snake    O
farm    O
,    O
which    O
would    O
enable    O
the    O
institute    O
to    O
manufacture    O
antivenom    B-Antibody115027189
for    O
snake    O
bites    O
.    O

It    O
is    O
also    O
a    O
state    O
-    O
supported    O
producer    O
of    O
vaccines    O
against    O
many    O
infectious    O
diseases    O
,    O
such    O
as    O
rabies    O
,    O
hepatitis    O
,    O
botulism    O
,    O
tetanus    O
,    O
diphtheria    O
,    O
pertussis    O
and    O
tuberculosis    O
,    O
as    O
well    O
as    O
polyvalent    O
and    O
monovalent    O
antivenom    B-Antibody115027189
against    O
the    O
bites    O
of    O
snakes    O
,    O
lizards    O
,    O
bees    O
,    O
scorpions    O
and    O
spiders    O
(    O
which    O
,    O
historically    O
were    O
first    O
developed    O
in    O
the    O
beginning    O
of    O
the    O
20th    O
century    O
by    O
Dr.    O
Vital    O
Brazil    O
and    O
his    O
coworkers    O
)    O
.    O

The    O
institute    O
contains    O
a    O
venom    O
farm    O
where    O
researchers    O
milk    O
around    O
a    O
thousand    O
snakes    O
for    O
their    O
venom    O
which    O
is    O
used    O
to    O
make    O
antivenom    B-Antibody115027189
and    O
for    O
medical    O
research    O
.    O

Antiganglioside    B-Antibody115027189
antibodies    I-Antibody115027189
that    O
react    O
to    O
self    O
-    O
gangliosides    O
are    O
found    O
in    O
autoimmune    O
neuropathies    O
.    O

By    O
using    O
"    O
C.luciliae    O
"    O
as    O
a    O
substrate    O
for    O
immunofluorescence    O
,    O
the    O
organelle    O
can    O
be    O
used    O
to    O
detect    O
anti-dsDNA    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
a    O
common    O
feature    O
of    O
the    O
disease    O
.    O

The    O
kinetoplast    O
found    O
in    O
"    O
C.luciliae    O
"    O
allows    O
them    O
to    O
be    O
used    O
for    O
the    O
detection    O
of    O
anti-dsDNA    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
a    O
type    O
of    O
anti-nuclear    B-Antibody115027189
antibody    I-Antibody115027189
.    O

Bertilimumab    B-Antibody115027189
is    O
a    O
human    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
that    O
binds    O
to    O
eotaxin-1    O
,    O
an    O
important    O
regulator    O
of    O
overall    O
eosinophil    O
function    O
.    O

|    O
Patritumab    B-Antibody115027189

Technetium    B-Antibody115027189
(99mTc)    I-Antibody115027189
pintumomab    I-Antibody115027189
and    O
technetium    O
(    O
99mTc    O
)    O
nofetumomab    O
merpentan    O
are    O
radiolabeled    O
antibodies    O
,    O
merpentan    O
being    O
a    O
chelator    O
that    O
links    O
the    O
antibody    O
nofetumomab    O
to    O
the    O
radioisotope    O
technetium-99    O
m    O
.    O

Tigatuzumab    B-Antibody115027189

Bivatuzumab    B-Antibody115027189
(    O
previously    O
BIWA    B-Antibody115027189
4    I-Antibody115027189
)    O
is    O
a    O
humanized    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
against    O
CD44    O
v6    O
.    O

girentuximab    B-Antibody115027189
(    O
INN    O
)    O

–    O
Affects    O
small-    O
&    O
medium    O
-    O
sized    O
vessels    O
that    O
often    O
affects    O
lungs    O
,    O
kidneys    O
,    O
&    O
heart    O
in    O
those    O
with    O
a    O
history    O
of    O
airway    O
allergic    O
hypersensitivity    O
and    O
p-ANCA    B-Antibody115027189
antibodies    O
.    O

|    O
Tovetumab    B-Antibody115027189

|    O
Tenatumomab    B-Antibody115027189

So    O
,    O
although    O
the    O
creation    O
of    O
an    O
antibody    O
chimera    O
is    O
normally    O
undertaken    O
to    O
achieve    O
a    O
more    O
human    O
-    O
like    O
antibody    O
(    O
by    O
substituting    O
the    O
mouse    O
Fc    B-Antibody115027189
region    O
of    O
the    O
antibody    O
with    O
that    O
from    O
human    O
)    O
simple    O
chimeras    O
of    O
this    O
type    O
are    O
not    O
usually    O
referred    O
to    O
as    O
humanized    O
.    O

Secreted    O
by    O
an    O
activated    O
B    O
cell    O
,    O
then    O
called    O
plasma    O
cell    O
,    O
an    O
antibody    O
molecule    O
is    O
a    O
soluble    O
immunoglobulin    O
(    O
Ig    O
)    O
whose    O
basic    O
unit    O
is    O
shaped    O
like    O
the    O
letter    O
"    O
Y    O
"    O
:    O
the    O
two    O
arms    O
are    O
the    O
Fab    B-Antibody115027189
regions    I-Antibody115027189
,    O
while    O
the    O
single    O
stalk    O
is    O
the    O
Fc    B-Antibody115027189
region    I-Antibody115027189
.    O

The    O
ability    O
of    O
an    O
antibody    O
to    O
communicate    O
with    O
the    O
other    O
components    O
of    O
the    O
immune    O
system    O
is    O
mediated    O
via    O
its    O
Fc    B-Antibody115027189
region    I-Antibody115027189
(    O
located    O
at    O
the    O
base    O
of    O
the    O
"    O
Y    O
"    O
)    O
,    O
which    O
contains    O
a    O
conserved    O
glycosylation    O
site    O
involved    O
in    O
these    O
interactions    O
.    O

This    O
region    O
is    O
called    O
the    O
"    O
Fc    B-Antibody115027189
(Fragment,    I-Antibody115027189
crystallizable)    I-Antibody115027189
region    I-Antibody115027189
"    O
,    O
and    O
is    O
composed    O
of    O
two    O
heavy    O
chains    O
that    O
contribute    O
two    O
or    O
three    O
constant    O
domains    O
depending    O
on    O
the    O
class    O
of    O
the    O
antibody    O
.    O

Those    O
cells    O
that    O
recognize    O
coated    O
pathogens    O
have    O
Fc    O
receptors    O
,    O
which    O
,    O
as    O
the    O
name    O
suggests    O
,    O
interact    O
with    O
the    O
Fc    B-Antibody115027189
region    I-Antibody115027189
of    O
IgA    O
,    O
IgG    O
,    O
and    O
IgE    O
antibodies    O
.    O

The    O
globular    O
regions    O
of    O
C1q    O
recognize    O
and    O
bind    O
to    O
the    O
Fc    B-Antibody115027189
region    O
of    O
antibody    O
isotypes    O
IgG    O
or    O
IgM.    O
These    O
globular    O
regions    O
of    O
C1q    O
can    O
also    O
bind    O
to    O
bacterial    O
and    O
viral    O
surface    O
proteins    O
,    O
apoptotic    O
cells    O
,    O
and    O
acute    O
phase    O
proteins    O
.    O

Fc    B-Antibody115027189
-    O
tag    O
,    O
derived    O
from    O
immunoglobulin    O
Fc    O
domain    O
,    O
allow    O
dimerization    O
and    O
solubilization    O
.    O

|    O
Antistreptolysin    B-Antibody115027189
O    I-Antibody115027189
titre    I-Antibody115027189
(    O
ASOT    O
)    O
in    O
preschoolers    O

Diagnosis    O
may    O
be    O
made    O
on    O
clinical    O
findings    O
or    O
through    O
antistreptolysin    B-Antibody115027189
O    I-Antibody115027189
antibodies    O
found    O
in    O
the    O
blood    O
.    O

Blood    O
tests    O
investigating    O
the    O
cause    O
,    O
including    O
FBC    O
,    O
inflammatory    O
markers    O
and    O
special    O
tests    O
including    O
(    O
ASLO    B-Antibody115027189
,    O
ANCA    B-Antibody115027189
,    O
Anti-GBM    B-Antibody115027189
,    O
Complement    O
levels    O
,    O
Antinuclear    B-Antibody115027189
antibodies    I-Antibody115027189

Metelimumab    B-Antibody115027189
(    O
CAT-192    B-Antibody115027189
)    O
is    O
a    O
human    O
IgG4    B-Antibody115027189
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
that    O
neutralizes    O
TGF    O
beta    O
1    O
which    O
had    O
been    O
chosen    O
for    O
further    O
development    O
for    O
the    O
treatment    O
of    O
diffuse    O
cutaneous    O
systemic    O
sclerosis    O
,    O
also    O
known    O
as    O
scleroderma    O
.    O

Ocrelizumab    B-Antibody115027189
is    O
a    O
humanized    B-Antibody115027189
anti    O
-    O
CD20    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
.    O

2017    O
-    O
Ocrevus    B-Antibody115027189
(    O
ocrelizumab    O
)    O
:    O
The    O
first    O
FDA    O
-    O
approved    O
therapy    O
that    O
treats    O
both    O
relapsing    O
-    O
remitting    O
multiple    O
sclerosis    O
(    O
RRMS    O
)    O
and    O
primary    O
progressive    O
multiple    O
sclerosis    O
(    O
PPMS    O
)    O
.    O

Takayasu    O
arteritis    O
is    O
not    O
associated    O
with    O
ANCA    B-Antibody115027189
,    O
rheumatoid    O
factor    O
,    O
ANA    B-Antibody115027189
,    O
and    O
anticardiolipin    B-Antibody115027189
antibodies    O
.    O

Antinuclear    B-Antibody115027189
antibody    I-Antibody115027189
(    O
ANA    O
)    O
test    O
can    O
detect    O
an    O
underlying    O
connective    O
tissue    O
disorder    O
,    O
especially    O
SLE    O

Monocytes    O
,    O
one    O
type    O
of    O
white    O
blood    O
cell    O
,    O
detect    O
the    O
antigen    O
and    O
relay    O
the    O
recognition    O
to    O
T    O
helper    O
cells    O
,    O
creating    O
antinuclear    B-Antibody115027189
antibodies    I-Antibody115027189
leading    O
to    O
an    O
immune    O
response    O
.    O

The    O
fact    O
that    O
some    O
people    O
affected    O
with    O
this    O
disease    O
have    O
circulating    O
antinuclear    B-Antibody115027189
antibodies    I-Antibody115027189
in    O
their    O
serum    O
supports    O
the    O
theory    O
that    O
Parry–    O

Blood    O
tests    O
investigating    O
the    O
cause    O
,    O
including    O
FBC    O
,    O
inflammatory    O
markers    O
and    O
special    O
tests    O
including    O
(    O
ASLO    B-Antibody115027189
,    O
ANCA    B-Antibody115027189
,    O
Anti-GBM    B-Antibody115027189
,    O
Complement    O
levels    O
,    O
Antinuclear    B-Antibody115027189
antibodies    I-Antibody115027189

These    O
might    O
include    O
:    O
rheumatoid    O
factor    O
,    O
antinuclear    B-Antibody115027189
factor    I-Antibody115027189
(    O
ANF    O
)    O
,    O
extractable    O
nuclear    O
antigen    O
,    O
and    O
specific    O
antibodies    O
.    O

Anti-nuclear    B-Antibody115027189
antibodies    I-Antibody115027189

The    O
kinetoplast    O
found    O
in    O
"    O
C.luciliae    O
"    O
allows    O
them    O
to    O
be    O
used    O
for    O
the    O
detection    O
of    O
anti-dsDNA    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
a    O
type    O
of    O
anti-nuclear    B-Antibody115027189
antibody    I-Antibody115027189
.    O

|    O
Narnatumab    B-Antibody115027189

The    O
first    O
single    O
-    O
domain    O
antibodies    O
were    O
engineered    O
from    O
heavy-chain    B-Antibody115027189
antibodies    I-Antibody115027189
found    O
in    O
camelids    O
;    O
these    O
are    O
called    O
VHH    O
fragments    O
.    O
Cartilaginous    O
fishes    O
also    O
have    O
heavy    O
-    O
chain    O
antibodies    O
(    O
IgNAR    O
,    O
'    O
immunoglobulin    O
new    O
antigen    O
receptor    O
'    O
)    O
,    O
from    O
which    O
single    O
-    O
domain    O
antibodies    O
called    O
VNAR    O
fragments    O
can    O
be    O
obtained    O
.    O

|    O
Tadocizumab    B-Antibody115027189

Anti-CD19    B-Antibody115027189
immunotoxin    I-Antibody115027189
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
linked    O
to    O
a    O
toxic    O
substance    O
.    O

Perakizumab    B-Antibody115027189
(    O
INN    O
)    O
is    O
a    O
humanized    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
arthritis    O
.    O

A    O
number    O
of    O
specific    O
antibodies    O
found    O
in    O
the    O
blood    O
(    O
antinuclear    B-Antibody115027189
antibody    I-Antibody115027189
(    O
ANA    O
)    O
,    O
anti-smooth    B-Antibody115027189
muscle    I-Antibody115027189
antibody    I-Antibody115027189
(    O
SMA    O
)    O
,    O
anti-liver    B-Antibody115027189
kidney    I-Antibody115027189
microsomal    I-Antibody115027189
antibodies    I-Antibody115027189
(    O
LKM-1    O
,    O
LKM-2    O
,    O
LKM-3    O
)    O
,    O
anti    O
soluble    O
liver    O
antigen    O
(    O
SLA    O
)    O
,    O
liver    O
–    O
pancreas    O
antigen    O
(    O
LP    O
)    O
,    O
and    O
anti-mitochondrial    B-Antibody115027189
antibody    I-Antibody115027189
(    O
AMA    O
)    O
)    O
are    O
of    O
use    O
,    O
as    O
is    O
finding    O
an    O
increased    O
Immunoglobulin    B-Antibody115027189
G    I-Antibody115027189
level    O
.    O

Olaratumab    B-Antibody115027189
is    O
an    O
antineoplastic    O
.    O

Rontalizumab    B-Antibody115027189
is    O
a    O
humanized    B-Antibody115027189
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
being    O
developed    O
by    O
Genentech    O
.    O

libivirumab    B-Antibody115027189
(    O
INN    O
)    O

In    O
2017    O
,    O
the    O
biologic    O
agent    O
dupilumab    B-Antibody115027189
was    O
approved    O
to    O
treat    O
moderate    O
-    O
to    O
-    O
severe    O
eczema    O
.    O

edobacomab    B-Antibody115027189
(    O
INN    O
)    O

cBR96-doxorubicin    B-Antibody115027189
immunoconjugate    I-Antibody115027189
(    O
BMS-182248/SGN-15    O
;    O
also    O
known    O
as    O
cBR96-Dox    O
)    O
is    O
an    O
antibody    O
-    O
drug    O
conjugate    O
or    O
(    O
ADC    O
)    O
directed    O
to    O
the    O
Lewis    O
-    O
Y    O
antigen    O
designed    O
for    O
the    O
treatment    O
of    O
cancer    O
.    O

Vepalimomab    B-Antibody115027189
is    O
a    O
mouse    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
developed    O
for    O
the    O
treatment    O
of    O
inflammations    O
.    O

Crofab    B-Antibody115027189
is    O
the    O
antivenom    O
developed    O
to    O
treat    O
the    O
bite    O
of    O
North    O
American    O
pit    O
-    O
vipers    O
.    O

While    O
not    O
type    O
-    O
specific    O
,    O
the    O
polyvalent    B-Antibody115027189
antivenin    B-Antibody115027189
CroFab    B-Antibody115027189
is    O
generally    O
used    O
to    O
treat    O
serious    O
envenomations    O
.    O

Anticardiolipin    B-Antibody115027189
antibodies    I-Antibody115027189

Takayasu    O
arteritis    O
is    O
not    O
associated    O
with    O
ANCA    B-Antibody115027189
,    O
rheumatoid    O
factor    O
,    O
ANA    B-Antibody115027189
,    O
and    O
anticardiolipin    B-Antibody115027189
antibodies    O
.    O

The    O
activity    O
of    O
anti-cardiolipin    B-Antibody115027189
antibodies    I-Antibody115027189
in    O
autoimmune    O
antiphospholipid    B-Antibody115027189
syndrome    I-Antibody115027189
requires    O
apolipoprotein    O
H.    O
The    O
subset    O
of    O
antibodies    O
that    O
bind    O
Apo    O
-    O
H    O
and    O
alter    O
its    O
activity    O
are    O
considered    O
different    O
from    O

Granulomatosis    O
with    O
polyangiitis    O
(    O
GPA    O
;    O
formerly    O
known    O
as    O
Wegener    O
's    O
granulomatosis    O
)    O
–    O
Affects    O
small-    O
&    O
medium    O
-    O
sized    O
vessels    O
that    O
often    O
affects    O
the    O
lung    O
&    O
kidneys    O
(    O
RPGN    O
)    O
with    O
classic    O
saddle    O
nose    O
and    O
c-ANCA    B-Antibody115027189
antibodies    O
.    O

He    O
is    O
currently    O
co    O
-    O
chief    O
of    O
the    O
LMB    O
and    O
is    O
working    O
on    O
various    O
Immunotoxin    B-Antibody115027189
Therapies    I-Antibody115027189
.    O

His    O
current    O
research    O
is    O
focused    O
on    O
developing    O
Recombinant    B-Antibody115027189
Immunotoxins    I-Antibody115027189
(    O
RITs    O
)    O
as    O
a    O
new    O
treatment    O
for    O
cancer    O
.    O

Pastan    O
is    O
currently    O
developing    O
a    O
new    O
therapy    O
for    O
cancer    O
by    O
making    O
fusion    O
proteins    O
composed    O
of    O
the    O
Fv    O
portion    O
of    O
monoclonal    O
antibodies    O
directed    O
at    O
receptor    O
proteins    O
on    O
cancer    O
cells    O
fused    O
to    O
a    O
genetically    O
modified    O
form    O
of    O
a    O
powerful    O
bacterial    O
toxin    O
,    O
Pseudomonas    O
exotoxin    O
A.    O
Three    O
of    O
these    O
genetically    O
engineered    O
proteins    O
,    O
which    O
he    O
named    O
recombinant    O
immunotoxin    B-Antibody115027189
(    O
RITs    O
)    O
,    O
are    O
being    O
tested    O
in    O
humans    O
with    O
various    O
forms    O
of    O
cancer    O
.    O

Another    O
immunotoxin    B-Antibody115027189
,    O
SS1P    O
,    O
targets    O
the    O
mesothelin    O
antigen    O
.    O

Indium    B-Antibody115027189
(111In)    I-Antibody115027189
satumomab    I-Antibody115027189
pendetide    I-Antibody115027189
(    O
other    O
cancer    O
types    O
)    O

Dengue    O
fever    O
becomes    O
more    O
virulent    O
during    O
a    O
second    O
infection    O
by    O
means    O
of    O
antibody    B-Antibody115027189
dependent    I-Antibody115027189
enhancement    I-Antibody115027189
.    O

Some    O
viruses    O
such    O
as    O
flaviviruses    O
use    O
Fc    O
receptors    O
to    O
help    O
them    O
infect    O
cells    O
,    O
by    O
a    O
mechanism    O
known    O
as    O
"    O
antibody-dependent    B-Antibody115027189
enhancement    I-Antibody115027189
of    I-Antibody115027189
infection    I-Antibody115027189
"    O
.    O

The    O
furthest    O
developed    O
of    O
these    O
are    O
bispecific    O
tandem    O
di    O
-    O
scFvs    O
,    O
known    O
as    O
bi-specific    B-Antibody115027189
T-cell    I-Antibody115027189
engager    I-Antibody115027189
(    O
BiTE    O
antibody    O
constructs    O
)    O
.    O

Vectibix    B-Antibody115027189
(Panitumumab)    I-Antibody115027189
(    O
for    O
colon    O
cancer    O
)    O

Panitumumab    B-Antibody115027189
also    O
targets    O
the    O
EGFR    O
.    O

Drugs    O
such    O
as    O
panitumumab    B-Antibody115027189
,    O
cetuximab    B-Antibody115027189
,    O
gefitinib    O
,    O
erlotinib    O
,    O
afatinib    O
,    O
and    O
lapatinib    O
are    O
used    O
to    O
inhibit    O
it    O
.    O

Blood    O
tests    O
investigating    O
the    O
cause    O
,    O
including    O
FBC    O
,    O
inflammatory    O
markers    O
and    O
special    O
tests    O
including    O
(    O
ASLO    B-Antibody115027189
,    O
ANCA    B-Antibody115027189
,    O
Anti-GBM    B-Antibody115027189
,    O
Complement    O
levels    O
,    O
Antinuclear    B-Antibody115027189
antibodies    I-Antibody115027189

Indium    B-Antibody115027189
(111In)    I-Antibody115027189
altumomab    I-Antibody115027189
pentetate    I-Antibody115027189
(    O
INN    O
)    O
(    O
USP    O
,    O
indium    O
In    O
111    O
altumomab    O
pentetate    O
;    O
trade    O
name    O
Hybri-ceaker    B-Antibody115027189
)    O
is    O
a    O
mouse    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
linked    O
to    O
pentetate    O
which    O
acts    O
as    O
a    O
chelating    O
agent    O
for    O
the    O
radioisotope    O
indium-111    O
.    O

matuzumab    B-Antibody115027189
(    O
INN    O
)    O

Anifrolumab    B-Antibody115027189
is    O
a    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
systemic    O
lupus    O
erythematosus    O
.    O

|    O
Suvizumab    B-Antibody115027189

|    O
Roledumab    B-Antibody115027189

|    O
Vedolizumab    B-Antibody115027189

This    O
can    O
be    O
contrasted    O
with    O
lupus    B-Antibody115027189
anticoagulant    I-Antibody115027189
which    O
inhibits    O
agglutination    O
in    O
the    O
presence    O
of    O
thrombin    O
.    O

Lupus    B-Antibody115027189
anticoagulant    I-Antibody115027189
,    O
an    O
antibody    O
causing    O
a    O
delay    O
in    O
coagulation    O
assays    O

Lupus    B-Antibody115027189
anticoagulant    I-Antibody115027189

Lupus    B-Antibody115027189
anticoagulant    I-Antibody115027189

In    O
1947    O
he    O
discovered    O
and    O
described    O
lupus    B-Antibody115027189
anticoagulant    I-Antibody115027189
.    O

One    O
typical    O
investment    O
saw    O
DRI    O
acquire    O
royalty    O
rights    O
to    O
the    O
lupus    O
drug    O
,    O
Benlysta    O
(    O
belimumab    B-Antibody115027189
)    O
from    O
Biogen    O
Idec    O
Inc.    O
for    O
$    O
18.3    O
million    O
.    O

Biogen    O
had    O
licensed    O
belimumab    B-Antibody115027189
from    O
GlaxoSmithKline    O
PLC    O
in    O
2008    O
.    O

Like    O
the    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
belimumab    B-Antibody115027189
,    O
atacicept    O
blocks    O
the    O
binding    O
of    O
BLyS    O
,    O
but    O
it    O
also    O
blocks    O
APRIL    O
.    O

Tositumomab    B-Antibody115027189
(    O
Bexxar    O
)    O
.    O

These    O
include    O
Zevalin    B-Antibody115027189
and    O
Bexxar    B-Antibody115027189
.    O

Omalizumab    O
is    O
a    O
recombinant    O
DNA    O
-    O
derived    O
humanized    O
IgG1k    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
that    O
specifically    O
binds    O
to    O
free    O
human    O
immunoglobulin    B-Antibody115027189
E    I-Antibody115027189
(    O
IgE    O
)    O
in    O
the    O
blood    O
and    O
interstitial    O
fluid    O
and    O
to    O
membrane    O
-    O
bound    O
form    O
of    O
IgE    O
(    O
mIgE    O
)    O
on    O
the    O
surface    O
of    O
mIgE    O
-    O
expressing    O
B    O
lymphocytes    O
.    O

There    O
appears    O
to    O
be    O
a    O
correlation    O
with    O
both    O
total    O
IgE    B-Antibody115027189
levels    O
and    O
asthma    O
and    O
mutations    O
in    O
the    O
Duffy    O
antigen    O
.    O

Food    O
allergies    O
are    O
immune    O
reactions    O
,    O
typically    O
an    O
IgE    B-Antibody115027189
reaction    O
caused    O
by    O
the    O
release    O
of    O
histamine    O
but    O
also    O
encompassing    O
non    O
-    O
IgE    O
immune    O
responses    O
.    O

Hyperimmunoglobulin    O
E    O
syndrome    O
(    O
IgE    B-Antibody115027189
)    O

Several    O
serological    O
tests    O
can    O
be    O
performed    O
to    O
assess    O
total    O
IgE    O
and    O
allergen    O
specific    O
IgE    B-Antibody115027189
and    O
IgG    B-Antibody115027189
:    O
ELISA    O
,    O
MAST    O
,    O
HIA    O
,    O
and    O
CAP    O
RAST    O
.    O

In    O
serum    O
-    O
based    O
allergy    O
diagnosis    O
,    O
antibodies    O
of    O
the    O
IgE    B-Antibody115027189
class    O
directed    O
against    O
CCDs    O
therefore    O
give    O
the    O
impression    O
of    O
polysensitization    O
.    O

For    O
example    O
,    O
those    O
that    O
bind    O
the    O
most    O
common    O
class    O
of    O
antibody    O
,    O
IgG    B-Antibody115027189
,    O
are    O
called    O
"    O
Fc    O
-    O
gamma    O
receptors    O
"    O
(    O
FcγR    O
)    O
,    O
those    O
that    O
bind    O
IgA    B-Antibody115027189
are    O
called    O
"    O
Fc    O
-    O
alpha    O
receptors    O
"    O
(    O
FcαR    O
)    O
and    O
those    O
that    O
bind    O
IgE    B-Antibody115027189
are    O
called    O
"    O
Fc    O
-    O
epsilon    O
receptors    O
"    O
(    O
FcεR    O
)    O
.    O

When    O
an    O
appropriate    O
allergic    O
antigen    O
or    O
parasite    O
is    O
present    O
,    O
the    O
cross    O
-    O
linking    O
of    O
a    O
least    O
two    O
of    O
IgE    B-Antibody115027189
molecules    O
and    O
their    O
Fc    O
receptors    O
on    O
the    O
surface    O
of    O
a    O
granulocyte    O
will    O
trigger    O
the    O
cell    O
to    O
rapidly    O
release    O
preformed    O
mediators    O
from    O
its    O
granules    O
.    O

IgE    B-Antibody115027189
antibodies    O
bind    O
to    O
antigens    O
of    O
allergens    O
.    O

Specific    O
allergen    O
exposure    O
(    O
e.g.    O
,    O
dust    O
mites    O
)    O
under    O
the    O
influence    O
of    O
helper    O
T2    O
lymphocytes    O
leads    O
to    O
B    O
-    O
lymphocyte    O
elaboration    O
of    O
immunoglobulin    B-Antibody115027189
E    I-Antibody115027189
(    O
IgE    O
)    O
antibodies    O
specific    O
to    O
that    O
allergen    O
.    O

Type    O
I    O
hypersensitivity    O
is    O
mediated    O
by    O
IgE    B-Antibody115027189
,    O
which    O
triggers    O
degranulation    O
of    O
mast    O
cells    O
and    O
basophils    O
when    O
cross    O
-    O
linked    O
by    O
antigen    O
.    O

TH2-type    O
lymphocytes    O
are    O
activated    O
,    O
with    O
an    O
increase    O
in    O
T    O
cells    O
expressing    O
CD25    O
(    O
IL-2R    O
)    O
,    O
and    O
B    O
cells    O
expressing    O
CD    O
23    O
,    O
causing    O
increased    O
production    O
of    O
IgE    B-Antibody115027189
After    O
exercise    O
,    O
the    O
conditions    O
will    O
fade    O
within    O
one    O
to    O
three    O
minutes    O
.    O

|    O
IgE    B-Antibody115027189

Such    O
patients    O
often    O
give    O
family    O
history    O
of    O
other    O
atopic    O
diseases    O
such    O
as    O
hay    O
fever    O
,    O
asthma    O
or    O
eczema    O
,    O
and    O
their    O
peripheral    O
blood    O
shows    O
eosinophilia    O
and    O
increased    O
serum    O
IgE    B-Antibody115027189
levels    O
.    O

The    O
combination    O
of    O
this    O
cytokine    O
and    O
IL12    O
has    O
been    O
shown    O
to    O
inhibit    O
IL-4    O
dependent    O
IgE    B-Antibody115027189
and    O
IgG1    B-Antibody115027189
production    O
,    O
and    O
enhance    O
IgG2a    O
production    O
in    O
B    O
cells    O
.    O

Rather    O
,    O
they    O
find    O
that    O
:    O
a    O
)    O
cells    O
expressing    O
both    O
CysLTR1    O
and    O
GPR17    O
receptors    O
exhibit    O
a    O
marked    O
reduction    O
in    O
binding    O
and    O
responding    O
to    O
LTD4    O
and    O
b    O
)    O
mice    O
lacking    O
GPR17    O
are    O
hyper    O
-    O
responsive    O
to    O
igE    B-Antibody115027189
in    O
a    O
model    O
for    O
passive    O
cutaneous    O
anaphylaxis    O
.    O

It    O
dilates    O
airways    O
(    O
bronchodilation    O
)    O
contracted    O
by    O
the    O
allergic    O
mediator    O
,    O
histamine    O
;    O
inhibits    O
Immunoglobulin    B-Antibody115027189
E    I-Antibody115027189
-    O
activated    O
mast    O
cells    O
from    O
releasing    O
histamine    O
and    O
leukotrienes    O
(    O
viz    O
.    O

Model    O
studies    O
indicate    O
that    O
PG2    O
(    O
but    O
not    O
specific    O
antigens    O
or    O
IgE    B-Antibody115027189
cross    O
-    O
linkage    O
)    O
stimulates    O
mouse    O
and    O
human    O
mast    O
cells    O
to    O
release    O
histamine    O
by    O
an    O
EP3-dependent    O
mechanism    O
.    O

Immunoglobulin    B-Antibody115027189
E    I-Antibody115027189
(    O
IgE    O
)    O
,    O
an    O
antibody    O

For    O
allergy    O
testing    O
,    O
Hycor    O
has    O
developed    O
specific    O
and    O
total    O
IgE    B-Antibody115027189
,    O
specific    O
IgG    B-Antibody115027189
,    O
specific    O
IgG4    B-Antibody115027189
,    O
and    O
specific    O
IgE    O
EIA    O
tests    O
.    O

Both    O
provide    O
accurate    O
and    O
precise    O
specific    O
-    O
IgE    B-Antibody115027189
results    O
(    O
kU    O
/    O
L    O
)    O
and    O
a    O
class    O
of    O
allergic    O
response    O
.    O

CD23    O
,    O
also    O
known    O
as    O
Fc    O
epsilon    O
RII    O
,    O
or    O
FcεRII    O
,    O
is    O
the    O
"    O
low    O
-    O
affinity    O
"    O
receptor    O
for    O
IgE    B-Antibody115027189
,    O
an    O
antibody    O
isotype    O
involved    O
in    O
allergy    O
and    O
resistance    O
to    O
parasites    O
,    O
and    O
is    O
important    O
in    O
regulation    O
of    O
IgE    O
levels    O
.    O

For    O
example    O
,    O
IgE    B-Antibody115027189
is    O
responsible    O
for    O
an    O
allergic    O
response    O
consisting    O
of    O
mast    O
cell    O
degranulation    O
and    O
histamine    O
release    O
.    O

While    O
most    O
of    O
these    O
early    O
studies    O
focused    O
on    O
IgM    O
and    O
IgG    O
,    O
other    O
immunoglobulin    O
isotypes    O
were    O
identified    O
in    O
the    O
1960s    O
:    O
Thomas    O
Tomasi    O
discovered    O
secretory    O
antibody    O
(    O
IgA    B-Antibody115027189
)    O
;    O
David    O
S.    O
Rowe    O
and    O
John    O
L.    O
Fahey    O
discovered    O
IgD    O
;    O
and    O
Kimishige    O
Ishizaka    O
and    O
Teruko    O
Ishizaka    O
discovered    O
IgE    B-Antibody115027189
and    O
showed    O
it    O
was    O
a    O
class    O
of    O
antibodies    O
involved    O
in    O
allergic    O
reactions    O
.    O

Tanaka    O
et    O
al    O
.    O
found    O
that    O
the    O
sweat    O
hyper    O
-    O
sensitivities    O
of    O
CU    O
and    O
atopic    O
dermatitis    O
seem    O
to    O
be    O
virtually    O
the    O
same    O
,    O
and    O
therefore    O
,    O
the    O
sweat    O
-    O
induced    O
histamine    O
release    O
from    O
basophils    O
may    O
also    O
be    O
mediated    O
by    O
a    O
specific    O
IgE    B-Antibody115027189
for    O
sweat    O
in    O
atopic    O
dermatitis    O
as    O
well    O
as    O
CU    O
.    O

His    O
broader    O
interpretation    O
of    O
"    O
allergies    O
"    O
beyond    O
that    O
of    O
IgE    B-Antibody115027189
antibodies    O
in    O
true    O
allergy    O
conflicted    O
with    O
traditional    O
allergists    O
of    O
his    O
time    O
.    O

|    O
Mogamulizumab    B-Antibody115027189

|    O
Lucatumumab    B-Antibody115027189

This    O
drug    O
was    O
developed    O
by    O
MedImmune    O
,    O
which    O
chose    O
to    O
move    O
anifrolumab    O
instead    O
of    O
sifalimumab    B-Antibody115027189
into    O
Phase    O
III    O
trials    O
for    O
lupus    O
in    O
2015    O
.    O

Like    O
ordinary    O
monoclonal    O
antibodies    O
,    O
SMIPs    O
are    O
monospecific    B-Antibody115027189
,    O
meaning    O
they    O
recognize    O
and    O
attach    O
to    O
a    O
single    O
antigen    O
target    O
to    O
initiate    O
their    O
biological    O
activity    O
.    O

Lorvotuzumab    B-Antibody115027189
mertansine    I-Antibody115027189
(    O
IMGN901    O
)    O
for    O
CD56    O
positive    O
cancers    O
,    O
for    O
example    O
multiple    O
myeloma    O

Pexelizumab    B-Antibody115027189
,    O
a    O
scFv    O
binding    O
to    O
component    O
5    O
of    O
the    O
complement    O
system    O
and    O
used    O
to    O
reduce    O
side    O
effects    O
of    O
cardiac    O
surgery    O

Briakinumab    B-Antibody115027189
(    O
ABT-874    B-Antibody115027189
)    O
is    O
a    O
human    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
being    O
developed    O
by    O
Abbott    O
Laboratories    O
for    O
the    O
treatment    O
of    O
rheumatoid    O
arthritis    O
,    O
inflammatory    O
bowel    O
disease    O
,    O
and    O
multiple    O
sclerosis    O
.    O

Pemtumomab    B-Antibody115027189
(    O
trade    O
name    O
Theragyn    B-Antibody115027189
)    O
is    O
a    O
mouse    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
used    O
to    O
treat    O
cancer    O
.    O

Rovelizumab    B-Antibody115027189
,    O
also    O
known    O
as    O
LeukArrest    B-Antibody115027189
and    O
Hu23F2G    B-Antibody115027189
,    O
is    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
which    O
was    O
an    O
experimental    O
immunosuppressive    O
drug    O
.    O

This    O
therapeutic    O
has    O
been    O
superseded    O
by    O
HA22    B-Antibody115027189
,    O
a    O
slightly    O
modified    O
version    O
.    O

|    O
Atinumab    B-Antibody115027189

Later    O
in    O
the    O
same    O
week    O
,    O
the    O
company    O
(    O
in    O
conjunction    O
with    O
AstraZeneca    O
)    O
reported    O
positive    O
results    O
for    O
brodalumab    B-Antibody115027189
in    O
a    O
phase    O
III    O
trial    O
comparing    O
the    O
compound    O
with    O
ustekinumab    B-Antibody115027189
and    O
a    O
placebo    O
in    O
treating    O
psoriasis    O
.    O

|    O
Pateclizumab    B-Antibody115027189

Women    O
with    O
antiphospholipid    B-Antibody115027189
syndrome    I-Antibody115027189
should    O
have    O
an    O
additional    O
low    O
-    O
dose    O
prophylactic    O
treatment    O
of    O
aspirin    O
.    O

Antiphospholipid    B-Antibody115027189
antibodies    I-Antibody115027189

Antiphospholipid    B-Antibody115027189
antibody    I-Antibody115027189
syndrome    I-Antibody115027189

He    O
says    O
it    O
is    O
primary    B-Antibody115027189
antiphospholipid    I-Antibody115027189
syndrome    I-Antibody115027189
and    O
tells    O
him    O
to    O
start    O
Jack    O
on    O
heparin    O
and    O
IV    B-Antibody115027189
immunoglobulin    I-Antibody115027189
.    O

The    O
activity    O
of    O
anti-cardiolipin    B-Antibody115027189
antibodies    I-Antibody115027189
in    O
autoimmune    O
antiphospholipid    B-Antibody115027189
syndrome    I-Antibody115027189
requires    O
apolipoprotein    O
H.    O
The    O
subset    O
of    O
antibodies    O
that    O
bind    O
Apo    O
-    O
H    O
and    O
alter    O
its    O
activity    O
are    O
considered    O
different    O
from    O

Problems    O
such    O
as    O
a    O
mutation    O
in    O
this    O
protein    O
would    O
lead    O
to    O
Antiphospholipid    B-Antibody115027189
syndrome    I-Antibody115027189
which    O
often    O
leads    O
to    O
pregnancy    O
complications    O
.    O

Other    O
less    O
common    O
causes    O
include    O
hypercoagulable    O
state    O
,    O
cancer    O
,    O
renal    O
transplantation    O
,    O
behcet    O
syndrome    O
,    O
antiphospholipid    B-Antibody115027189
antibody    I-Antibody115027189
syndrome    I-Antibody115027189
or    O
blunt    O
trauma    O
to    O
the    O
back    O
or    O
abdomen    O
.    O

Other    O
less    O
common    O
causes    O
include    O
hypercoagulable    O
state    O
,    O
invasion    O
by    O
renal    O
cell    O
cancer    O
,    O
renal    O
transplantation    O
,    O
behcet    O
syndrome    O
,    O
antiphospholipid    B-Antibody115027189
antibody    I-Antibody115027189
syndrome    I-Antibody115027189
or    O
blunt    O
trauma    O
to    O
the    O
back    O
or    O
abdomen    O
.    O

|    O
Anti-phospholipid    B-Antibody115027189
IgG    O

Anti-phospholipid    B-Antibody115027189
antibody    I-Antibody115027189
syndrome    I-Antibody115027189
,    O
an    O
autoimmune    O
condition    O
that    O
may    O
be    O
seen    O
in    O
systemic    O
lupus    O
erythematosus    O

PankoMab    B-Antibody115027189
is    O
a    O
humanized    O
monoclonal    O
antibody    O
recognizing    O
the    O
tumor    O
-    O
specific    O
epitope    O
of    O
mucin-1    O
(    O
TA    O
-    O
MUC1    O
)    O
,    O
enabling    O
it    O
to    O
differentiate    O
between    O
tumor    O
MUC1    O
and    O
non    O
-    O
tumor    O
MUC1    O
epitopes    O
.    O

Benralizumab    B-Antibody115027189
(    O
INN    O
,    O
trade    O
name    O
Fasenra    B-Antibody115027189
)    O
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
which    O
is    O
being    O
developed    O
by    O
MedImmune    O
for    O
the    O
treatment    O
of    O
asthma    O
.    O

Sibrotuzumab    B-Antibody115027189
is    O
a    O
monoclonal    O
antibody    O
against    O
FAP    O
.    O

Common    O
crosslinkers    O
for    O
this    O
application    O
include    O
the    O
non    O
-    O
cleavable    O
[    O
NHS    O
-    O
ester    O
]    O
crosslinker    O
,    O
[    O
"    O
bis    O
"-    O
sulfosuccinimidyl    O
suberate    O
]    O
(    O
BS3    O
)    O
;    O
a    O
cleavable    O
version    O
of    O
BS3    O
,    O
[    O
dithiobis(sulfosuccinimidyl    O
propionate)](DTSSP    O
)    O
;    O
and    O
the    O
[    O
imidoester    O
]    O
crosslinker    O
[    O
dimethyl    O
dithiobispropionimidate    O
]    O
(    O
DTBP    O
)    O
that    O
is    O
popular    O
for    O
fixing    O
interactions    O
in    O
ChIP    B-Antibody115027189
assays    O
.    O

Because    O
neocentromeres    O
do    O
not    O
contain    O
repetitive    O
sequences    O
,    O
they    O
are    O
good    O
candidates    O
for    O
studying    O
the    O
epigenetic    O
regulation    O
of    O
distributing    O
centromeric    O
proteins    O
,    O
using    O
chromatin    B-Antibody115027189
immunoprecipitation    I-Antibody115027189
(ChIP)    I-Antibody115027189
methods    O
.    O

Using    O
chromatin    B-Antibody115027189
immuno-precipitation    I-Antibody115027189
(ChIP)    I-Antibody115027189
followed    O
by    O
ChIP    O
-    O
seq    O
,    O
it    O
was    O
found    O
that    O
CTCF    O
localizes    O
with    O
cohesin    O
genome    O
-    O
wide    O
and    O
affects    O
gene    O
regulatory    O
mechanisms    O
and    O
the    O
higher    O
-    O
order    O
chromatin    O
structure    O
.    O

Methylated    O
DNA    O
immunoprecipitation    O
(    O
MeDIP    O
)    O
,    O
analogous    O
to    O
chromatin    B-Antibody115027189
immunoprecipitation    I-Antibody115027189
,    O
immunoprecipitation    O
is    O
used    O
to    O
isolate    O
methylated    O
DNA    O
fragments    O
for    O
input    O
into    O
DNA    O
detection    O
methods    O
such    O
as    O
DNA    O
microarrays    O
(    O
MeDIP    O
-    O
chip    O
)    O
or    O
DNA    O
sequencing    O
(    O
MeDIP    O
-    O
seq    O
)    O
.    O

DREME    O
is    O
very    O
computationally    O
efficient    O
and    O
therefore    O
is    O
suitable    O
for    O
motif    O
search    O
on    O
large    O
data    O
sets    O
derived    O
from    O
ChIP    O
-    O
seq    O
(    O
Chromatin    B-Antibody115027189
immunoprecipitation    I-Antibody115027189
followed    O
by    O
sequencing    O
)    O
experiments    O
.    O

MEME    O
-    O
ChIP    O
is    O
a    O
tool    O
for    O
discovering    O
motifs    O
in    O
data    O
sets    O
derived    O
from    O
ChIP    O
-    O
seq    O
(    O
Chromatin    B-Antibody115027189
immunoprecipitation    I-Antibody115027189
followed    O
by    O
sequencing    O
)    O
experiments    O
.    O

dalotuzumab    B-Antibody115027189
(    O
INN    O
,    O
USAN    O
)    O

e.g.    O
for    O
rheumatoid    O
arthritis    O
:    O
clazakizumab    B-Antibody115027189
,    O
olokizumab    O
,    O
sarilumab    O
and    O
sirukumab    O
have    O
all    O
reported    O
encouraging    O
phase    O
2    O
results    O
.    O

Anti-CD3    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189

Cedelizumab    B-Antibody115027189
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
acting    O
on    O
the    O
immune    O
system    O
.    O

This    O
approach    O
is    O
similar    O
to    O
the    O
one    O
taken    O
in    O
the    O
development    O
of    O
bispecific    B-Antibody115027189
monoclonal    I-Antibody115027189
antibodies    I-Antibody115027189
.    O

A    O
bispecific    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
(    O
BsMAb    B-Antibody115027189
,    O
BsAb    B-Antibody115027189
)    O
is    O
an    O
artificial    O
protein    O
that    O
can    O
simultaneously    O
bind    O
to    O
two    O
different    O
types    O
of    O
antigen    O
.    O

All    O
of    O
these    O
formats    O
can    O
be    O
composed    O
from    O
variable    O
fragments    O
with    O
specificity    O
for    O
two    O
different    O
antigens    O
,    O
in    O
which    O
case    O
they    O
are    O
types    O
of    O
bispecific    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

It    O
consists    O
of    O
the    O
Fab'    B-Antibody115027189
fragment    I-Antibody115027189
of    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
(    O
arcitumomab    O
,    O
trade    O
name    O
CEA-Scan    B-Antibody115027189
)    O
and    O
a    O
radionuclide    O
,    O
technetium-99    O
m    O
.    O

|    O
Ublituximab    B-Antibody115027189

Vorsetuzumab    B-Antibody115027189
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
developed    O
by    O
Seattle    O
Genetics    O
,    O
designed    O
for    O
the    O
treatment    O
of    O
cancer    O
.    O

The    O
nontoxic    O
recombinant    O
protein    O
can    O
induce    O
a    O
level    O
of    O
circulating    O
antibodies    O
sufficient    O
to    O
neutralize    O
the    O
toxic    O
effects    O
of    O
Tityus    O
toxins    O
and    O
is    O
a    O
good    O
candidate    O
for    O
use    O
in    O
the    O
production    O
of    O
a    O
new    O
generation    O
of    O
neutralizing    O
polyclonal    B-Antibody115027189
antibodies    I-Antibody115027189
for    O
clinical    B-Antibody115027189
use    I-Antibody115027189
.    O

It    O
works    O
by    O
adhering    O
to    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
which    O
in    O
turn    O
bind    O
to    O
cancer    O
cells    O
and    O
kill    O
them    O
via    O
intense    O
β-radiation    O
from    O
the    O
yttrium-90    O
(    O
see    O
Monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
therapy    I-Antibody115027189
)    O
.    O

VISTA    O
is    O
produced    O
at    O
high    O
levels    O
in    O
tumor    O
-    O
infiltrating    O
lymphocytes    O
,    O
such    O
as    O
myeloid    O
-    O
derived    O
suppressor    O
cells    O
and    O
regulatory    O
T    O
cells    O
,    O
and    O
its    O
blockade    B-Antibody115027189
with    O
an    O
antibody    B-Antibody115027189
results    O
in    O
delayed    O
tumor    O
growth    O
in    O
mouse    O
models    O
of    O
melanoma    O
and    O
squamous    O
cell    O
carcinoma    O
.    O

There    O
is    O
an    O
ongoing    O
cancer    B-Antibody115027189
immunotherapy    I-Antibody115027189
clinical    O
trial    O
for    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
targeting    O
VISTA    O
in    O
advanced    O
cancer    O
.    O

Targeted    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
therapy    I-Antibody115027189
is    O
employed    O
to    O
treat    O
diseases    O
such    O
as    O
rheumatoid    O
arthritis    O
,    O
multiple    O
sclerosis    O
,    O
psoriasis    O
,    O
and    O
many    O
forms    O
of    O
cancer    O
including    O
non    O
-    O
Hodgkin    O
's    O
lymphoma    O
,    O
colorectal    O
cancer    O
,    O
head    O
and    O
neck    O
cancer    O
and    O
breast    O
cancer    O
.    O

Amyloid    O
-    O
related    O
imaging    O
abnormalities    O
(    O
ARIA    O
)    O
are    O
abnormal    O
differences    O
seen    O
in    O
neuroimaging    O
of    O
Alzheimer    O
's    O
Disease    O
patients    O
,    O
associated    O
with    O
amyloid    O
-    O
modifying    O
therapies    O
,    O
particularly    O
human    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
such    O
as    O
aducanumab    B-Antibody115027189
.    O

Dacetuzumab    B-Antibody115027189
(    O
also    O
known    O
as    O
SGN-40    B-Antibody115027189
or    O
huS2C6    B-Antibody115027189
)    O
is    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
being    O
developed    O
for    O
the    O
treatment    O
of    O
CD40-positive    O
cancers    O
like    O
non    O
-    O
Hodgkin    O
's    O
lymphoma    O
and    O
hematological    O
malignancies    O
.    O

In    O
March    O
2016    O
a    O
district    O
court    O
found    O
that    O
Regeneron    O
's    O
drug    O
alirocumab    B-Antibody115027189
infringed    O
Amgen    O
's    O
patents    O
;    O
Amgen    O
then    O
requested    O
an    O
injunction    O
barring    O
Regeneron    O
and    O
Sanofi    O
from    O
marketing    O
alirocumab    O
,    O
which    O
was    O
granted    O
in    O
January    O
2017    O
.    O

Alirocumab    B-Antibody115027189
(    O
trade    O
name    O
Praluent    B-Antibody115027189
)    O
is    O
a    O
biopharmaceutical    O
drug    O
approved    O
by    O
the    O
FDA    O
on    O
July    O
24    O
,    O
2015    O
as    O
a    O
second    O
line    O
treatment    O
for    O
high    O
cholesterol    O
for    O
adults    O
whose    O
cholesterol    O
is    O
not    O
controlled    O
by    O
diet    O
and    O
statin    O
treatment    O
.    O

Atacicept    B-Antibody115027189
is    O
a    O
recombinant    O
fusion    O
protein    O
designed    O
to    O
inhibit    O
B    O
cells    O
,    O
thereby    O
suppressing    O
autoimmune    O
disease    O
.    O

etaracizumab    B-Antibody115027189
(    O
USAN    O
,    O
INN    O
)    O

|    O
Anti-glycoprotein-210    B-Antibody115027189
antibodies    I-Antibody115027189

However    O
,    O
CREST    O
syndrome    O
is    O
more    O
closely    O
associated    O
with    O
Anti-centromere    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

Anti-centromere    B-Antibody115027189
antibodies    I-Antibody115027189

2003    O
–    O
Xolair    B-Antibody115027189
(    O
omalizumab    O
)    O
:    O
Subcutaneous    O
injection    O
for    O
moderate    O
to    O
severe    O
persistent    O
asthma    O
.    O

Omalizumab    B-Antibody115027189
,    O
sold    O
under    O
the    O
trade    O
name    O
Xolair    B-Antibody115027189
,    O
is    O
a    O
medication    O
originally    O
designed    O
to    O
reduce    O
sensitivity    O
to    O
allergens    O
.    O

The    O
International    O
Nonproprietary    O
Names    O
of    O
humanized    O
antibodies    O
end    O
in    O
"    O
-zumab    O
"    O
,    O
as    O
in    O
"    O
omalizumab    B-Antibody115027189
"    O
(    O
see    O
Nomenclature    B-Antibody115027189
of    I-Antibody115027189
monoclonal    I-Antibody115027189
antibodies    I-Antibody115027189
)    O
.    O

Treatment(s    O
)    O
with    O
mixed    O
success    O
:    O
omalizumab    B-Antibody115027189
(    O
anti    O
-    O
IgE    O
therapy    O
)    O
,    O
danazol    O
(    O
synthetic    O
androgen    O
)    O
,    O
propranolol    O
(    O
beta    O
blocker    O
)    O
,    O
zileuton    O
(    O
antileukotriene    O
)    O
.    O

Also    O
,    O
intravenous    B-Antibody115027189
immunoglobulin    I-Antibody115027189
(    O
IVIGs    O
)    O
can    O
be    O
used    O
to    O
bind    O
the    O
circulating    O
antibodies    O
.    O

He    O
says    O
it    O
is    O
primary    B-Antibody115027189
antiphospholipid    I-Antibody115027189
syndrome    I-Antibody115027189
and    O
tells    O
him    O
to    O
start    O
Jack    O
on    O
heparin    O
and    O
IV    B-Antibody115027189
immunoglobulin    I-Antibody115027189
.    O

Intravenous    B-Antibody115027189
Immunoglobulin    I-Antibody115027189
may    O
also    O
occasionally    O
be    O
used    O
.    O

In    O
medicine    O
,    O
protective    O
passive    O
immunity    O
can    O
also    O
be    O
transferred    B-Antibody115027189
artificially    I-Antibody115027189
from    O
one    O
individual    O
to    O
another    O
via    O
antibody    O
-    O
rich    O
serum    O
.    O

Corticosteroids    O
or    O
intravenous    B-Antibody115027189
immunoglobulin    I-Antibody115027189
(    O
IVIG    O
)    O
may    O
be    O
useful    O
in    O
certain    O
cases    O
.    O

A    O
2015    O
Cochrane    O
review    O
found    O
no    O
evidence    O
of    O
benefit    O
of    O
using    O
intravenous    B-Antibody115027189
immunoglobulin    I-Antibody115027189
(    O
IVIG    O
)    O
in    O
adults    O
and    O
tentative    O
benefit    O
in    O
certain    O
children    O
.    O

Passive    O
immunity    O
can    O
occur    O
naturally    O
,    O
when    O
maternal    O
antibodies    O
are    O
transferred    O
to    O
the    O
fetus    O
through    O
the    O
placenta    O
,    O
and    O
it    O
can    O
also    O
be    O
induced    O
artificially    O
,    O
when    O
high    O
levels    O
of    O
antibodies    O
specific    O
to    O
a    O
pathogen    O
or    O
toxin    O
(    O
obtained    O
from    O
humans    O
,    O
horses    O
,    O
or    O
other    O
animals    O
)    O
are    O
transferred    O
to    O
non    O
-    O
immune    O
persons    O
through    O
blood    O
products    O
that    O
contain    O
antibodies    O
,    O
such    O
as    O
in    O
immunoglobulin    B-Antibody115027189
therapy    I-Antibody115027189
or    O
antiserum    O
therapy    O
.    O

Artificially    O
acquired    O
passive    O
immunity    O
is    O
a    O
short    O
-    O
term    O
immunization    O
achieved    O
by    O
the    O
transfer    O
of    O
antibodies    O
,    O
which    O
can    O
be    O
administered    O
in    O
several    O
forms    O
;    O
as    O
human    O
or    O
animal    O
blood    O
plasma    O
or    O
serum    O
,    O
as    O
pooled    O
human    O
immunoglobulin    O
for    O
intravenous    O
(    O
IVIG    B-Antibody115027189
)    O
or    O
intramuscular    O
(    O
IG    O
)    O
use    O
,    O
as    O
high    O
-    O
titer    O
human    O
IVIG    O
or    O
IG    O
from    O
immunized    O
donors    O
or    O
from    O
donors    O
recovering    O
from    O
the    O
disease    O
,    O
and    O
as    O
monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
MAb    O
)    O
.    O

Intravenous    B-Antibody115027189
immunoglobulin    I-Antibody115027189
,    O
if    O
not    O
otherwise    O
noted    O
,    O
consists    O
of    O
polyvalent    O
IgG.    O

Intravenous    B-Antibody115027189
immunoglobulin    I-Antibody115027189
(    O
IVIg    O
)    O

There    O
are    O
three    O
types    O
of    O
prophylactic    O
treatments    O
,    O
namely    O
,    O
the    O
use    O
of    O
medication    O
,    O
sterile    O
environments    O
,    O
and    O
intravenous    B-Antibody115027189
immunoglobulin    I-Antibody115027189
therapy    O
(    O
IVIG    O
)    O
.    O

In    O
addition    O
,    O
the    O
patient    O
can    O
also    O
undergo    O
intravenous    B-Antibody115027189
immunoglobulin    I-Antibody115027189
(    O
IVIG    O
)    O
supplementation    O
.    O

Eltrombopag    O
was    O
initially    O
approved    O
by    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
on    O
November    O
20    O
,    O
2008    O
,    O
for    O
the    O
treatment    O
of    O
thrombocytopenia    O
in    O
patients    O
with    O
chronic    O
immune    O
(    O
idiopathic    O
)    O
thrombocytopenic    O
purpura    O
who    O
have    O
had    O
an    O
insufficient    O
response    O
to    O
corticosteroids    O
,    O
immunoglobulin    B-Antibody115027189
therapy    I-Antibody115027189
,    O
or    O
splenectomy    O
.    O

The    O
Alzheimer    O
's    O
drug    O
Gammagard    B-Antibody115027189
fails    O
to    O
produce    O
results    O
in    O
a    O
large    O
-    O
scale    O
clinical    O
trial    O
.    O

The    O
second    O
,    O
more    O
recent    O
approach    O
pioneered    O
in    O
France    O
during    O
the    O
last    O
decade    O
(    O
early    O
2000s    O
)    O
involves    O
monthly    O
intravenous    O
infusions    O
of    O
immunoglobulins    B-Antibody115027189
(    O
IVIG    O
)    O
,    O
with    O
an    O
initial    O
dose    O
of    O
2    O
gr    O
/    O
kg    O
/    O
month    O
of    O
body    O
weight    O
,    O
which    O
has    O
proven    O
very    O
successful    O
as    O
per    O
abundant    O
case    O
-    O
report    O
evidence    O
from    O
around    O
the    O
world    O
.    O

milatuzumab    B-Antibody115027189
(    O
USAN    O
)    O

|    O
Blosozumab    B-Antibody115027189

|    O
Raxibacumab    B-Antibody115027189

Raxibacumab    B-Antibody115027189

Anti-transglutaminase    B-Antibody115027189
antibodies    I-Antibody115027189

Anti-transglutaminase    B-Antibody115027189
antibodies    I-Antibody115027189
are    O
found    O
in    O
celiac    O
disease    O
and    O
may    O
play    O
a    O
role    O
in    O
the    O
small    O
bowel    O
damage    O
in    O
response    O
to    O
dietary    O
gliadin    O
that    O
characterises    O
this    O
condition    O
.    O

Anti    O
-    O
gliadin    O
antibodies    O
are    O
frequently    O
found    O
with    O
anti-transglutaminase    B-Antibody115027189
antibodies    I-Antibody115027189
.    O

|    O
Lexatumumab    B-Antibody115027189

|    O
Flanvotumab    B-Antibody115027189

|    O
Carlumab    B-Antibody115027189

|    O
Tuvirumab    B-Antibody115027189

Palivizumab    B-Antibody115027189
(    O
brand    O
name    O
Synagis    B-Antibody115027189
which    O
is    O
manufactured    O
by    O
MedImmune    O
)    O
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
produced    O
by    O
recombinant    O
DNA    O
technology    O
.    O

Its    O
humanization    O
technology    O
was    O
used    O
in    O
several    O
monoclonal    O
antibody    O
drugs    O
under    O
licensing    O
and    O
collaboration    O
agreements    O
;    O
such    O
products    O
included    O
rituximab    B-Antibody115027189
(    O
Rituxan    O
)    O
,    O
bevacizumab    B-Antibody115027189
(    O
Avastin    O
)    O
,    O
and    O
palivizumab    B-Antibody115027189
(    O
Synagis    O
)    O
.    O

In    O
2012    O
,    O
OncoMed    O
sponsored    O
the    O
USAN    O
nonproprietary    O
name    O
vantictumab    B-Antibody115027189
for    O
a    O
human    O
IgG2    B-Antibody115027189
anti    O
-    O
Frizzled    O
antibody    O
,    O
an    O
anti    O
-    O
cancer    O
therapeutic    O
.    O

Drugs    O
such    O
as    O
aflibercept    O
,    O
bevacizumab    B-Antibody115027189
,    O
and    O
ranibizumab    B-Antibody115027189
can    O
inhibit    O
VEGF    O
and    O
control    O
or    O
slow    O
those    O
diseases    O
.    O

The    O
first    O
anti    O
-    O
VEGF    O
drug    O
,    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
named    O
bevacizumab    B-Antibody115027189
,    O
was    O
approved    O
in    O
2004    O
.    O

avastin    B-Antibody115027189
for    O
current    O
anti    O
-    O
VEGF    O
approaches    O
)    O
.    O

The    O
list    O
of    O
offending    O
interventions    O
that    O
are    O
paid    O
for    O
and    O
widely    O
used    O
but    O
either    O
unproven    O
or    O
of    O
marginal    O
benefit    O
to    O
patients    O
is    O
vast    O
–    O
IMRT    O
and    O
proton    O
beam    O
for    O
early    O
prostate    O
cancer    O
,    O
CT    O
and    O
MRI    O
angiograms    O
,    O
Epogen    O
for    O
chemotherapy    O
induced    O
anemia    O
,    O
Erbitux    B-Antibody115027189
and    O
Avastin    B-Antibody115027189
for    O
colorectal    O
cancer    O
,    O
and    O
drug    O
eluting    O
stents    O
for    O
coronary    O
artery    O
disease    O
.    O

Its    O
humanization    O
technology    O
was    O
used    O
in    O
several    O
monoclonal    O
antibody    O
drugs    O
under    O
licensing    O
and    O
collaboration    O
agreements    O
;    O
such    O
products    O
included    O
rituximab    B-Antibody115027189
(    O
Rituxan    O
)    O
,    O
bevacizumab    B-Antibody115027189
(    O
Avastin    O
)    O
,    O
and    O
palivizumab    B-Antibody115027189
(    O
Synagis    O
)    O
.    O

Bevacizumab    B-Antibody115027189
targets    O
circulating    O
VEGF    O
ligand    O
.    O

2004    O
–    O
Avastin    B-Antibody115027189
(    O
bevacizumab    O
)    O
:    O
Anti    O
-    O
VEGF    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
for    O
the    O
treatment    O
of    O
metastatic    O
cancer    O
of    O
the    O
colon    O
or    O
rectum    O
.    O

It    O
is    O
usually    O
given    O
with    O
bevacizumab    B-Antibody115027189
,    O
unlike    O
FOLFIRINOX    O
for    O
treatment    O
of    O
advanced    O
pancreatic    O
cancer    O
.    O

In    O
another    O
case    O
,    O
vials    O
of    O
the    O
cancer    O
medicine    O
Avastin    B-Antibody115027189
were    O
found    O
to    O
contain    O
no    O
active    O
ingredients    O
.    O

BCRF    O
has    O
funded    O
basic    O
research    O
on    O
genetic    O
susceptibility    O
to    O
breast    O
cancer    O
,    O
breast    O
cancer    O
stem    O
cells    O
,    O
trastuzumab    B-Antibody115027189
(    O
Herceptin    O
)    O
,    O
anti    O
-    O
angiogenesis    O
treatment    O
with    O
bevacizumab    B-Antibody115027189
(    O
Avastin    O
)    O
,    O
MRI    O
imaging    O
,    O
aromatase    O
inhibitors    O
,    O
tamoxifen    O
;    O
and    O
also    O
clinical    O
trials    O
of    O
new    O
treatments    O
with    O
the    O
Translational    O
Breast    O
Cancer    O
Research    O
Consortium    O
.    O

Puliafito    O
participated    O
in    O
research    O
into    O
the    O
use    O
of    O
bevacizumab    B-Antibody115027189
for    O
the    O
treatment    O
of    O
retinal    O
disorders    O
.    O

In    O
2004    O
,    O
the    O
first    O
angiogenesis    O
inhibitor    O
,    O
bevacizumab    B-Antibody115027189
(    O
Avastin    O
)    O
,    O
was    O
approved    O
by    O
the    O
FDA    O
,    O
as    O
a    O
treatment    O
for    O
colon    O
cancer    O
.    O

|    O
Iratumumab    B-Antibody115027189

Dr.    O
Beasley    O
“    O
demonstrated    O
the    O
efficacy    O
of    O
hepatitis    B-Antibody115027189
B    I-Antibody115027189
immune    I-Antibody115027189
globulin    I-Antibody115027189
in    O
blocking    O
infection    O
,    O
especially    O
maternal    O
-    O
infant    O
,    O
and    O
hepatitis    O
B    O
vaccine    O
in    O
its    O
prevention    O
.    O

The    O
mainstay    O
of    O
PEP    O
is    O
the    O
hepatitis    O
B    O
vaccine    O
;    O
in    O
certain    O
circumstances    O
,    O
hepatitis    B-Antibody115027189
B    I-Antibody115027189
immunoglobulin    I-Antibody115027189
is    O
recommended    O
for    O
added    O
protection    O
.    O

Tefibazumab    B-Antibody115027189

|    O
Enokizumab    B-Antibody115027189

Sarilumab    B-Antibody115027189
was    O
approved    O
by    O
US    O
FDA    O
in    O
2017    O
for    O
rheumatoid    O
arthritis    O
.    O

Teplizumab    B-Antibody115027189
(    O
also    O
known    O
as    O
MGA031    B-Antibody115027189
and    O
hOKT3γ1(Ala-Ala)    B-Antibody115027189
)    O
is    O
a    O
humanized    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
that    O
failed    O
tests    O
meant    O
to    O
show    O
it    O
is    O
an    O
immunosuppressive    O
drug    O
.    O

Autoimmune    O
conditions    O
such    O
as    O
anti-p62    B-Antibody115027189
antibodies    I-Antibody115027189
,    O
which    O
inhibit    O
p62    O
complexes    O
have    O
links    O
to    O
primary    O
biliary    O
cirrhosis    O
which    O
destroys    O
the    O
bile    O
ducts    O
of    O
the    O
liver    O
.    O

ganitumab    B-Antibody115027189
(    O
USAN    O
)    O

His    O
name    O
is    O
also    O
associated    O
with    O
the    O
following    O
two    O
terms    O
:    O
"    O
Forssman    O
antibody    O
"    O
(    O
heterophile    B-Antibody115027189
antibody    I-Antibody115027189
)    O
and    O
"    O
Forssman    O
reaction    O
"    O
,    O
also    O
referred    O
to    O
as    O
a    O
"    O
Forssman    O
antigen    O
-    O
antibody    O
reaction    O
"    O
.    O

Heterophile    B-Antibody115027189
antibodies    O
(    O
which    O
include    O
human    O
anti    O
-    O
mouse    O
antibodies    O
(    O
HAMA    O
)    O
and    O
Rheumatoid    O
Factor    O
(    O
RF    O
)    O
)    O
,    O
which    O
bind    O
weakly    O
to    O
the    O
test    O
assay    O
's    O
animal    O
antibodies    O
,    O
causing    O
a    O
higher    O
(    O
or    O
less    O
commonly    O
lower    O
)    O
TSH    O
result    O
than    O
the    O
actual    O
true    O
TSH    O
level    O
.    O

|    O
Vatelizumab    B-Antibody115027189

As    O
of    O
August    O
2014    O
,    O
a    O
clinical    O
trial    O
administering    O
sipuleucel    O
-    O
T    O
in    O
conjunction    O
with    O
ipilimumab    B-Antibody115027189
(    O
Yervoy    O
)    O
was    O
tracking    O
subjects    O
but    O
no    O
longer    O
enrolling    O
new    O
subjects    O
;    O
the    O
trial    O
evaluates    O
the    O
clinical    O
safety    O
and    O
anti    O
-    O
cancer    O
effects    O
(    O
quantified    O
in    O
PSA    O
,    O
radiographic    O
and    O
T    O
cell    O
response    O
)    O
of    O
the    O
combination    O
therapy    O
in    O
patients    O
with    O
advanced    O
prostate    O
cancer    O
.    O

It    O
is    O
used    O
as    O
a    O
first    O
line    O
treatment    O
for    O
inoperable    O
or    O
metastatic    O
melanoma    O
in    O
combination    O
with    O
ipilimumab    B-Antibody115027189
if    O
the    O
cancer    O
does    O
not    O
have    O
a    O
mutation    O
in    O
BRAF    O
,    O
as    O
a    O
second    O
-    O
line    O
treatment    O
following    O
treatment    O
with    O
ipilimumab    O
and    O
if    O
the    O
cancer    O
has    O
a    O
mutation    O
in    O
BRAF    O
,    O
with    O
a    O
BRAF    O
inhibitor    O
,    O
as    O
a    O
second    O
-    O
line    O
treatment    O
for    O
squamous    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O
,    O
and    O
as    O
a    O
second    O
-    O
line    O
treatment    O
for    O
renal    O
cell    O
carcinoma    O
.    O

Nivolumab    O
is    O
used    O
as    O
a    O
first    O
line    O
treatment    O
for    O
inoperable    O
or    O
metastatic    O
melanoma    O
in    O
combination    O
with    O
ipilimumab    B-Antibody115027189
if    O
the    O
cancer    O
does    O
not    O
have    O
a    O
mutation    O
in    O
BRAF    O
,    O
and    O
as    O
a    O
second    O
-    O
line    O
treatment    O
for    O
inoperable    O
or    O
metastatic    O
melanoma    O
following    O
treatment    O
of    O
ipilimumab    B-Antibody115027189
and    O
,    O
if    O
the    O
cancer    O
has    O
a    O
BRAF    O
mutation    O
,    O
a    O
BRAF    O
inhibitor    O
.    O

Whereas    O
these    O
reports    O
were    O
extremely    O
rare    O
throughout    O
the    O
20th    O
century    O
,    O
the    O
clinical    O
use    O
of    O
immune    O
checkpoint    O
blocking    O
antibodies    O
such    O
as    O
ipilimumab    B-Antibody115027189
or    O
pembrolizumab    B-Antibody115027189
has    O
greatly    O
increased    O
the    O
number    O
of    O
abscopally    O
responding    O
patients    O
in    O
selected    O
groups    O
of    O
patients    O
such    O
as    O
those    O
with    O
metastatic    O
melanoma    O
.    O

Since    O
around    O
2010    O
inhibitory    O
checkpoint    O
molecules    O
have    O
been    O
increasingly    O
considered    O
as    O
new    O
targets    O
for    O
cancer    O
immunotherapies    O
due    O
to    O
the    O
effectiveness    O
of    O
two    O
checkpoint    O
inhibitor    O
drugs    O
that    O
were    O
initially    O
indicated    O
for    O
advanced    O
melanoma    O
-    O
Yervoy    B-Antibody115027189
,    O
from    O
Bristol    O
-    O
Myers    O
Squibb    O
,    O
and    O
Keytruda    B-Antibody115027189
,    O
from    O
Merck    O
.    O

The    O
second    O
antitoxin    O
is    O
Heptavalent    B-Antibody115027189
(A,B,C,D,E,F,G)    I-Antibody115027189
botulinum    I-Antibody115027189
antitoxin    I-Antibody115027189
,    O
which    O
is    O
derived    O
from    O
equine    O
antibodies    O
which    O
have    O
been    O
altered    O
to    O
make    O
them    O
less    O
immunogenic    O
.    O

minretumomab    B-Antibody115027189
(    O
INN    O
)    O

This    O
distinction    O
is    O
based    O
on    O
the    O
maturity    O
of    O
the    O
lymphocytes    O
as    O
discerned    O
by    O
the    O
immunoglobulin    O
variable    O
-    O
region    O
heavy    B-Antibody115027189
chain    I-Antibody115027189
(    O
IgVH    O
)    O
gene    O
mutation    O
status    O
.    O

In    O
addition    O
to    O
the    O
immunoglobulin    O
variable    O
-    O
region    O
heavy    B-Antibody115027189
chain    I-Antibody115027189
(    O
IgVH    O
)    O
gene    O
mutation    O
status    O
,    O
the    O
prognosis    O
of    O
patients    O
with    O
CLL    O
is    O
dependent    O
on    O
the    O
genetic    O
changes    O
within    O
the    O
neoplastic    O
cell    O
population    O
.    O

Conditional    O
(    O
CD21-cre    O
-    O
mediated    O
)    O
deletion    O
of    O
the    O
XRCC4    O
NHEJ    O
gene    O
in    O
p53-deficient    O
peripheral    O
mouse    O
B    O
cells    O
resulted    O
in    O
surface    O
Ig    O
-    O
negative    O
B    O
-    O
cell    O
lymphomas    O
,    O
and    O
these    O
lymphomas    O
often    O
had    O
a    O
"    O
reciprocal    O
chromosomal    O
translocation    O
"    O
fusing    O
IgH    B-Antibody115027189
to    O
Myc    O
(    O
and    O
also    O
had    O
"    O
large    O
chromosomal    O
deletions    O
or    O
translocations    O
"    O
involving    O
IgK    O
or    O
IgL    O
,    O
with    O
IgL    O
"    O
fusing    O
"    O
to    O
oncogenes    O
or    O
to    O
IgH    B-Antibody115027189
)    O
.    O

IGH@    B-Antibody115027189
:    O
immunoglobulin    O
heavy    B-Antibody115027189
chain    I-Antibody115027189
locus    O

each    O
with    O
two    O
large    O
heavy    B-Antibody115027189
chain    I-Antibody115027189
and    O
two    O
small    O
light    O
chains    O
.    O

There    O
are    O
five    O
types    O
of    O
mammalian    O
Ig    O
heavy    B-Antibody115027189
chain    I-Antibody115027189
denoted    O
by    O
the    O
Greek    O
letters    O
:    O
α    O
,    O
δ    O
,    O
ε    O
,    O
γ    O
,    O
and    O
μ.    O
The    O
type    O
of    O
heavy    O
chain    O
present    O
defines    O
the    O
"    O
class    O
"    O
of    O
antibody    O
;    O
these    O
chains    O
are    O
found    O
in    O
IgA    O
,    O
IgD    O
,    O
IgE    O
,    O
IgG    O
,    O
and    O
IgM    O
antibodies    O
,    O
respectively    O
.    O

V    O
,    O
D    O
and    O
J    O
segments    O
are    O
found    O
in    O
Ig    B-Antibody115027189
heavy    I-Antibody115027189
chains    I-Antibody115027189
,    O
but    O
only    O
V    O
and    O
J    O
segments    O
are    O
found    O
in    O
Ig    O
light    O
chains    O
.    O

In    O
B    O
lymphocytes    O
,    O
successful    O
heavy    B-Antibody115027189
chain    I-Antibody115027189
gene    O
rearrangement    O
of    O
the    O
genetic    O
material    O
from    O
one    O
chromosome    O
results    O
in    O
the    O
shutting    O
down    O
of    O
rearrangement    O
of    O
genetic    O
material    O
from    O
the    O
second    O
chromosome    O
.    O

|    O
Caplacizumab    B-Antibody115027189

Orticumab    B-Antibody115027189
(    O
INN    O
)    O
is    O
a    O
human    O
monoclonal    O
antibody    O
that    O
is    O
used    O
as    O
an    O
anti    O
-    O
inflammatory    O
agent    O
and    O
binds    O
to    O
oxLDL    O
.    O

Additional    O
monoclonal    O
antibodies    O
,    O
such    O
as    O
ixekizumab    B-Antibody115027189
,    O
have    O
been    O
developed    O
against    O
pro    O
-    O
inflammatory    O
cytokines    O
and    O
inhibit    O
the    O
inflammatory    O
pathway    O
at    O
a    O
different    O
point    O
than    O
the    O
anti    O
-    O
TNF-α    O
antibodies    O
.    O

3F8    B-Antibody115027189

|    O
Intetumumab    B-Antibody115027189

Diagnostic    O
markers    O
include    O
eosinophil    O
granulocytes    O
and    O
granulomas    O
in    O
affected    O
tissue    O
,    O
and    O
antineutrophil    B-Antibody115027189
cytoplasmic    I-Antibody115027189
antibodies    I-Antibody115027189
(    O
ANCA    O
)    O
against    O
neutrophil    O
granulocytes    O
.    O

|    O
Cytoplasmic    O
/    O
classical    O
anti-neutrophil    B-Antibody115027189
cytoplasmic    I-Antibody115027189
antibodies    I-Antibody115027189
(    O
c    O
-    O
ANCA    O
)    O

No    O
immune    O
deposits    O
can    O
be    O
seen    O
on    O
staining    O
,    O
however    O
blood    O
tests    O
may    O
be    O
positive    O
for    O
the    O
ANCA    B-Antibody115027189
antibody    O
.    O

Blood    O
tests    O
investigating    O
the    O
cause    O
,    O
including    O
FBC    O
,    O
inflammatory    O
markers    O
and    O
special    O
tests    O
including    O
(    O
ASLO    B-Antibody115027189
,    O
ANCA    B-Antibody115027189
,    O
Anti-GBM    B-Antibody115027189
,    O
Complement    O
levels    O
,    O
Antinuclear    B-Antibody115027189
antibodies    I-Antibody115027189

:*    O
ANCA-associated    B-Antibody115027189
vasculitis    I-Antibody115027189

As    O
of    O
2017    O
,    O
the    O
combination    O
of    O
epacadostat    O
with    O
pembrolizumab    B-Antibody115027189
(    O
Keytruda    O
)    O
was    O
being    O
investigated    O
by    O
Incyte    O
and    O
Merck    O
&    O
Co.    O
in    O
several    O
cancers    O
,    O
as    O
was    O
the    O
combination    O
of    O
epacadostat    O
with    O
nivolumab    B-Antibody115027189
(    O
Opdivo    O
)    O
by    O
Incyte    O
and    O
Bristol    O
Myers    O
Squibb    O
.    O

Promising    O
clinical    O
trial    O
results    O
made    O
public    O
in    O
2012    O
caused    O
excitement    O
among    O
industry    O
analysts    O
and    O
in    O
the    O
mainstream    O
media    O
;    O
PD-1    O
was    O
being    O
avidly    O
pursued    O
as    O
a    O
biological    O
target    O
at    O
that    O
time    O
,    O
with    O
companies    O
including    O
Merck    O
with    O
pembrolizumab    B-Antibody115027189
(    O
Keytruda    O
)    O
,    O
Roche    O
(    O
via    O
its    O
subsidiary    O
Genentech    O
)    O
with    O
atezolizumab    O
,    O
GlaxoSmithKline    O
in    O
collaboration    O
with    O
the    O
Maryland    O
biotech    O
company    O
Amplimmune    O
;    O
and    O
Teva    O
in    O
collaboration    O
with    O
the    O
Israeli    O
biotech    O
company    O
CureTech    O
competing    O
.    O

Whereas    O
these    O
reports    O
were    O
extremely    O
rare    O
throughout    O
the    O
20th    O
century    O
,    O
the    O
clinical    O
use    O
of    O
immune    O
checkpoint    O
blocking    O
antibodies    O
such    O
as    O
ipilimumab    B-Antibody115027189
or    O
pembrolizumab    B-Antibody115027189
has    O
greatly    O
increased    O
the    O
number    O
of    O
abscopally    O
responding    O
patients    O
in    O
selected    O
groups    O
of    O
patients    O
such    O
as    O
those    O
with    O
metastatic    O
melanoma    O
.    O

Since    O
around    O
2010    O
inhibitory    O
checkpoint    O
molecules    O
have    O
been    O
increasingly    O
considered    O
as    O
new    O
targets    O
for    O
cancer    O
immunotherapies    O
due    O
to    O
the    O
effectiveness    O
of    O
two    O
checkpoint    O
inhibitor    O
drugs    O
that    O
were    O
initially    O
indicated    O
for    O
advanced    O
melanoma    O
-    O
Yervoy    B-Antibody115027189
,    O
from    O
Bristol    O
-    O
Myers    O
Squibb    O
,    O
and    O
Keytruda    B-Antibody115027189
,    O
from    O
Merck    O
.    O

Necitumumab    B-Antibody115027189
—    O
development    O
terminated    O

Otelixizumab    B-Antibody115027189
is    O
an    O
example    O
of    O
a    O
humanized    O
chimera    O
currently    O
in    O
clinical    O
trials    O
for    O
treatment    O
of    O
rheumatoid    O
arthritis    O
and    O
diabetes    O
mellitus    O
.    O

Other    O
drugs    O
in    O
early    O
stage    O
development    O
targeting    O
PD-1    O
receptors    O
(    O
checkpoint    O
inhibitors    O
)    O
are    O
Pidilizumab    B-Antibody115027189
(    O
CT-011    O
,    O
Cure    O
Tech    O
)    O
and    O
BMS-936559    O
(    O
Bristol    O
Myers    O
Squibb    O
)    O
.    O

Tethers    O
come    O
in    O
two    O
"    O
flavors    O
"    O
:    O
long    O
protein(s    O
)    O
with    O
domains    O
called    O
"    O
coiled    O
-    O
coil    O
,    O
"    O
or    O
complexes    O
of    O
many    O
subunits    O
which    O
are    O
for    O
the    O
most    O
part    O
globular    B-Antibody115027189
.    O

Actin    O
is    O
a    O
family    O
of    O
globular    B-Antibody115027189
multi    O
-    O
functional    O
proteins    O
that    O
form    O
microfilaments    O
.    O

Cellular    O
actin    O
has    O
two    O
forms    O
:    O
monomeric    O
globules    B-Antibody115027189
called    O
G    O
-    O
actin    O
and    O
polymeric    O
filaments    O
called    O
F    O
-    O
actin    O
(    O
that    O
is    O
,    O
as    O
filaments    O
made    O
up    O
of    O
many    O
G    O
-    O
actin    O
monomers    O
)    O
.    O

In    O
concert    O
with    O
larger    O
databases    O
of    O
known    O
protein    O
structures    O
and    O
modern    O
machine    O
learning    O
methods    O
such    O
as    O
neural    O
nets    O
and    O
support    O
vector    O
machines    O
,    O
these    O
methods    O
can    O
achieve    O
up    O
80%    O
overall    O
accuracy    O
in    O
globular    B-Antibody115027189
protein    I-Antibody115027189
.    O

Globular    B-Antibody115027189
protein    I-Antibody115027189
,    O
one    O
of    O
the    O
two    O
main    O
protein    O
classes    O

Alpha    O
globulins    O
are    O
a    O
group    O
of    O
globular    B-Antibody115027189
protein    I-Antibody115027189
in    O
plasma    O
that    O
are    O
highly    O
mobile    O
in    O
alkaline    O
or    O
electrically    O
charged    O
solutions    O
.    O

Antibodies    O
are    O
heavy    O
(    O
~150    O
kDa    O
)    O
globular    B-Antibody115027189
plasma    O
proteins    O
.    O

Beta    O
globulins    O
are    O
a    O
group    O
of    O
globular    B-Antibody115027189
protein    I-Antibody115027189
in    O
plasma    O
that    O
are    O
more    O
mobile    O
in    O
alkaline    O
or    O
electrically    O
charged    O
solutions    O
than    O
gamma    O
globulins    O
,    O
but    O
less    O
mobile    O
than    O
alpha    O
globulins    O
.    O

ensituximab    B-Antibody115027189
(    O
USAN    O
)    O

Pertuzumab    B-Antibody115027189
(    O
also    O
called    O
2C4    B-Antibody115027189
,    O
trade    O
name    O
Perjeta    B-Antibody115027189
)    O
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
used    O
in    O
combination    O
with    O
trastuzumab    B-Antibody115027189
and    O
docetaxel    O
for    O
the    O
treatment    O
of    O
metastatic    O
HER2-positive    O
breast    O
cancer    O
;    O
it    O
also    O
used    O
in    O
the    O
same    O
combination    O
as    O
a    O
neoadjuvant    O
in    O
early    O
HER2-positive    O
breast    O
cancer    O
.    O

2012    O
–    O
Perjeta    B-Antibody115027189
(    O
pertuzumab    O
)    O
:    O
For    O
use    O
in    O
combination    O
with    O
Herceptin    O
(    O
trastuzumab    O
)    O
and    O
docetaxel    O
chemotherapy    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
previously    O
untreated    O
HER2-positive    O
metastatic    O
breast    O
cancer    O
.    O

|    O
Fezakinumab    B-Antibody115027189

This    O
translation    O
of    O
basic    O
research    O
discoveries    O
into    O
clinical    O
applications    O
led    O
to    O
the    O
development    O
with    O
Innate    O
Pharma    O
of    O
a    O
first    O
-    O
in    O
-    O
class    O
therapeutic    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
to    O
KIR    O
(    O
lirilumab    B-Antibody115027189
)    O
,    O
the    O
efficacy    O
of    O
which    O
against    O
various    O
cancers    O
is    O
currently    O
being    O
assessed    O
.    O

In    O
autoimmune    O
disease    O
,    O
anti-apolipoprotein    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
Anti    O
β2    O
glycoprotein    O
I    O
antibodies    O
)    O
strongly    O
associate    O
with    O
thrombotic    O
forms    O
of    O
lupus    O
and    O
sclerosis    O
.    O

|    O
Anti-mitochondrial    B-Antibody115027189
antibodies    I-Antibody115027189
(    O
AMA    O
)    O

Anti-mitochondrial    B-Antibody115027189
antibodies    I-Antibody115027189

Figitumumab    B-Antibody115027189
(    O
previously    O
CP-751871    O
)    O
is    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
targeting    O
the    O
insulin    O
-    O
like    O
growth    O
factor-1    O
receptor    O
that    O
was    O
investigated    O
for    O
the    O
treatment    O
of    O
various    O
types    O
of    O
cancer    O
,    O
for    O
example    O
adrenocortical    O
carcinoma    O
and    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O
(    O
NSCLC    O
)    O
.    O

Demcizumab    B-Antibody115027189
is    O
a    O
humanized    O
monoclonal    O
antibody    O
which    O
is    O
treating    O
patients    O
with    O
pancreatic    O
cancer    O
or    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O
.    O

The    O
FlmA-FlmB    B-Antibody115027189
toxin-antitoxin    I-Antibody115027189
system    I-Antibody115027189
consists    O
of    O
FlmB    O
RNA    O
(    O
F    O
leading    O
-    O
region    O
maintenance    O
B    O
)    O
,    O
a    O
family    O
of    O
non    O
-    O
coding    O
RNAs    O
and    O
the    O
protein    O
toxin    O
FlmA.    O
The    O
FlmB    O
RNA    O
transcript    O
is    O
100    O
nucleotides    O
in    O
length    O
and    O
is    O
homologous    O
to    O
sok    O
RNA    O
from    O
the    O
hok    O
/    O
sok    O
system    O
and    O
fulfills    O
the    O
identical    O
function    O
as    O
a    O
post    O
-    O
segregational    O
killing    O
(    O
PSK    O
)    O
mechanism    O
.    O

efungumab    B-Antibody115027189
(    O
INN    O
)    O

The    O
SkBr3    O
cell    O
line    O
has    O
been    O
used    O
in    O
studies    O
seeking    O
to    O
overcome    O
Herceptin    B-Antibody115027189
resistance    O
to    O
HER2-overexpressing    O
breast    O
cancer    O
.    O

Trastuzumab    B-Antibody115027189
targets    O
the    O
Her2/neu    O
(    O
also    O
known    O
as    O
ErbB2    O
)    O
receptor    O
expressed    O
in    O
some    O
types    O
of    O
breast    O
cancer    O

1998    O
–    O
Herceptin    B-Antibody115027189
(    O
trastuzumab    O
)    O
:    O
Treatment    O
for    O
metastatic    O
breast    O
cancer    O
patients    O
with    O
tumors    O
that    O
overexpress    O
the    O
HER2    O
gene    O
.    O

PlantForm    O
Corporation    O
–    O
biosimilar    O
trastuzumab    B-Antibody115027189
in    O
tobacco    O
–    O

Important    O
role    O
(    O
David    O
Cameron    O
as    O
joint    O
global    O
Chief    O
Investigator    O
)    O
in    O
the    O
pivotal    O
clinical    O
trial    O
that    O
tested    O
the    O
hypothesis    O
that    O
the    O
combination    O
of    O
lapatinib    O
and    O
the    O
cytotoxic    O
drug    O
capecitabine    O
would    O
be    O
superior    O
to    O
capecitabine    O
alone    O
in    O
patients    O
with    O
HER2    O
+    O
metastatic    O
breast    O
cancer    O
that    O
had    O
progressed    O
despite    O
trastuzumab    B-Antibody115027189
treatment    O
.    O

Image    O
of    O
Her3    O
and    O
Her2    O
,    O
target    O
of    O
the    O
breast    O
cancer    O
drug    O
Trastuzumab    B-Antibody115027189
,    O
within    O
a    O
cancer    O
cell    O
.    O

"    O
Living    O
Proof    O
"    O
(    O
2008    O
)    O
–    O
based    O
on    O
the    O
true    O
life    O
story    O
of    O
Denny    O
Slamon    O
,    O
who    O
helped    O
develop    O
the    O
breast    O
cancer    O
drug    O
Herceptin    B-Antibody115027189
2    O

BCRF    O
has    O
funded    O
basic    O
research    O
on    O
genetic    O
susceptibility    O
to    O
breast    O
cancer    O
,    O
breast    O
cancer    O
stem    O
cells    O
,    O
trastuzumab    B-Antibody115027189
(    O
Herceptin    O
)    O
,    O
anti    O
-    O
angiogenesis    O
treatment    O
with    O
bevacizumab    B-Antibody115027189
(    O
Avastin    O
)    O
,    O
MRI    O
imaging    O
,    O
aromatase    O
inhibitors    O
,    O
tamoxifen    O
;    O
and    O
also    O
clinical    O
trials    O
of    O
new    O
treatments    O
with    O
the    O
Translational    O
Breast    O
Cancer    O
Research    O
Consortium    O
.    O

"    O
BRCA1    O
"    O
is    O
associated    O
with    O
triple    O
-    O
negative    O
breast    O
cancer    O
,    O
which    O
does    O
not    O
respond    O
to    O
hormonal    O
treatments    O
and    O
can    O
not    O
be    O
usefully    O
treated    O
with    O
some    O
drugs    O
,    O
such    O
as    O
trastuzumab    B-Antibody115027189
.    O

Past    O
recipients    O
have    O
included    O
Dr.    O
Sabin    O
himself    O
,    O
Nobel    O
laureate    O
Joseph    O
E.    O
Murray    O
,    O
vaccine    O
designer    O
Maurice    O
Hilleman    O
,    O
and    O
herceptin    B-Antibody115027189
developer    O
Dennis    O
Slamon    O
,    O
as    O
well    O
as    O
opera    O
legend    O
Beverly    O
Sills    O
,    O
actress    O
Barbara    O
Barrie    O
,    O
and    O
former    O
U.    O
S.    O
Representatives    O
John    O
E.    O
Porter    O
and    O
Patricia    O
Schroeder    O
for    O
their    O
support    O
and    O
advocacy    O
of    O
medical    O
research    O
.    O

Who    O
are    O
undergoing    O
cardiotoxic    O
drug    O
agents    O
such    O
as    O
in    O
chemotherapy    O
e.g.    O
,    O
with    O
doxorubicin    O
or    O
immunotherapy    O
(    O
herceptin    B-Antibody115027189
)    O

MUGA    O
scans    O
are    O
also    O
used    O
to    O
evaluate    O
heart    O
function    O
prior    O
to    O
and    O
while    O
receiving    O
certain    O
chemotherapies    O
(    O
e.g.    O
doxorubicin    O
(    O
Adriamycin    O
)    O
)    O
or    O
immunotherapy    O
(    O
specifically    O
,    O
herceptin    B-Antibody115027189
)    O
that    O
have    O
a    O
known    O
effect    O
on    O
heart    O
function    O
.    O

This    O
results    O
in    O
the    O
eventual    O
up    O
-    O
regulation    O
of    O
the    O
p50    O
subunit    O
of    O
protein    O
complex    O
NF-κB    O
(    O
"    O
NFKB1    O
"    O
)    O
,    O
and    O
ultimately    O
activation    O
of    O
the    O
homeobox    O
gene    O
"    O
CDX2    O
"    O
,    O
which    O
is    O
responsible    O
for    O
the    O
expression    O
of    O
intestinal    O
enzymes    O
such    O
as    O
guanylate    O
cyclase    O
2C.    O
This    O
mechanism    O
also    O
explains    O
the    O
selection    O
of    O
HER2/neu    O
(    O
also    O
called    O
ERBB2    O
)    O
and    O
the    O
overexpressing    O
(    O
lineage    O
-    O
addicted    O
)    O
cancer    O
cells    O
during    O
the    O
process    O
of    O
carcinogenesis    O
,    O
and    O
the    O
efficacy    O
of    O
targeted    O
therapy    O
against    O
the    O
Her-2    O
receptor    O
with    O
trastuzumab    B-Antibody115027189
(    O
Herceptin    B-Antibody115027189
)    O
in    O
the    O
treatment    O
of    O
adenocarcinomas    O
at    O
the    O
gastroesophageal    O
junction    O
.    O

These    O
breast    O
cancers    O
do    O
not    O
express    O
human    O
epidermal    O
growth    O
factor    O
receptor-2    O
or    O
receptors    O
for    O
estrogen    O
or    O
progesterone    O
,    O
making    O
them    O
immune    O
to    O
Trastuzumab/Herceptin    B-Antibody115027189
and    O
hormonal    O
therapies    O
,    O
which    O
are    O
very    O
effective    O
against    O
other    O
breast    O
cancer    O
types    O
.    O

Ablynx    O
is    O
a    O
biopharmaceutical    O
company    O
engaged    O
in    O
the    O
discovery    O
and    O
development    O
of    O
Nanobodies    B-Antibody115027189
.    O

Another    O
example    O
is    O
the    O
development    O
of    O
so    O
-    O
called    O
"    O
nanobullets    O
"    O
,    O
which    O
are    O
small    O
antibody    O
fragments    O
,    O
based    O
on    O
the    O
single-chain    B-Antibody115027189
antibodies    I-Antibody115027189
found    O
in    O
llamas    O
to    O
target    O
chemotheurapeutics    O
directly    O
to    O
cancer    O
cells    O
in    O
a    O
cancer    O
patient    O
.    O

Single-domain    B-Antibody115027189
antibody    I-Antibody115027189

One    O
approach    O
is    O
to    O
reduce    O
amyloid    O
beta    O
,    O
for    O
example    O
with    O
bapineuzumab    B-Antibody115027189
,    O
an    O
antibody    O
in    O
phase    O
III    O
studies    O
for    O
patients    O
in    O
mild    O
to    O
moderate    O
stage    O
;    O
semagacestat    O
,    O
a    O
γ-secretase    O
inhibitor    O
,    O
MPC-7869    O
;    O
and    O
acc-001    O
or    O
CAD106    O
,    O
vaccines    O
against    O
amyloid    O
beta    O
.    O

Bapineuzumab    B-Antibody115027189
,    O
an    O
antibody    O
to    O
amyloid-β    O
,    O
was    O
previously    O
being    O
developed    O
;    O
however    O
,    O
the    O
drug    O
failed    O
in    O
phase    O
3    O
clinical    O
trials    O
.    O

|    O
Onartuzumab    B-Antibody115027189

Odulimomab    B-Antibody115027189
is    O
an    O
investigational    O
drug    O
for    O
the    O
prevention    O
of    O
transplant    O
rejection    O
and    O
for    O
the    O
treatment    O
of    O
various    O
immunological    O
diseases    O
.    O

Drugs    O
such    O
as    O
aflibercept    O
,    O
bevacizumab    B-Antibody115027189
,    O
and    O
ranibizumab    B-Antibody115027189
can    O
inhibit    O
VEGF    O
and    O
control    O
or    O
slow    O
those    O
diseases    O
.    O

In    O
June    O
2007    O
,    O
Genentech    O
began    O
the    O
construction    O
and    O
development    O
of    O
an    O
"    O
E.    O
coli    O
"    O
manufacturing    O
facility    O
,    O
also    O
in    O
Singapore    O
,    O
for    O
the    O
worldwide    O
production    O
of    O
Lucentis    B-Antibody115027189
(    O
ranibizumab    B-Antibody115027189
injection    O
)    O
bulk    O
drug    O
substance    O
.    O

2006    O
–    O
Lucentis    B-Antibody115027189
(    O
ranibizumab    O
injection    O
)    O
:    O
Treatment    O
of    O
neovascular    O
(    O
wet    O
)    O
age    O
-    O
related    O
macular    O
degeneration    O
(    O
AMD    O
)    O
.    O

A    O
similar    O
drug    O
,    O
Lucentis    B-Antibody115027189
,    O
was    O
later    O
approved    O
for    O
treating    O
macular    O
degeneration    O
.    O

|    O
Panobacumab    B-Antibody115027189

Fasinumab    B-Antibody115027189
is    O
a    O
human    O
monoclonal    O
antibody    O
designed    O
for    O
the    O
treatment    O
of    O
pain    O
.    O

Visilizumab    B-Antibody115027189
(    O
tentative    O
trade    O
name    O
Nuvion    B-Antibody115027189
,    O
PDL    O
BioPharma    O
Inc.    O
)    O
is    O
a    O
humanized    B-Antibody115027189
monoclonal    I-Antibody115027189
antibody    I-Antibody115027189
.    O

ecromeximab    B-Antibody115027189
(    O
INN    O
,    O
USAN    O
)    O

Drugs    O
or    O
drug    O
candidates    O
that    O
inhibit    O
/    O
block    O
the    O
inhibitory    O
checkpoint    O
molecules    O
(    O
above    O
)    O
are    O
confusingly    O
sometimes    O
known    O
as    O
immune    B-Antibody115027189
checkpoint    I-Antibody115027189
inhibitor    I-Antibody115027189
;    O
this    O
idea    O
is    O
often    O
referred    O
to    O
as    O
immune    O
checkpoint    O
blockade    O
,    O
or    O
simply    O
checkpoint    O
blockade    O
.    O

The    O
Research    O
Park    O
hosts    O
about    O
50    O
companies    O
,    O
among    O
them    O
NewLink    O
Genetics    O
,    O
which    O
develops    O
cancer    B-Antibody115027189
immunotherapeutics    I-Antibody115027189
,    O
and    O
the    O
U.S.    O
animal    O
health    O
division    O
of    O
Boehringer    O
Ingelheim    O
,    O
Vetmedica    O
.    O

Cancer    B-Antibody115027189
immunotherapy    I-Antibody115027189
covers    O
the    O
medical    O
ways    O
to    O
stimulate    O
the    O
immune    O
system    O
to    O
attack    O
cancer    O
tumours    O
.    O

Through    O
the    O
next    O
few    O
years    O
the    O
PCRF    O
moved    O
into    O
the    O
areas    O
of    O
immuno-oncology    B-Antibody115027189
research    O
and    O
molecular    O
and    O
cellular    O
biology    O
research    O
.    O

Miller    O
was    O
also    O
the    O
first    O
to    O
provide    O
evidence    O
that    O
thymus    O
-    O
derived    O
immune    O
cells    O
are    O
important    O
for    O
the    O
defense    O
against    O
certain    O
tumors    O
,    O
which    O
forms    O
the    O
basis    O
for    O
modern    O
cancer    B-Antibody115027189
immunotherapy    I-Antibody115027189
.    O

PROSTVAC    O
(    O
rilimogene    O
galvacirepvec    O
/    O
rilimogene    O
glafolivec    O
)    O
is    O
a    O
cancer    B-Antibody115027189
immunotherapy    I-Antibody115027189
candidate    O
in    O
clinical    O
development    O
by    O
Bavarian    O
Nordic    O
for    O
the    O
treatment    O
of    O
all    O
prostate    O
cancer    O
although    O
clinical    O
trials    O
are    O
focusing    O
on    O
more    O
advanced    O
cases    O
of    O
metastatic    O
castration    O
-    O
resistant    O
prostate    O
cancer    O
(    O
mCRPC    O
)    O
.    O

In    O
2016    O
,    O
the    O
University    O
Hospital    O
of    O
Lausanne    O
inaugurated    O
a    O
cell    O
production    O
laboratory    O
for    O
cancer    B-Antibody115027189
immunotherapy    I-Antibody115027189
on    O
the    O
Biopôle    O
campus    O
(    O
Épalinges    O
)    O
.    O

Immunotherapy    O
with    O
these    O
immune    B-Antibody115027189
checkpoint    I-Antibody115027189
inhibitor    I-Antibody115027189
appears    O
to    O
shrink    O
tumours    O
in    O
a    O
higher    O
number    O
of    O
patients    O
across    O
a    O
wider    O
range    O
of    O
tumour    O
types    O
and    O
is    O
associated    O
with    O
lower    O
toxicity    O
levels    O
than    O
other    O
immunotherapies    O
,    O
with    O
durable    O
responses    O
.    O

Phase    O
III    O
trials    O
for    O
the    O
treatment    O
of    O
metastatic    O
urothelial    O
bladder    O
cancer    O
in    O
combination    O
with    O
an    O
alternative    O
immune    B-Antibody115027189
checkpoint    I-Antibody115027189
inhibitor    I-Antibody115027189
have    O
been    O
reached    O
.    O

PD-1    B-Antibody115027189
inhibitor    I-Antibody115027189

There    O
is    O
an    O
ongoing    O
cancer    B-Antibody115027189
immunotherapy    I-Antibody115027189
clinical    O
trial    O
for    O
a    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
targeting    O
VISTA    O
in    O
advanced    O
cancer    O
.    O

His    O
research    O
has    O
focused    O
on    O
the    O
immunotherapy    B-Antibody115027189
of    I-Antibody115027189
cancer    I-Antibody115027189
.    O

|    O
Nesvacumab    B-Antibody115027189

:    O
V09HA04    O
Technetium    B-Antibody115027189
(99mTc)    I-Antibody115027189
sulesomab    I-Antibody115027189

Since    O
Genentech    O
acquired    O
Tanox    O
in    O
2007    O
,    O
the    O
anti    O
-    O
M1’    O
program    O
has    O
been    O
carried    O
out    O
in    O
a    O
fast    O
pace    O
and    O
favorable    O
results    O
have    O
been    O
obtained    O
from    O
two    O
Phase    O
I    O
and    O
one    O
Phase    O
IIa    O
clinical    O
trails    O
on    O
a    O
humanized    O
antibody    O
,    O
47H4    O
(    O
also    O
referred    O
to    O
as    O
MEMP1972A    O
,    O
or    O
quilizumab    B-Antibody115027189
)    O
.    O

Monoclonal    B-Antibody115027189
antibodies    I-Antibody115027189

The    O
International    O
Nonproprietary    O
Names    O
of    O
humanized    O
antibodies    O
end    O
in    O
"    O
-zumab    O
"    O
,    O
as    O
in    O
"    O
omalizumab    B-Antibody115027189
"    O
(    O
see    O
Nomenclature    B-Antibody115027189
of    I-Antibody115027189
monoclonal    I-Antibody115027189
antibodies    I-Antibody115027189
)    O
.    O

|    O
Apolizumab    B-Antibody115027189

Hyperimmune    B-Antibody115027189
globulin    I-Antibody115027189
is    O
similar    O
to    O
intravenous    B-Antibody115027189
immunoglobulin    I-Antibody115027189
(    O
IVIG    O
)    O
except    O
that    O
it    O
is    O
prepared    O
from    O
the    O
plasma    O
of    O
donors    O
with    O
high    O
titers    O
of    O
antibody    O
against    O
a    O
specific    O
organism    O
or    O
antigen    O
.    O

Immunoglobulin    B-Antibody115027189
Y    I-Antibody115027189
(    O
abbreviated    O
as    O
IgY    B-Antibody115027189
)    O
is    O
a    O
type    O
of    O
immunoglobulin    O
which    O
is    O
the    O
major    O
antibody    O
in    O
bird    O
,    O
reptile    O
,    O
and    O
lungfish    O
blood    O
.    O

|    O
Gevokizumab    B-Antibody115027189

glembatumumab    B-Antibody115027189
(    O
USAN    O
,    O
INN    O
)    O

Elotuzumab    B-Antibody115027189
(    O
BMS-901608    O
)    O
—    O
phase    O
III    O

An    O
antibody    O
that    O
inhibits    O
the    O
activity    O
of    O
LOXL2    O
,    O
simtuzumab    B-Antibody115027189
and    O
is    O
currently    O
in    O
clinical    O
trials    O
for    O
the    O
treatment    O
of    O
several    O
types    O
of    O
cancer    O
and    O
fibrotic    O
diseases    O
such    O
as    O
liver    O
fibrosis    O
.    O

Siplizumab    B-Antibody115027189
(    O
MEDI-507    O
)    O
is    O
a    O
novel    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
with    O
a    O
human    O
IgG1    B-Antibody115027189
,    O
kappa    O
directed    O
to    O
CD2    O
.    O

Rituximab    B-Antibody115027189
targets    O
CD20    O
found    O
on    O
B    O
cells    O
.    O

Treatments    O
include    O
intravenous    B-Antibody115027189
immunoglobulin    I-Antibody115027189
,    O
which    O
is    O
a    O
short    O
-    O
term    O
treatment    O
,    O
immunosuppressants    O
,    O
though    O
they    O
have    O
not    O
been    O
shown    O
to    O
be    O
effective    O
,    O
autologous    O
stem    O
cell    O
transplantation    O
,    O
and    O
rituximab    B-Antibody115027189
.    O

1997    O
–    O
Rituxan    B-Antibody115027189
(    O
rituximab    O
)    O
:    O
Treatment    O
for    O
specific    O
kinds    O
of    O
non    O
-    O
Hodgkins    O
lymphomas    O
.    O

In    O
older    O
patients    O
treatment    O
may    O
be    O
dose    O
-    O
adjusted    O
EPOCH    O
with    O
rituximab    B-Antibody115027189
.    O

Biologic    O
agent    O
Rituximab    B-Antibody115027189
(    O
Anti    O
-    O
B    O
-    O
Cell    O
Therapy    O
)    O
is    O
now    O
licensed    O
for    O
use    O
in    O
refractory    O
Rheumatoid    O
Arthritis    O
.    O

Other    O
immune    O
suppressing    O
medications    O
may    O
also    O
be    O
used    O
including    O
rituximab    B-Antibody115027189
.    O

Zevalin    O
(    O
ibritumomab    B-Antibody115027189
)    O
is    O
indicated    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
relapsed    O
or    O
refractory    O
,    O
low‑grade    O
or    O
follicular    O
B‑cell    O
non‑Hodgkin    O
's    O
lymphoma    O
(    O
NHL    O
)    O
,    O
including    O
patients    O
with    O
rituximab    B-Antibody115027189
-    O
refractory    O
follicular    O
NHL    O
.    O

The    O
boxed    O
warning    O
for    O
the    O
drug    O
rituximab    B-Antibody115027189
(    O
Rituxan    O
,    O
co    O
-    O
marketed    O
by    O
Genentech    O
BioOncology    O
and    O
Biogen    O
Idec    O
)    O
includes    O
a    O
statement    O
that    O
JC    O
virus    O
infection    O
resulting    O
in    O
progressive    O
multifocal    O
leukoencephalopathy    O
,    O
and    O
death    O
has    O
been    O
reported    O
in    O
patients    O
treated    O
with    O
the    O
drug    O
.    O

An    O
initial    O
treatment    O
regimen    O
that    O
contains    O
fludarabine    O
,    O
cyclophosphamide    O
,    O
and    O
rituximab    B-Antibody115027189
(    O
known    O
as    O
FCR    O
)    O
has    O
demonstrated    O
higher    O
overall    O
response    O
rates    O
and    O
complete    O
response    O
rates    O
.    O

FR    O
(    O
fludarabine    O
with    O
rituximab    B-Antibody115027189
)    O

FCR    O
(    O
fludarabine    O
,    O
cyclophosphamide    O
,    O
and    O
rituximab    B-Antibody115027189
)    O

Rituximab    B-Antibody115027189
,    O
ofatumumab    B-Antibody115027189
,    O
and    O
obinutuzumab    B-Antibody115027189
are    O
antibodies    O
against    O
CD20    O
used    O
to    O
treat    O
CLL    O
.    O

Cytokine    O
storm    O
may    O
also    O
be    O
induced    O
by    O
certain    O
medications    O
,    O
such    O
as    O
the    O
CD20    O
antibody    O
rituximab    B-Antibody115027189
and    O
the    O
CD19    O
antibody    O
tisagenlecleucel    O
.    O

Examples    O
of    O
chimeric    O
antibodies    O
approved    O
for    O
human    O
therapy    O
include    O
abciximab    B-Antibody115027189
(    O
ReoPro    O
)    O
,    O
basiliximab    B-Antibody115027189
(    O
Simulect    O
)    O
,    O
cetuximab    B-Antibody115027189
(    O
Erbitux    O
)    O
,    O
infliximab    O
(    O
Remicade    O
)    O
and    O
rituximab    B-Antibody115027189
(    O
MabThera    O
)    O
.    O

IL-21    O
proceeded    O
to    O
Phase    O
2    O
clinical    O
trials    O
where    O
it    O
was    O
administered    O
alone    O
or    O
coupled    O
with    O
drugs    O
as    O
sorafinib    O
and    O
rituximab    B-Antibody115027189
.    O

For    O
frontline    O
treatment    O
,    O
CHOP    O
with    O
rituximab    B-Antibody115027189
is    O
the    O
most    O
common    O
chemotherapy    O
,    O
and    O
often    O
given    O
as    O
outpatient    O
by    O
IV    O
.    O

Immune    O
-    O
based    O
therapy    O
is    O
dominated    O
by    O
the    O
use    O
of    O
the    O
rituximab    B-Antibody115027189
monoclonal    O
antibody    O
,    O
sold    O
under    O
the    O
trade    O
name    O
Rituxan    O
(    O
or    O
as    O
Mabthera    O
in    O
Europe    O
and    O
Australia    O
)    O
.    O

Rituximab    B-Antibody115027189

His    O
work    O
has    O
led    O
to    O
the    O
concept    O
that    O
antibodies    O
can    O
be    O
used    O
as    O
personalized    O
anticancer    O
drugs    O
and    O
to    O
the    O
development    O
of    O
an    O
antibody    O
-    O
based    O
drug    O
,    O
Rituxan    B-Antibody115027189
,    O
that    O
is    O
widely    O
used    O
to    O
treat    O
lymphoma    O
.    O

It    O
remains    O
to    O
be    O
determined    O
whether    O
immunosuppressive    O
drugs    O
,    O
including    O
B    O
cell    O
-    O
depleting    O
drugs    O
such    O
as    O
rituximab    B-Antibody115027189
,    O
could    O
be    O
effective    O
for    O
treating    O
BENTA    O
disease    O
.    O

Nacolomab    B-Antibody115027189
tafenatox    I-Antibody115027189
,    O
a    O
drug    O
with    O
a    O
similar    O
chemical    O
structure    O
and    O
mechanism    O

Cantuzumab    B-Antibody115027189
ravtansine    I-Antibody115027189
(    O
huC242-SPDB    O
-    O
DM4    O
)    O
is    O
an    O
antibody    O
-    O
drug    O
conjugate    O
designed    O
for    O
the    O
treatment    O
of    O
cancers    O
.    O

Hypervariable    B-Antibody115027189
region    I-Antibody115027189

:    O
:    O
:    O
:    O
Hypervariable    B-Antibody115027189
region    I-Antibody115027189

mtDNA    O
haplogroups    O
are    O
defined    O
by    O
the    O
presence    O
of    O
a    O
series    O
of    O
single    O
-    O
nucleotide    O
polymorphism    O
(    O
SNP    O
)    O
markers    O
in    O
the    O
hypervariable    B-Antibody115027189
region    I-Antibody115027189
and    O
the    O
coding    O
region    O
of    O
mitochondrial    O
DNA    O
.    O

Apennine    O
birds    O
are    O
not    O
consistently    O
recognizable    O
by    O
external    O
morphology    O
,    O
and    O
are    O
only    O
weakly    O
differentiated    O
with    O
regards    O
to    O
mtDNA    O
D    O
-    O
loop    O
and    O
hypervariable    B-Antibody115027189
control    I-Antibody115027189
region    I-Antibody115027189
sequences    O
and    O
microsatellite    O
genotyping    O
.    O

Human    B-Antibody115027189
platelet    I-Antibody115027189
antigens    I-Antibody115027189
,    O
in    O
clinical    O
medicine    O

MassBiologics    O
participates    O
in    O
the    O
discovery    O
,    O
production    O
and    O
clinical    O
testing    O
of    O
monoclonal    O
antibodies    O
(    O
including    O
antibodies    O
to    O
Clostridium    O
difficile    O
)    O
,    O
antibodies    O
now    O
known    O
as    O
actoxumab    B-Antibody115027189
and    O
bezlotoxumab    B-Antibody115027189
In    O
2005    O
,    O
the    O
firm    O
opened    O
an    O
$    O
80-million    O
facility    O
for    O
monoclonal    O
-    O
antibody    O
production    O
.    O

lintuzumab    B-Antibody115027189
(    O
INN    O
)    O

Anatumomab    B-Antibody115027189
mafenatox    I-Antibody115027189
is    O
a    O
mouse    O
monoclonal    B-Antibody115027189
antibody    I-Antibody115027189
studied    O
for    O
the    O
treatment    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O
,    O
which    O
acts    O
as    O
a    O
tumor    O
-    O
targeted    O
superantigen    O
.    O

|    O
Etrolizumab    B-Antibody115027189


